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Abstract
The fTdefensins are a family o f  small, cationic antimicrobial peptides. They are 
conserved in a variety of species ranging from lower vertebrates to mammals and 
plants, and were first identified for their broad-spectrum antimicrobial activity. Since 
their initial discovery, this role has broadened to include a number o f  diverse 
additional functions including the chemotaxis o f  immune cells (immature dendritic 
cells, macrophages and CD4+ T cells), the determination o f  coat colour in dogs and 
seed maturation in tomatoes.
The aim o f  this thesis is to investigate the function o f  vertebrate beta-defensins. 1 
address this question by assessing how mouse P-defensin structure affects its 
bactericidal activity and also by carrying out P-defensin knockdown studies in 
zebrafish.
In this work, 1 address the question o f  how P-defensin structure affects its 
bactericidal activity by examining the effects o f  sequentially removing amino acids 
from the N-terminal o f  murine Defbl4. I show that these deletions reduce 
bactericidal activity however the effects are much more striking in gram positive 
species than gram negative. Through the comparison o f  monomeric and dimeric 
species as well as analysis of peptide charge and hydrophobicity, this work indicates 
that a combination o f  primary sequence and structure is responsible for the 
bactericidal properties of this peptide.
In addition, this thesis describes the characterisation o f  three P-defensin-like peptides 
(Defbll, Defbl2 and DefbB) previously described in zebrafish. 1 utilise antimicrobial 
assays to determine the bactericidal properties o f  synthetic Defbl2 and DefbB against 
a panel o f  microbes and also show that Defbll is antimicrobially inactive. 
Furthermore, this work identifies the expression o f  defb ll during zebrafish 
gastrulation and utilises a combination o f  wholemount in situ hybridisation, 
morpholino knockdown and rescue and microarray analysis to ascertain a novel 
essential role for this peptide in early development.
■
This work is the first report o f  a P-defensin being involved in vertebrate development 
and presents a further widening o f  the influence o f  the defensin family.
Acknowledgem ents
Firstly, 1 would like to thank Dr. Julia Dorin and Dr Liz Patton for giving me the 
opportunity to start up this project and for giving me the freedom to come up with 
my own ideas and investigate them freely. Your trust and guidance has been 
invaluable.
Dr. Colin Semple has patiently guided me through a number o f  bioinformatical crises 
(often at short notice), for which I'm very grateful and without whom I would have 
struggled.
I’d like to thank the C3 lab for providing a welcoming and lively working 
environment, with special thanks to Heather for noting down all my seminar 
comments and questions when I was too nervous to remember them, and to Fiona S 
for LPS advice and an endless supply o f  (free!) gloves, eppendorfs and spare 
Gilsons. Thanks also to Laura for cloning and in situ advice and reagents.
This work would also not have been possible without the care and attention o f  the 
fish room staff, old and new -  Sue, Keith and Karthika, whose hard work ensured 
that my fish remained happy, healthy and well-fed, as well as the HGU Core 
Services, whose work shouldn’t go unnoticed.
A final thank you to my Edinburgh “family” : Anna, Corina, Emily, Jenny, Kirsty and 
Niki. I’ve loved every minute o f  working with you - on bad science days, the 
company’s usually (always!) been good, and that makes all the difference. Special 
thanks to Niki -  the other half of the C3 fish group, for in situ advice, probes and 
useful “fish-chat” . Thanks also to Jenny for tireless proofreading of this manuscript 
as well as for sharing p53 fish.
Thanks to Mum, Dad, George and Jan for pretending to find morpholinos fascinating 
and for taking an interest in everything that 1 do. Also to my grandparents Brenda 
and George Reynolds -  I hope that wherever you are, you’re proud o f  this latest 
ology”.
IV
Finally, thanks to Graeme -  for so much. For learning more biology than you ever 
really wanted to know, for your endless patience, for being a personal 24hr taxi and 
unpaid slave to science (and me!). This thesis would have been possible without you, 




D eclara tion ....................................................................................................................................... i
A b s t ra c t ............................................................................................................................................ii
A cknow ledgem ents ......................................................................................................................iv
Table of C o n te n ts ........................................................................................................................vi
List of F igu res ..............................................................................................................................xii
List of T a b le s .............................................................................................................................xvii
A bbrevia tions ........................................................................................................................... xviii
Amino Acid Single Letter C odes .......................................................................................xxi
C h ap te r  1: In t ro d u c t io n .............................................................................................................1
1.1 THE IMPORTANCE OF ANTIMICROBIAL A G E N T S .......................................2
1.1.1 Antibiotic resistance.............................................................................................. 4
1.1.2 The slowing of novel antibiotic development.................................................7
1.2 ANTIMICROBIAL PEPTIDES OF THE INNATE IMMUNE SYSTEM
8
1.2.1 Categories o f  antimicrobial pep tide ................................................................ 10
1.3 THE DEFENSIN FAM ILY ....................................................................................... 10
1.3.1 The a-defensins.....................................................................................................14
1.3.2 a-defensin structure and function..................................................................... 16
1.3.3 The 0-defensins.....................................................................................................18
1.3.4 The P-defensins....................................................................................................20
1.3.5 The structure and interactions o f  f3-defensins.............................................. 21
1.4 HUMAN AND MURINE (3-DEFENSINS............................................................21
1.4.1 Human (3-defensins............................................................................................. 21
1.4.2 Murine P-defensins.............................................................................................24
1.4.3 The association of |3-defensins with human d isease .................................. 25
1.5 THE INDUCTION AND FUNCTION OF THE p-D EFEN SIN S................ 27
1.5.1 Antimicrobial activ ity ........................................................................................ 27
1.5.2 Proposed mechanisms o f  antimicrobial ac tiv ity ......................................... 28
1.5.3 Suitability of the |3-defensins as novel therapeutics................................... 32
1.5.4 Chemoattractant properties...............................................................................33
1.5.5 A surprising role for p-defensins in pigment distribution.........................36
1.6 THE ZEBRAFISH AS A MODEL FOR p-DEFENSIN S T U D IE S  38
1.6 .1 The zebrafish as a model organism................................................................. 38
1.6.2 The zebrafish immune system.........................................................................40
1.6.3 The zebrafish defensins.................................................................................... 41
1.7 THESIS AIMS............................................................................................................. 45
C h ap te r  2: The S tructure-A ctiv ity  Relationship of M urine  D e f b l4 .......................46
2.1 PR EFA C E ..........................................................................................................................47
2.2 A IM S ............................................................................................................................. 54
2.3 ANTIMICROBIAL ACTIVITY OF A DEFB 14-INSPIRED PEPTIDE 
DELETION SERIES.............................................................................................................. 55
2.3.1 The bactericidal efficiency o f  the monomeric D efbl4  deletion series
varies according to bacterial gram s ta tus ..................................................................... 55
2.3.2 Dimerisation does not improve bactericidal activity in full length
D efb l4 - lC v, but preserves the activity o f  the deletion series.................................57
2.3.3 N-terminal substitutions have no effect on peptide activ ity ....................... 64
2.3.4 The Defbl4-1CN deletion series lose their salt insensitivity as the peptide 
shortens 72
vii
2.3.5 Improving the antimicrobial activity o f  D efb l41C v(6-17): serum
sensitivity, cyclicisation and stereoisomers..................................................................... 74
2.4 DISCUSSION.............................................................................................................. 80
2.4.1 Primary peptide sequence has a crucial role in the determination of 
bactericidal activity against different bacterial strains..............................................80
2.4.2 Peptide dimérisation protects bactericidal ac tiv ity ................................... 83
2.4.3 Salt sensitivity increases as the N-terminal deletions o f  D e fb l4 - lC x 
increase 84
2.4.4 The serum sensitivity o f  D e fb l4 - lC v(6~17) derivatives can be 
manipulated by chiral isomérisation..............................................................................85
2.5 CONCLUSIONS AND FUTURE D IRECTIO N S.............................................87
Chapter 3: The Antimicrobial Function of the Zebrafish D efensins ......................89
3.1 PREFA CE.......................................................................................................................... 90
3.2 A IM S................................................................................................................................... 92
3.3 THE GENOMIC ORGANISATION OF THE ZEBRAFISH DEFENSINS93
3.3.1 Searching for novel members o f  the zebrafish defensin family................... 93
3.3.2 defh ll and defb!2 have reported paralogues in an adjacent gene c luster  95
3.4 EXPRESSION OF THE ZEBRAFISH D EFEN SIN S .......................................99
3.4.1 Expression o f  zebrafish defensins in em bryos.....................................................99
3.5 ANTIMICROBIAL ACTIVITY OF THE ZEBRAFISH DEFENSINS 101
3.5.1 Antimicrobial activity of the zebrafish defensins against human and 
zebrafish pathogens.......................................................................................................... 103
3.5.2 Antimicrobial activity of the zebrafish defensins against human and 
zebrafish pathogens.......................................................................................................... 104
3.5.3 Serum and salt sensitivity o f  the antimicrobial activity of Defbl2 and 
Defbl3.................................................................................................................................110
3.6 DISCU SSION ..................................................................................................................114
3.6.1 Novel members o f  the zebrafish [3-defensin-like family...................................114
3.6.2 Expression o f  the zebrafish defensins............................................................... 115
3.6.3 Antimicrobial activity o f  the zebrafish defensins ..........................................117
3.7 CONCLUSIONS AND FUTURE DIRECTIONS.................................................120
Chapter 4: The Role of defbll in Development in Danio rerio .................................122
4.1 PREFA CE........................................................................................................................ 123
4.1.1 Zebrafish development: an overview of the first 24 h o u rs .............................. 123
4.2 A IM S..................................................................................................................................126
4.3 DEFBL1 EX PRESSION .............................................................................................. 127
4.3.1 defb ll is expressed in the early em bryo ........................................................... 127
4.3.2 Transient knockdown o f  defb ll causes multiple developmental defects 127
4.3.3 defb ll morphants develop brain and eye abnormalities............................... 137
4.3.4 Verifying the defb ll morphant phenotype.......................................................137
4.3.5 Rescue of defb ll morphants................................................................................ 140
4.4 MICROARRAY ANALYSIS OF DEFBL1 M ORPH A NTS.............................. 144
4.4.1 Microarray analysis o f  defb ll morphants compared to controls................144
4.4.2 Validation of microarray data using quantitative RT-PCR......................... 151
4.5 D ISCUSSION................................................................................................................. 153
4.5.1 The defbll morphant phenotype......................................................................... 153
4.5.2 defb ll and convergence extension m ovem ents.............................................. 156
4.5.3 Genome-wide analysis of defb ll m orphants................................................... 157
4.5.4 defb ll and the Wnt-PCP pathw ay......................................................................158
4.6 CONCLUSIONS AND FUTURE DIRECTIONS.................................................161
ix
Chapter 5: Concluding Remarks 163
C h ap te r  6: M ateria ls  and M e th o d s ................................................................................... 168
6.1 MOLECULAR M ETHODS.........................................................................................169
6.1.1 List of Solutions......................................................................................................169
6.1.2 Polymerase chain reaction (P C R ) .................................................................... 170
6.1.3 RNA extraction....................................................................................................... 170
6.1.4 Reverse-transcription polymerase chain reaction (RT-PCR)......................172
6.1.5 Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
 172
6.1.6 Gel electrophoresis............................................................................................... 172
6.1.7 Sequencing............................................................................................................... 172
6.1.8 Cloning of d e jb ll .................................................................................................... 173
6.2 MICROBIOLOGICAL TE C H N IQ U ES.................................................................. 174
6.2.1 List o f  Solutions......................................................................................................174
6.2.2 List o f  category 2 strains.................................................................................... 1 75
6.2.3 Preparation, maintenance and growth o f  microbial s to ck s ......................... 175
6.2.4 In vitro antimicrobial a ssays ............................................................................... 176
6.2.5 Serum and salt sensitivity a s say s .......................................................................176
6.2.6 Transformation o f  competent cells.....................................................................177
6.2.7 Isolation o f  plasmid D N A ..................................................................................177
6.3 ZEBRAFISH TECHN IQ UES..................................................................................... 178
6.3.1 List o f  Solutions......................................................................................................178
6.3.2 List of Strains.......................................................................................................... 178
6.3.3 Zebrafish maintenance and husbandry..............................................................179
6.3.4 LPS and microbial treatment o f  zebrafish larvae...........................................179
x
6.3.5 Morpholino and RNA injections........................................................................ 179
6.3.6 In vitro transcription o f  mRNA for morpholino rescue ............................... 180
6.3.7 Imaging zebrafish em bryos..................................................................................180
6.3.8 Zebrafish embryo h isto logy............................................................................... 181
6.3.9 Zebrafish wholemount in situ hybridisation (WISH)..................................  181
6.3.10 Zebrafish microarrays and analysis................................................................. 182
6.4 BIOINFORMATIC AND COMPUTATIONAL TECHN IQ UES...................183
6.4.1 List o f  programs and databases used................................................................. 183
6.4.2 Defensin gene prediction...................................................................................... 183
6.4.3 DAVID analysis (as described in Huang et a/., 2009a,b)............................183
Chapter 7: References.............................................................................................................184
Chapter 8: A ppendices .......................................................................................................... 201
Appendix 1............................................................................................................................. 202
Appendix 2 ............................................................................................................................. 204
XI





































































































































































































































































o . 2 0‘X -4—4 ’X






















o , 0 O«4-1 X X




TO T 3 "O
G C
G G G





























X X X■4—4 * *0 -4—4































. sin G £ G t"- ’ g
CN 00 CN 00 CN 00
<D
G G G
C/3 <D 1)1-1 (-1 C/3 !h C/3
3 .22 3 . 2 3 CD0 0 ’ G 00 ■p 00 *G

























































































































___ < e n r - 00 (N VD 00 O <N in r - oo cn
































































































































O  CM CM CO
in  m  o  o






























































VO ON O m 3 - co 3 - OV VO Ov Ov OV
in VO r - r - Ov O O 0 •3- 3 |- 3 " in
Abbreviations
a-MSH a-melanocyte stimulating hormone
°C degrees Celsius
cAMP cyclic adenosine monophosphate
cDNA complementary DNA
CF cystic fibrosis
CFTR cystic fibrosis transmembrane conductance regulator
cGMP cyclic guanosine monophosphate
CNV copy number variation
DEPC diethylpyrocarbonate
d f f O  distilled water
DNA deoxyribonucleic acid
dpf days post fertilisation
DTT dithiothreitol
EARSS European Antimicrobial Resistance Surveillance
System
EDTA ethylenediamine tetraacetic acid
EST expressed sequence tag
ECS foetal calf serum
g gram
xviii
GFP green fluorescent protein
HNP human neutrophil peptide
hpf hours post fertilisation
HSV herpes simplex virus
1L1 ß interleukin lß
kb kilobase
1 litre




MBC minimum bactericidal concentration
MBT midblastula transition












rpm revolutions per minute
RT-PCR reverse transcription polymerase chain reaction
SEM standard error o f  mean
TAP tracheal antimicrobial peptide
TB tuberculosis
TLR Toll-like receptor
TNFa tumour necrosis factor a
UTR untranslated region
UV ultraviolet
VRSA vancomycin-resistant Staphylococcus aureus
v/v volume per volume
WHO World Health Organisation
WISH wholemount in situ hybridisation
w/v weight per volume
XDR-TB extensively drug resistant tuberculosis
ZFIN Zebrafish Information Network
XX






















“I  have been trying to point out that in our lives chance may have an astonishing  
influence and, i f  I may offer advice to the young  laboratory worker, it would be this — 
never to neglect an extraordinary appearance or happening "
Sir Alexander Fleming
1
1.1 THE IMPORTANCE OF ANTIMICROBIAL AGENTS
A complex relationship exists between higher organisms and the microbial world. 
Shortly following birth, mammalian bodies are rapidly colonised by an array of 
bacteria to form a lifelong symbiotic relationship that benefits both the host and 
microbes. Recent data has shown that commensal bacteria o f  the Bifidobacterium  
genus confer protection against E.coli infection in mice (Fukuda et al., 2011), 
illustrating the critical role commensals play in host defence mechanisms.
However, despite the benefits commensal bacteria confer, an intricate host innate 
immune barrier is essential to ensure that these colonising bacteria do not cross host 
epithelial linings to cause systemic infections. In addition, there is a limit to the 
number of colonies a host is able to support, and so colony numbers must also be 
kept under control.
In healthy humans the control o f  commensal colonies is rarely problematic, however 
in immune-challenged patients these bacteria can rapidly overcome host defence 
efforts and lead to opportunistic and nosocomial (hospital-acquired) infections. It is 
important that in such circumstances we have a battery o f  antibiotic agents with 
which to treat these infections otherwise the prognosis for these patients is poor. 
Some data have suggested that some 70% of hospital-acquired infections in the USA 
require some form o f  antibiotic treatment (Coates et al., 2002).
Beyond the issue o f  control o f  commensals, antimicrobial agents have had a defining 
role throughout recent human history, proving to be vital in the control o f  diseases 
such as pneumonia, tuberculosis and systemic bacteraemia. In particular, the 
mortality rates of community-acquired bacterial meningitis strikingly demonstrate 
the impact antibiotics have had on the disease. As illustrated in Figure 1.1, 
meningitis mortality rates at the beginning o f  the century ranged from 80-100%, but 
the introduction of multiple antibiotics across the course o f  the century led to this 
dropping to a level of 7-30% in 2000 (Swartz, 2004).
In addition to controlling disease, antimicrobial agents have a critical role in the 
treatment o f  a range of injuries such as open wounds, fractures and post-operative 
incisions. Furthermore, surface infections which lead to sepsis are a major cause of 
mortality in bums patients and the causative microbes in these cases cover a range of
2
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Figure 1.1 Mortality rates associated with bacterial meningitis since 
from 1910-2000 (taken from Swartz, 2004)
Prior to the introduction o f  antibiotics, the mortality rates associated with bacterial 
meningitis caused by S.pneumoniae, H. influenzae and N.meningitidis ranged 
between 80-100%. The introduction o f  firstly antisera, then varied antibiotics as 
treatments for the different strains o f  disease resulted in the mortality rates dropping 
to 7-30% by 2000.
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bacterial and fungal species (Mahar el a/., 2010), underlining the need for effective 
antimicrobials to control these cases.
It is clear that on a number of levels, antimicrobials have revolutionised human 
health and are critical for the maintenance and improvement o f  modern healthcare.
1.1.1 Antibiotic resistance
With the use of antibiotics in medical, agricultural and industrial environments 
increasing in recent years, the problem o f  bacteria acquiring resistance to treatments 
is becoming more and more prevalent. Knowledge o f  antibiotic resistance was 
reported as early as 1945 when Alexander Fleming warned against the misuse o f  
penicillin. In an interview with the New York Times, he made the precise prediction 
that with the use o f  “too-small doses” we could enter into the situation where:
“microbes are educated to resist penicillin and a host o f  penicillin-fast organisms is
bred out until they reach someone who gets a septicaemia or a pneum onia which
penicillin cannot save ” (Fleming, 1946).
These predictions were rapidly realised following the introduction o f  over-the- 
counter oral penicillin and the associated self-medication that followed (Levy, 2002). 
The problem of single-drug resistance rapidly evolved to become multidrug 
resistance when multidrug resistant dysentery-causing E.coli and Shigella  species 
were reported in the 1959 (reviewed in Watanabe, 1963).
Multidrug resistance in opportunistic bacterial strains has become a heavily 
publicised and growing problem. Staphylococcus aureus is a common bacterium 
which is estimated to be carried in the nose and skin o f  approximately 30% of 
healthy humans (EARSS Anuual Report, 2008), however it is notorious for causing 
serious infections in hospitalised patients, which can result in prolonged hospital 
stays and mortality rates o f  up to 50% (Cosgrove et a/., 2003). Methicillin-resistant 
S.aureus species (MRSA) were first reported in the UK in 1961 (Jevons, 1961), 
however the incidence o f  MRSA-related deaths in the UK increased more than 15- 
fold between 1993 and 2002 (Figure 1.2, UK National Statistics Office), illustrating 
the growing problem of  resistance. Current estimates suggest that up to 50% clinical 
S.aureus isolates in Europe are methicillin-resistant (Figure 1.3, EARSS Annual
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Figure 1.2 Incidence of MRSA-related deaths in England and Wales 
from 1993-2006 (taken from www.statistics.gov.uk)
The incidence o f  deaths related to MRSA in England and Wales rose steadily from 
1993-2006, while deaths from methicillin-sensitive strains remained constant.
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Legend
□  No data* 
E l < 1%
■  1-5%
□  5 -1 0 %  
(SI 10 -25%
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■  > 50%
Figure 1.3 Reported levels of oxacillin**-resistant S.aureus species 
obtained from clinical isolates across Europe in 2008 (taken from EARSS 
report, 2008)
*countries labelled in white did not submit data
** oxacillin is similar in structure to methicillin and has replaced methicillin in 
clinical use
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Report, 2008), however the 2008 European Antimicrobial Resistance Surveillance 
System report described some early evidence o f  a downward trend o f  UK MRSA 
incidence. MRSA cases are commonly treated intravenously with vancomycin, 
however cases of fully vancomycin sensitive and resistant S.aureus have now 
emerged (EARSS Annual Report, 2008), driving the need for novel antibiotic agents.
Worryingly, bacterial antibiotic resistance is not limited to opportunistic strains. 
Annually, approximately 15 million infectious disease-related deaths are reported 
worldwide, with a disproportionate number coming from developing countries. 
Antibiotic resistance is beginning to emerge in these pathogenic bacteria, with ever 
increasing cases of resistant Mycobacterium tuberculimtm  (the pathogen responsible 
for tuberculosis) being reported (reviewed in (Jain and Mondal, 2008)). Prior to the 
introduction o f  antibiotics in the 1940-50s, the tuberculosis survival rate was only 
50% (Coates et a/., 2002), illustrating how effective antibiotic treatments are 
essential for global health. Currently, extensively drug-resistant tuberculosis (XDR- 
TB) is treatable using a combination o f  drugs to which the organism still shows 
susceptibility (Jassal and Bishai, 2009). The problem of XDR-TB is worsened by the 
incompatibility o f  certain antibiotics with drugs used to treat HIV (Koul el a!., 2011), 
reducing the number of drugs available to treat tuberculosis in HIV-positive patients. 
This, and the emergence of fully resistant tuberculosis may one day render the 
disease untreatable.
The emergence of multidrug resistant bacteria serves to remind us o f  how modern 
healthcare is dependent on effective and reliable antimicrobial agents.
1.1.2 The slowing of novel antibiotic development
In the last three decades, only two new categories of antibiotic have been 
successfully developed and marketed (Linezolid in 2000 and Daptomycin in 2003) 
(Coates et a /., 2002; Woodworth et a l, 1992) with all others being modifications of 
existing drugs. Although the global market for antimicrobial agents in 2008 was 
estimated to be worth US $24billion, a number o f  key pharmaceuticals no longer 
develop new drugs in the field (for example, Roche), and Eli Lilley, the company
7
which developed vancomycin, currently has no novel antimicrobials in their 
production pipeline. This slowing in interest in antimicrobials is largely believed to 
be happening due to the increased financial incentive o f  producing drugs to treat 
chronic illnesses which require longer courses o f  drugs. In addition, the rate at which 
resistant strains emerge to novel antibiotics shortens the financial lifespan o f  the 
drugs, making them a less attractive research area.
The problem o f antibiotic resistance is being addressed by implementing a number o f  
measures to slow its progression. For example, reducing the misuse of antibiotics 
(often the mis-prescription o f  antibiotics for viral complaints) as well as increasing 
hygiene and sterilisation protocols in hospitals has led to an apparent containment in 
the number o f  reported cases o f  MRSA in the UK (EARSS Annual Report, 2008). 
However, these methods will only slow the spread o f  fully resistant pathogenic 
bacteria and therefore there is a vital requirement for novel antibiotics. One 
promising source o f  novel drugs may come from the study and development of 
natural antimicrobial peptides o f  the innate immune system.
1.2 ANTIMICROBIAL PEPTIDES OF THE INNATE IMMUNE 
SYSTEM
Antimicrobial peptides are diverse and are distributed throughout both the plant and 
animal kingdoms, where they provide a non-specific “first defence” against invading 
microbes. They are generally short, positively charged (cationic) peptides which fold 
to form amphiphilic structures. This optimises their ability to insert specifically into 
microbial cell walls in order to permeabilise them (Ganz, 2003). Furthermore, 
antimicrobial peptides possess a broad, non-specific spectrum of antibiotic activity 
and are microbicidal to a variety o f  organisms, including both gram positive and 
negative bacteria, enveloped viruses, fungi and protozoa (Zasloff, 2002). To further 
this effect, certain peptides have been shown to modulate the adaptive immune 





















Figure 1.4 Roles of innate host antimicrobial peptides (taken from 
Hancock and Sahl, 2006)
Host antimicrobial peptides taken on a dual role in fighting microbial attacks. The 
peptides directly attack microbial membranes while recruiting cells from the adaptive 
immune system to the site o f  infection.
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Despite the high costs associated with peptide synthesis, the above properties make 
antimicrobial peptides attractive candidates for novel antibiotic drugs. Accordingly, 
companies including Novobiotics, AM-Pharma and Polymedix are carrying out 
clinical trials using derivatives of natural antimicrobial peptides (Hancock and Sahl, 
2006).
1.2.1 Categories of antimicrobial peptide
The antimicrobial peptides can be subdivided into three families based on their 
structure and primary sequence: Group I: linear, a-helical peptides with a lack of 
cysteine residues (e.g. LL37 from humans, magainins from Xenopits); Group II: 
peptides rich in cysteine residues which form stabilising disulphide bonds (e.g. 
defensins) and Group III peptides (histatins) which are enriched with a high 
proportion of one or two amino acids (e.g. porcine PR-39) (Bals, 2000). In humans, 
the three main categories o f  antimicrobial peptide are the cathelicidins, P -defensins 
and histatins.
1.3 THE DEFENSIN FAMILY
The defensins comprise one o f  the largest, most common groups o f  antimicrobial 
peptides and are found in species throughout the animal and plant kingdom, 
including fungi, arthropods, plants, molluscs, primates, chickens and platypus (Froy 
and Gurevitz, 2003; Lehrer, 2004; Patil el a/., 2004; Patil el a l., 2005; Thomma et al., 
2002; Whittington et al., 2008; Xiao et al., 2004).
They are small (3.5-4.5kDa in mammals), positively charged (cationic) cysteine-rich 
peptides, characterised by the presence of even numbers o f  conserved cysteine 
residues. These residues form sets of intramolecular disulphide bonds which act to 
stabilise the peptides’ secondary and tertiary structure. In mammals, the defensins 
can be further sub-divided into a-, P- and 9-defensins according to the spacing and 
connectivity o f  their conserved cysteine residues, as well as their overall structure; 
the a-defensins fold with disulphide bonds forming between cysteines C1:C6, C2:C4 
and C3:C5 (Zhang et al., 1992), the P-defensins are stabilised by bonding between
10
cysteine residues C1:C5, C2:C4 and C3:C6 (Tang et al., 1993) and the cyclic 0- 
defensins cysteines adopt the conformation C1:C6, C2:C5 and C3:C4 (Tang et al., 
1999). These conformations are summarised in Figure 1.5.
The specific categories of defensin have not yet been observed in organisms outside 
the mammalian family; however defensin-like peptides exist in other species, which 
often adopt a tertiary structure similar to that o f  the P-defensins (Figure 1.6). The 
evolutionary relationship between these defensins and mammalian defensins remains 
somewhat unclear but one theory argues that they all descended from a common 
ancestral gene following gene duplication events and subsequent divergence 
(reviewed in Hughes, 1999). However, the defensins have been subject to very rapid 
evolution driven by positive selection (reviewed in (Semple et al., 2006)) and share 
very little primary sequence homology between and within subfamilies and species 
(their homology lies at the level o f  secondary and tertiary structure). This has led to 
proposals that the plant, platypus and insect defensins have arisen via convergent 
evolution, and share no evolutionary relationship with the rest o f  the p-defensin 
group (Froy et a l., 2005; Whittington et al., 2008). However, a contradictory report 
has found that, based on 3D structure, the homology between plant and insect 
defensins and human P-defensins is greater than that between the human a- and p- 
defensins. This supports the suggestion in Hughes, 1999 that a single ancestral 
eukaryotic defensin is likely to have originated prior to the divergence o f  plants and 
animals (Thomma et a l., 2002).
Additional support for the divergent evolution o f  the vertebrate a- and P-defensin 
families was reported in Xiao et a /., 2004 where comparative analysis of the chicken, 
mouse and human genomes suggested that all modem defensins evolved from a 
single ancestral P-defensin-like gene. This appears to have undergone rapid 
duplication throughout evolution to give rise to the clusters of defensins seen in 
current genomes (Xiao et a l., 2004).
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Figure 1.5 The mammalian defensin subfamilies (taken from Selsted and 
Ouellette, 2005)
The defensin subfamilies are largely categorised according to the spacing and 
connectivity o f  their six conserved cysteine residues. As shown above, the a- 
defensins show a C1:C6, C2:C4, C3:C5 pattern, the (3-defensins show a C1:C5, 












Figure 1.6 The defensin family shows homology in the secondary and 
tertiary structures (taken from Thomma et al., 2002)
Due to rapid, diversifying evolution, the defensin genes show little homology at the 
primary sequence level, even when aligning mammalian a- and P-defensins. 
However, this figure shows that the mammalian P-defensins and P-defensin-like 
peptides found in other vertebrates, invertebrates and plants retain a similar folding 
pattern. This level o f  homology is not seen in the a-defensins.
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It has been reported that a-defensins arose specifically in the mammalian lineage 
from two ancestral (3-defensins following a gene duplication event. Further 
duplications and positive, diversifying selection are thought to have given rise to the 
modern a-defensin cluster (Patil et al., 2004). 0-defensins are thought to have 
originated from the fusion of two ancestral a-defensins, following the divergence of 
the Old World Monkeys from other hominids (Nguyen et al., 2003).
Regardless of their species, the defensins are best-known for their antimicrobial 
activity. However, roles for these molecules are beginning to emerge in a variety of 
processes including the chemotaxis of key adaptive immune response cells, wound 
repair and inflammation (summarised in Figure 1.7).
1.3.1 The a-defensins
The a-defensins were first discovered as isolates from human and rabbit neutrophil 
granules (Ganz et al., 1985; Selsted et al., 1985) and were the first members o f  the 
defensin family to be identified. The name “human neutrophil peptide” (HNP) was 
coined and it was found that a mixture of H NPl, HNP2 and HNP3 was able to kill 
both gram positive and gram negative bacteria (S.aureus, P.aeruginosa  and E.coli).
a-defensins are encoded by genes comprising three exons, initially synthesised as 
prepropeptides (Lehrer et al., 1993) and a cluster containing HNP 1-4 has been 
mapped to human chromosome 8p23.1 (Sparkes et al., 1989).
Polymorphonuclear leukocytes (PMNs) synthesise, process and package H N P l-4 
into their azurophil granules (Valore and Ganz, 1992). These myeloid defensins are 
synthesised as inactive precursors and metabolic labelling studies have shown that 
these preprodefensins are processed to form mature peptides via two intermediates: a 
75 amino acid, cytoplasmic preprodefensin, (containing a signal sequence) and a 56 
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Figure 1.7 The a- and (3- defensins have varied, diverse roles in host 
defence (taken from Lehrer, 2004)
The defensins are best known for their antimicrobial activity however they also have 
a role in a number o f  additional defence mechanisms including wound repair, 
chemotaxis, opsonisation and inflammation.
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Following cleavage, the active mature peptide is stored in granules ready for its 
release within the phagolysosomes (Valore and Ganz, 1992).
Following initial work on FIN PI -4, a further two enteric a-defensins, FID-5 and HD- 
6 showing expression in the intestinal epithelia and Paneth cells were discovered 
(Jones and Bevins, 1992). Interestingly, whilst myeloid a-defensins such as HNP1-4 
are not found in mouse (Eisenhauer and Lehrer, 1992), enteric defensins -  
“cryptidins” have been purified from the mouse intestine and skin ((Ouellette and 
Selsted, 1996; Selsted et a/., 1992). Less is known about the processing o f  these 
peptides but, unlike PMNs, Paneth cells store the HD-5 and HD-6 as propeptides 
until they are secreted into the lumen for extracellular processing (Cunliffe et al., 
2001). It has been demonstrated that this can be performed by Paneth cell trypsin 
(Ghosh et al., 2002) or by matrilysin in mice (Wilson et al., 1999). Deletion of 
matrilysin results in mice with a reduced antibacterial activity against the gram 
negative species S.typhimiirinm  and E.coli (Wilson et al., 1999).
1.3.2 a-defensin structure and function
As described previously, the a-defensins form a tertiary structure stabilised by 
disulphide bonds formed between cysteine residues C1:C6, C2:C4 and C3:C5 (Zhang 
et al., 1992). Analysis of the crystal structure o f  HNP-3 revealed that its three 
internal disulphide bonds stabilise a dimeric tertiary conformation consisting mainly 
o f  a three-strand, antiparallel (3-sheet (Hill et al., 1991). X-ray-based structural 
analysis o f  HD-5 and HD-6 revealed that these peptides also form dimers in solution 
and that the tertiary structures o f  HNP3 and 4 are highly similar to HD-5 and HD-6 
(Szyk et al., 2006)(Figure 1.8).
Since the discovery of the a-defensins, much work has been carried out to further 
characterise the range of their antimicrobial activity. Strikingly, the activity o f  the 
individual defensins is variable and not limited to bacterial killing -  HNP1 can 
directly inactivate herpes simplex virus (HSV) 1 and 2, cytomegalovirus and 
influenza by incubation alone (Daher et al., 1986), as well as showing activity 
against the fungus Candida albicans (Lehrer et al., 1988). In contrast, HNP2 and
16
HNP3 HNP4 HD5 HD6
Figure 1.8 The tertiary structure of the a-defensins (taken from Szyk et 
al., 2006)
Analysis o f  these four human a-defensins revealed a conserved tertiary structure, 
comprising a triple strand anti-parallel [3-sheet.
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HNP3 are less active and only show activity against HSV-1, with HNP2 showing 
some activity against C.albicans. Interestingly, antimicrobial activity was shown to 
be greatly affected by salt concentrations, with killing being shown to be more 
effective under hypotonic conditions than physiological (Miyasaki et ah, 1990).
A further role for the a-defensins was identified when it was demonstrated that 
HNP1, HNP2 and HNP4 were chemotactic for monocytes, leading to speculation that 
they might be involved in recruiting monocytes (via neutrophils) to inflammatory 
sites ((Territo et ah, 1989). This is supported by the finding that human neutrophil 
defensins selectively induce C'D4" and C D 8’ naive T cells and are chemoattractive 
for immature dendritic cells. This activity is abrogated by treatment with pertussis 
toxin, suggesting that a G-coupled receptor is involved (Yang et a /., 2000). Finally, 
HNPs have also been shown to strongly bind C lq  following activation o f  the 
complement system (Panyutich el ah, 1994).
1.3.3 The 0-defensins
The 0-defensins represent the newest members o f  the defensin family and were 
identified in 1999 from the leukocytes o f  Rhesus macaques (Tang et al., 1999). They 
are 18-residue peptides characterised by a distinct cyclic structure. Rhesus 9-defensin 
1 (RTD-1), the first reported 0-defensin, is the product o f  the posttranslational “head- 
to-tail” ligation of two a-defensin-related nonapeptides, RTD la and R TD lb  (Tang et 
al., 1999). As with the a- and [3-defensins, the structure is stabilised by 
intramolecular disulphide bonds (Figure 1.9).
RTD-1 is antimicrobial towards both gram positive and gram negative bacteria, and 
fungi including C.albicans. This activity is salt-insensitive, a trait thought to be 
conferred by the peptide’s cyclic nature. It has been speculated that this cyclic 
structure makes the peptide more resistant to inflammation-recruited proteases and 
exopeptidases (Tang et ah, 1999).
Two further 0-defensins, RTD-2 and 3 have also been purified from the bone marrow 
of rhesus monkeys (Leonova et ah , 2001). These peptides are homologous to RTD-1 
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Figure 1.9 The 9-defensins are formed by a head-to-tail ligation of two 
a-defensin-like precursors (taken from Tang etal., 1999)
The 0-defensins are formed via the posttranslational head-to-tail ligation o f  two 
nonapeptide
precursors, R T D la  and RTDlb. This occurs via an unknown mechanism.
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they also show antimicrobial activity against S.aureus, C.albicans and E.coli, 
although RTD-2 is the least active o f  the three.
Although humans do not express 0-defensins, mRNA from at least two o f  these 
peptides have been isolated from human bone marrow, and a further four have been 
found bioinformatically (Cole et a/., 2002; Pazgier et al., 2006; Selsted, 2004). These 
transcripts are never translated due to the presence o f  a stop codon in the signal 
peptide region (Cole et a/., 2002). The sequences o f  these pseudogenes are 
homologous to the macaque 0-defensins. A synthetic preparation o f  the “corrected” 
version of one of these pseudogenes (termed “retrocyclin”) demonstrated anti­
microbial activity as well as the protection o f  CD4+ cells against HIV-1 infection (in 
vitro) by inhibiting proviral DNA formation. This interesting finding has led to work 
investigating the possibility for “reawakening” human 0-defensin pseudogenes as 
potential therapeutics (Venkataraman et a/., 2009). Although the mechanism by 
which the nonapeptide precursors of the 0-defensins are ligated is unknown, it has 
recently been shown that human cells are capable of carrying out this process in vivo. 
By utilising aminoglycoside treatment to reduce the integrity o f  translation (thereby 
bypassing the pseudogene stop codon), functional 0-defensin peptides have been 
produced in human cells (Venkataraman at al., 2009). Since this activity protected 
the cells from HIV-1 infection, this 0-defensin research presents interesting 
opportunities for the field o f  HIV therapeutics and prophylactics.
1.3.4 The p-defensins
The first (3-defensin was isolated from bovine tracheal epithelial cells (“tracheal 
antimicrobial peptide, TAP”), where it was noted as being similar to, but distinct 
from the a-defensins (Diamond et al., 19 9 1). This was followed by the discovery o f  
thirteen structurally homologous peptides from bovine blood neutrophils (B N B D l- 
13) (Selsted et al., 1993) whereupon this new family were reclassified as the (3- 
defensins. Further work demonstrated that the P-defensins showed different cysteine 
spacing and connectivity patterns to the a-defensins (Figure 1.5) (Tang and Selsted, 
1993), with a characteristic C1:C5, C2:C4 and C3:C6 binding pattern. The p- 
defensin family in humans is located in the same locus as the a-defensins at 8p23.1.
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1.3.5 The structure and interactions of f5-defensins
As with the a-defensins, the P-defensin genes encode prepropeptides consisting o f  a 
signal sequence, pro-sequence and six-cysteine mature peptide (Patil et a /., 2005). 
Generally, in mammals the peptides are encoded over two exons, with the signal and 
pro-sequence encoded on the first exon and the mature peptide on the second.
The mature P-defensins fold to form an amphipathic structure comprising a triple­
stranded antiparallel P-sheet, stabilised by intramolecular disulphide bonds, in a 
similar way to the a-defensins. However, unique to the p-defensin structure is an N- 
terminal a-helix, which may be important for the peptide’s chemotactic properties (J 
Lubkowski, personal communication).
1.4 HUMAN AND MURINE p-DEFENSINS
The first mammalian P-defensin to be documented was TAP (see previous section), 
which was rapidly followed by lingual antimicrobial peptide (LAP), which was 
isolated from bovine tongues (Schonwetter et al., 1995). Since then the isolation and 
characterisation of the mammalian p-defensins has blossomed. In this section, the 
well-characterised peptides in human and mouse will be described and the 
association o f  variant P-defensin expression and disease will be discussed.
1.4.1 Human P-defensins
Since their initial discovery, four human P-defensins have been characterised in 
detail, with more than 28 others being reported using bioinformatical searches o f  the 
human genome (Schutte el al., 2002).
Human P-defensin 1 (HBD1) was originally isolated from human blood filtrates, 
where it was noted that it shared homology to the previously described bovine and 
chicken P-defensins (Bensch et al., 1995). Constitutive HBD1 expression has been 
detected in normal epithelia from the trachea, bronchi, airways, mammary gland, 
salivary gland, testis, thymus, small intestine and skin (Fulton et al., 1997; McCray
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and Bentley, 1997; Zhao et al., 1996), with particularly high concentrations being 
detected in the kidney, loops o f  Henle, reproductive tract and urine (Valore et al., 
1998).
As with the a-defensins, recombinant HBD1 showed salt-sensitive bactericidal 
activity against E.coli (Valore et al., 1998), however, the expression of HBD1 is not 
up-regulated in response to infection. A recent report has suggested that HBD1 
becomes a more potent antimicrobial under reducing (anaerobic) conditions. It was 
shown that following the reduction of the peptide’s disulphide bonds, the peptide 
acquired effective antimicrobial activity against gram positive gut commensals 
(Schroeder et al., 2011).
Human (3-defensin 2 (HBD2) was isolated following the observation that patients 
with psoriasis suffer from fewer skin infections than expected, and it was 
hypothesised that psoriatic skin lesions might produce antimicrobial peptides. HBD2 
was purified from these lesions and found to be antimicrobial to P.aeruginosa  and 
C.albicans, but was ineffective against gram positive strains (Harder et al., 1997). 
However, this activity is salt-sensitive (Bals et a/., 1998).
Unlike H BD1 , HBD2 is up-regulated in response to TNFa and bacteria, and was the 
first defensin found to be up-regulated in this manner. In addition, constitutive 
expression of HBD2 was detected in the lung and trachea, with lower levels being 
found in the kidney, uterus and salivary gland (Harder et al., 1997). More recently, it 
has been shown that T h l7  cells (a subset o f  CD4 T cells) also induce HBD2 via the 
cytokine IL-22 (Liang et al., 2006).
Human [l-defensin 3 (HBD3) was initially identified as an anti-gram positive factor 
from psoriatic scales cloned from keratinocytes (Harder et al., 2001). This followed 
the discovery that psoriatic lesion-derived HBD2 had no effect on gram positive 
bacteria. Impressively, HBD3 demonstrates a salt-insensitive spectrum o f  
antimicrobial activity against MRSA, vancomycin-resistant E.faecium  and the 
notoriously hardy B. cepacia (Garcia et al., 2001a; Harder et al., 2001). Moreover, 
structural analysis o f  S.aureus treated with HBD3 revealed signs o f  cell wall 
perforation, demonstrating a possible mechanism o f action for the peptide (Harder et
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al., 2001). The reported action o f  HBD3 against B.cepacia  is particularly significant 
in the pathology of cystic fibrosis (CF), where no effective antibiotic treatment is 
available for CF sufferers with acute B.cepacia infections. This organism is 
notoriously resistant to both antimicrobial peptides and antibiotics and has even been 
reported to have utilised penicillin as a carbon source (Beckman and Lessie. 1979).
Expression o f  HBD3 is observed in the epithelia o f  multiple organs, including the 
heart, skeletal muscle, placenta, skin, tonsils, oesophagus, testis trachea and foetal 
thymus (Jia el al., 2001). In addition, this expression is increased following 
stimulation with IFN-y , TNFa, IL-lf3 and contact with bacteria (Garcia et al., 2001a; 
Harder et al., 2001; Jia et al., 2001).
Human (3-defensin 4 (HBD4) was first detected following genomic searches (mainly 
BLAST-based)(Garcia et al., 2001b). The distribution o f  its transcripts was 
widespread and the highest recorded expression was found in the testis. Lower levels 
o f  expression were also found in the uterus, neutrophils, thyroid gland, lung and 
kidney, but no detectable expression was reported elsewhere (Garcia et al., 2001b). 
As with HBD2 and HBD3, HBD4 was found to be induced upon treatment with heat- 
killed P.aeruginosa  and S.pneumoniae, however single immune components such as 
IL-la , IL-6, IFN-y or TNFa had no effect on expression.
As with HBD1 and HBD2, HBD4 showed activity against gram negative bacteria 
and weak activity against gram positive, but this activity was salt-sensitive.
HBD5 and HBD6 were discovered following a “mining” approach on the human 
genome, and epididymis-specific expression was reported for these peptides 
(Yamaguchi et a/., 2002). Following the discovery o f  HBD5 and HBD 6 , more 
complex genomic searches utilising hidden Markov models in combination with 
BLAST searches identified a further 28 new human (3-defensins, along with 43 
mouse peptides (Schutte et al., 2002). Preliminary expression studies completed at 
the time suggested that many of these sequences were transcribed, although a number 
of these were pseudogenes and included premature stop codons.
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1.4.2 Murine P-defensins
As with the human P-defensins, more murine p-defensins have been reported than 
have been functionally analysed. As of February 2 0 11, 49 murine defensins were 
described on the Ensembl database, however only three key genes will be discussed 
in this section.
The first murine P-defensin to be detected was D efb l, a homologue o f  HBD1 
showing expression at high levels in the kidney, with lower expression in the brain, 
heart, lung, uterus, spleen, muscle, stomach and small intestine (Huttner, 1997). Like 
HBD1 , the gene was found to map to chromosome 8 with the a-defensin cluster and 
the genomic organisation of the gene (two exons, separated by a single long intron) 
was similar to that o f  HBD1 (Bals et al., 1998; Morrison et al., 1998).
The activity o f  Defbl was again, similar to HBD1 with salt-sensitive activity against 
P.aeruginosa, but also displayed bactericidal effects on the gram positive bacteria 
E.coli and S.aureus (Morrison et a l., 1998).
D e fb P ' mice were not hampered in the clearance of S.aureus from their airways, but 
were found to excrete a significantly higher level o f  Staphylococcus species in the 
bladder, suggesting a role for Defbl in the resistance o f  urinary tract infections 
(Morrison et al., 2002). Further characterisation o f  this model showed that mutant 
mice also exhibited a delayed clearance of H. influenzae from the lung (Moser el al., 
2002).
Murine P-defensin 2 (Defb2) was reported and found to be expressed in the lungs, 
trachea, skin, uterus and kidney (Morrison et al., 1999) and its expression was found 
to be inducible in response to LPS. This induction following an inflammatory 
stimulus suggests that it may contribute to host airway defence. In addition, it has 
also been shown to bind the chemokine receptor, CCR6 to participate in the 
chemoattraction o f  bone marrow-derived immature dendritic cells (Biragyn et al., 
20 01 ).
Defb3 was initially identified as being a homologue of HBD2. Transcripts were 
detected at low levels in the epithelia of the intestine, airways, bowel, liver and lung 
and were found to be up-regulated in response to P.aeruginosa  inhalation (Bals el
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al., 1999). The peptide was shown to be antimicrobial towards both P.aeruginosa  
and E.coli in a salt-sensitive manner (Bals et al., 1999).
The synteny of the human [3-defensin cluster at 8p23.1and the related murine 
orthologues are depicted in Figure 1.10.
1.4.3 The association of (3-defensins with human disease
The (3-defensin clusters lies at chromosome band 8p23.1, a site which is known to be 
a frequent site of chromosome rearrangements. In 2003, it was found that this region 
is also subject to copy number variation, with most normal individuals carrying 
between 2 and 7 copies (Hollox et al., 2003). A number o f  studies have since 
investigated the effects o f  this variation and several key associations with high and 
low variation and disease have been made.
Crohn’s disease is a chronic intestinal disorder, characterised by gut inflammation. 
An individual’s first occurrence o f  Crohn’s disease often arises following a bacterial 
infection (Stallmach and Carstens, 2002), and it has been suggested that a defect in 
(3-defensin induction may be the reason gut inflammation occurs (Wehkamp et al., 
2005). This model is also supported by the finding that patients with an HBD2 copy 
number o f  less than 4 are more prone to Crohn’s disease (Fellermann et al., 2006). 
However, there is a level o f  controversy in the field, with conflicting reports 
suggesting that increased copy number o f  HBD2 associates with the disease (Bentley 
et a/., 2 0 10).
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A second disorder reported to have (3-defensin aetiology is psoriasis. Psoriasis is a 
skin disorder characterised by redness, scaling and elevated “plaques” . It has been 
shown that HBD2 expression is high in psoriatic lesions (Harder et a l., 2007), but 
further copy number analysis of the P-defensin cluster has revealed that individuals 
possessing more than the modal copy number of 4 cluster copies show an increased 
susceptibility to psoriasis (Hollox and Armour, 2008).
1.5 THE INDUCTION AND FUNCTION OF THE (3-DEFENSINS
The p-defensins exhibit an impressively diverse array o f  biological activities 
including antimicrobial effects and immunomodulation. These activities highlight 
both their importance in vivo and their potential for development as topical and 
systemic therapeutics. The P-defensins are unique within the defensin family in that 
they are inducible at the transcriptional level in response to a number o f  microbial 
stimuli. The induction is often mediated by the Toll-like receptors (TLRs) and it has 
been demonstrated that LPS activation o f  TLR2 leads to an induction of HBD2 
(Hertz et al., 2003), while TLR3 induction following treatment with poly I:C, LPS 
and bacterial peptidoglycan leads to the activation of HBD 1 , HBD2 and HBD3 in 
different cell types (Vora et al., 2004; Schaefer et al., 2005).
The biological activities resulting from the induction o f  the P-defensins will now be 
described in greater detail.
1.5.1 Antimicrobial activity
One o f  the most striking activities o f  the P-defensins is their collective ability to 
neutralise a wide range o f  microbes ranging from fungi and bacteria to enveloped 
viruses. This ability has been tested (in vitro) in the majority of reported, purified P- 
defensins and has been found to be most effective in low salt concentrations (Ganz 
and Lehrer, 1999; Garcia et al., 2 0 0 lb; Selsted et a!., 1993). Interestingly, in some 
respects a degree of degeneracy appears to exist amongst the P-defensins; HBD1, 2 
and 3 all show some degree of activity against gram negative bacteria (Garcia et a/.,
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2001a; Harder et al., 1997; Valore et a /., 1998), however potent activity against gram 
positive species seems to be niost obvious in HBD3, and is absent in HBD2.
The antimicrobial activity o f  individual p-defensins is determined by a number o f  
characteristics including their overall positive charge and hydrophobicity (a measure 
o f  the molecule’s ability to insert into microbial membranes). As described earlier, 
all (3-defensins comprise a set of three antiparallel beta-sheets (stabilised by internal 
disulphide bonds) and an alpha-helix at the N-terminus. Therefore, the individuality 
and specificities o f  the P-defensins has been suggested to originate from the unique 
and variable arrangements o f  the non-conserved residues (Sahl et al., 2005; Semple 
et a l., 2003). However, a conclusive and comprehensive explanation for this 
variation has not yet been published.
The activity o f  the majority o f  the mammalian P-defensins has been reported to be 
salt-sensitive. This has sparked debate in the literature as to whether this trait might 
play a part in the pathogenesis o f  cystic fibrosis. Cystic fibrosis is the most common 
lethal genetic disease in Caucasian populations. It is caused by mutations in the 
cystic fibrosis transmembrane receptor (CFTR) and results in dysfunctional ion 
transport across epithelial membranes. The disease affects many systems, but the 
most severe effects are seen in the lung, where the production of thick, mucus allows 
for chronic bacterial colonisations and repeated acute infections (Parmar and Nasser, 
2005). There are a number o f  theories which attempt to explain this susceptibility to 
infection. One proposal suggests that cystic fibrosis epithelia contain elevated 
sodium chloride concentrations, rendering HBD1 inactive (Goldman et a l., 1997). 
However, subsequent studies have failed to find evidence suggesting an elevation of 
salt levels in cystic fibrosis airways (Jayaraman et al., 2001).
1.5.2 Proposed mechanisms of antimicrobial activity
There has been much speculation and study into the mechanism by which P- 
defensins and other antimicrobial peptides function, and to date, there is not yet a 
conclusive answer. While it is not known how the defensins traverse the cell walls of 
bacteria, the root of their antimicrobial action is thought to lie at the cell membrane
28
level. Prokaryotic cell membranes are highly negatively charged and therefore will 
electrostatically interact with the positively charged defensins. Since the outer 
leaflets of eukaryotic cell membranes hold little or no charge, they cannot be targeted 
by the defensins, thus making microbial membranes a unique target for attacking 
host defensin peptides (Matsuzaki, 1999)(Figure 1.1 lb).
Initial studies investigated the interaction between the rabbit alveolar macrophage 
proteins MC’Pl and MCP2 with P.aeruginosa. It was found that both proteins bound 
LPS, suggesting that this provides an “anchor” for the peptides to bind the bacteria. 
The outer membranes were also found to be permeabilised by the peptide and were 
more efficiently phagocytosed by macrophages (Sawyer et at., 1988). This primary 
work implied that antimicrobial peptides might function by attacking the cell walls of 
microbes to permeabilise them and further indicates that the initial attraction between 
the target cell and peptide is electrostatic. This was supported by later work on 
indolicidin (a cationic bovine neutrophil peptide), which showed a high affinity for 
LPS and produced “discrete channels” in E.coli cell walls that led to the disruption of 
the cytoplasmic membrane (Falla et a/., 1996).
This early work, along with the molecular structure o f  P-defensins has led to it being 
accepted that defensins are membrane-attacking, pore-forming agents (Hancock and 
Lehrer, 1998). This is also concurrent with the prokaryotic specificity o f  the P- 
defensins. The presence o f  negatively charged bacterial cell wall structures such as 
LPS (gram negative) and teichoic acid (gram positive) provides a stark contrast to the 
overall neutral charges o f  eukaryotic cell membrane’s cholesterol inserts and 
therefore provide unique microbial targets for the P-defensins to attack.
Three key models have been proposed to describe the mechanism and structure o f  the 
pores formed in bacterial cell walls -  the "barrel-stave” model, the 
“toroidal”/”worm-hole” model and the “carpet” model (Brogden, 2005; Ganz and 
Lehrer, 1999, reviewed in Wiesner and Vilcinskas, 2010).
The barrel-stave model (Figure 1.11a) suggests that peptide helices form a “bundle” 
spanning the membrane, with hydrophilic residues pointing inwards to a central pore.
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Figure 1.11 Proposed mechanisms of action of antimicrobial peptides
(a) The Ihree proposed mechanisms o f  antimicrobial action. All three 
mechanisms rely on the antimicrobial peptides aligning with the bacterial 
membrane and compromising its integrity. The barrel-stave and toroidal 
models propose that peptides aggregate at membrane surfaces and insert 
perpendicularly into the membrane. The barrel-stave model proposes that 
hydrophobic residues align with the lipid cores and the hydrophilic residues 
with the interior of the pore. Instead, the toroidal model proposes that the 
membrane lipids distort so only the lipid cores interact with the antimicrobial 
peptide. The carpet model proposes that peptides aggregate at the membrane 
surface, neutralising charge and acting as a detergent. Figure taken from  
Wiesner and Vi/cinnskas, 2010.
(b ) Due to the zwitterionic nature o f  eukaryotic membranes, the outer leaflets 
carry little net charge, leading to hydrophobic interactions with antimicrobial 
peptides and no membrane breech. However, due to the highly charged 
acidic nature o f  prokaryotic membranes, electrostatic interactions between 
their negative charge and the antimicrobial peptides positive charge allow for 
membrane infiltration to commence. Figure taken from  Matsuzaki, 1999.
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The peptides would oligomerise across the pore to behave similarly to a 
transmembrane protein. The fungal antimicrobial peptide, alamethicin has been 
shown to behave in this manner, following x-ray scattering and neutron scattering 
analyses (Ganz and Lehrer, 1999; Oren and Shai. 1998).
The toroidal/worm-hole model is similar to the barrel-stave model, however it 
assumes that the antimicrobial peptides associate only with the lipid “heads” of the 
membrane. To accommodate this, the lipid membrane would bend to coat the inside 
o f  the whole, producing a continuous “worm-hole”-like structure (Figure 1.1 la).
In contrast, the carpet model (Figure 1.11a) suggests that peptides accumulate on the 
surface of the cell via electrostatic attraction. The peptides would cover the surface 
of the membrane until a threshold is reached where they effectively neutralise the 
negative charge o f  the bacterial wall. This is proposed to have a detergent effect, 
disrupting the membrane and allowing the formation o f  transient holes through 
which peptides and other molecules can pass (Ganz and Lehrer, 1999). This has been 
proposed to occur without the peptides ever spanning the membrane themselves.
It is unlikely that only one o f  these mechanisms is the entirely accurate, and more 
probable that a combination is involved in the actual mechanism. The amphipathic 
nature of the (Tdefensins supports all models, however the specific oligomerisation 
necessary for the barrel-stave mechanism to work has not yet been demonstrated in 
P-defensins (Pazgier el a/., 2006). It is also likely that the true mechanism is more 
complicated than either o f  the proposed models. An elegant piece of work 
demonstrated this when model vesicular membranes were synthesised from both 
random lipid mixes and mixes based on the E.coli membrane. Upon treating with 
rabbit neutrophil defensins, it was shown that the E.coli membrane was specifically 
attacked, causing fast leakage via “ large, transient membrane lesions” (Hristova et 
al., 1997). The presence of transient lesions supports the carpet model, but the 
specificity o f  the response implies that other factors are involved.
The mechanism by which this membrane breach causes cell death is also unknown 
and an added complexity of these studies is the difficulty involved with separating 
mechanisms o f  bacterial killing from artefacts o f  cell death. For example, it has been
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shown that D e fb l l8  can kill E.co/i in vitro following a fifteen minute incubation. 
However, microscopic analysis of the bacterial cell walls showed cellular damage 
occurring up to two hours after cell death (Yenugu et a/., 2004).
It has also been suggested that following a cell membrane breach, antimicrobial 
peptides are able to enter the cell to disrupt metabolic processes (Brogden, 2005; 
Hancock, 1997).
1.5.3 Suitability of the P-defensins as novel therapeutics
The potent antimicrobial activity o f  the [3-defensins makes them good candidates for 
development into novel antibiotics and antifungals. Clinical trials are currently 
ongoing to investigate the suitability of derivatives o f  the peptides for treatment o f  a 
number o f  diseases. It is therefore prudent to consider the mechanisms o f  resistance 
which may arise in response to treatment with therapeutic P-defensins.
The resistance mechanisms that microbes already employ and might develop in the 
future are o f  extreme importance when considering the use o f  P-defensins as 
therapeutics. In particular, the potential for resistance must be understood to guard 
against cross-resistance between synthetic antimicrobial therapeutics and innate, 
natural defences. A recurring theme in bacterial resistance mechanisms is the 
changing o f  the charge on the bacterial cell wall.
S.aureus is able to tolerate relatively high concentrations o f  some P-defensins, and 
HBD2 in particular has no reported activity against this organism. In 1999, a study 
was undertaken to identify key genes responsible for this insensitivity. A number of 
mutagenised strains of S.aureus showing increased sensitivity to the antimicrobial 
peptide gallidermin were obtained. It was found that a proportion of these mutants 
exhibited an altered teichoic acid structure which lacked D-alanine residues. This 
increased the overall negative charge o f  the cells, allowing them to bind more 
positively charged peptides. The sensitivity of these cells extended to HNP1, 2 and 3 
(Peschel et a/., 1999). This study implies that altering the surface structures and 
charge o f  bacterial cells will have a direct effect on their resistance to antimicrobial 
peptides.
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A further gene to have been implicated in bacterial resistance to (3-defensins is the 
virulence factor MprF (Peschel et ah, 2001). In this study, it was found that mprF  
mutants demonstrated attenuated virulence in vivo , and that these mutants were 
unable to modify a key inner membrane component phosphatidylglycerol with L- 
lysine. This normally results in a reduction o f  net negative charge in the membrane 
and serves to repel positively charged peptides (Staubitz et al., 2004).
1.5.4 Chemoattractant properties
Chemotaxis is the process by which a cell’s movement is defined by an extracellular 
chemical gradient. It was first observed in an immunological setting when leukocytes 
were found to migrate towards sites o f  corneal irritation in rabbits (McCutcheon,
1946). Chemotaxis is now known to be responsible for a variety o f  immunological 
processes including the recruitment of leukocytes to sites o f  infection and the 
movement o f  lymphocytes around the body (reviewed in (Jin el al., 2008)). Various 
immune cells are thought to move around the bloodstream and lymphatic system in 
search o f  pathogenic activity. Chemotactic gradients act as “pathways” leading the 
immune system to the source o f  invading pathogens (Delves and Roitt. 2000a, b). 
Cells can migrate along these gradients both in the bloodstream and across epithelia 
without damaging the intercellular tight junctions (Burns et ah, 2000).
One group o f  peptides that control chemotactic activity are the group of low 
molecular weight chemokines (Murdoch and Finn, 2000). These peptides have been 
shown to be selectively chemoattractive for leukocytes in vitro and elicit their effects 
via the binding of transmembrane G-protein-coupled receptors (Murphy, 1994). This 
binding elicits a signalling cascade in the target cell with transient increases in C a2+, 
cAMP and cGMP being observed (Parent and Devreotes, 1999). A summary of 
chemokine activity is shown in Figure 1.12.
Both the a- and (3-defensins have been reported to have chemotactic properties at 
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Figure 1.12 Chemokine activity (taken from Luster, 2002)
The chemokines are involved in a number of functions and coordinate the trafficking 
o f  a variety o f  immune cells, including dendritic cells and B and T cells. This helps 
mediate the immune response.
Toll-like receptors (TLRs) are activated specifically by a number o f  different 
microbial stimuli, and in turn the TLRs mediate a local release o f  chemokines, 
resulting in the chemoattraction o f  immature dendritic cells. This also results in the 
recruitment o f  naive T and B cells from the blood into the lymph nodes. Here, 
contact is made with dendritic cells and activation occurs.
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properties are important as they provide a mechanism for |3-defensins to act as “ link” 
peptides between the innate and adaptive immune responses.
As discussed earlier, HBD1 and HBD2 have been reported to be chemoattractant for 
both immature dendritic cells and memory T cells. Additional work showed that 
these (3-defensins are selectively chemotactic for cells expressing the chemokine 
receptor CCR6 in vitro (Yang et a!., 1999). The murine (3-defensin, a synthetic 
hybrid Defb2 has been reported to mirror the chemotactic abilities of HBD1 and 
HBD2 (Biragyn et a /., 2001).
In addition, HBD3 and HBD4 are chemoattractive for monocytes. Recent data has 
suggested that the receptor responsible for this interaction is the CCR2 chemokine 
receptor (Jin et a/., 2010; Rohr! et a t ., 2010). Other antimicrobial peptides have been 
shown to chemoattract monocytes via alternative receptors including LL37 (a human 
cathelicidin), which acts via formyl peptide receptor-like 1 (FPRLl)(Yang et al., 
2000 ).
A further factor affecting the [3-defensin’s chemoattractive properties is their ability 
to form dimers. A murine variant of Defb8, Defrl was discovered to contain only 
five cysteine residues (Morrison et al., 2002). This allowed the peptide to form 
dimers (Campopiano et al., 2004) via the free fifth cysteine residue (which was not 
bound via an intramolecular disulphide bond, as in six-cysteine defensins). This 
peptide maintains chemoattractive properties similar to those seen with Detb8. This 
activity was retained even when the peptide was monomerised following DTT 
treatment (Taylor et al., 2009). This, combined with the fact that D efbl4  maintains 
its chemoattractive properties even when five out o f  its six conserved cysteines have 
been substituted with tyrosine (Tyrrell et al., 2009) suggests that the P-defensin 
cysteines may only serve to stabilise the structure and perhaps perform some other 
function. In a-defensins, it has been suggested that the cysteines may stabilise the 
defensin fold in order to protect the peptides against degradation by serum proteases 
(Maemoto et a!., 2004).
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1.5.5 A surprising role for p-defensins in pigment distribution
In recent years, increasingly diverse roles have been reported for the P-defensins. A 
paper in 2007 reported a role for canine (3-defensin 3 (CBD103) in pigment type- 
switching in domestic dogs (Candille et a/., 2007).
The mechanism by which pigmentation occurs in dogs is largely conserved 
throughout mammals. Skin and hair colour is mainly the result of combinations of 
two pigments: eumelanin (brown/black) and pheomelanin (red/yellow)(reviewed in 
(Rees, 2003)). The ratio o f  synthesis o f  these pigments depends on a balance 
achieved between two principle genes: Agouti and Melanocortin 1 receptor 
(A/c7r,)( Anders son, 2003; Klungland and Vage, 2003). In this system, the MCI R 
receptor acts like a molecular “switch” and when activated by a-Melanocyte 
Stimulating Hormone (a-MSH), signals via cAMP to allow for the exclusive 
production of eumelanin by the melanocytes. The presence o f  the physiological 
antagonist, Agouti will inhibit M clr  activity and lead to the production of 
pheomelanin. This is summarised in Figure 1.13.
In 2007, it was found that dog coat colour is controlled by an additional locus 
(termed the “K” locus). The K locus was found to segregate with black coat colour 
and behaved in a dominant manner. The locus was mapped to the (3-defensin cluster, 
where a three base pair deletion in the CBD103 gene w'as detected and results in the 
loss of the first amino acid of the mature peptide. (Candille et a/., 2007). Expression 
of both the mutant and wild type CBD103 in mice resulted in the dominant 
inheritance o f  black coat colour, even in the presence o f  Agouti. It was also shown in 
vitro that CBD103, HBD1 and HBD3 bind the Mcl r  receptor, leading to the proposal 























Figure 1.13 The control of pigment-type switching (taken from Candille et 
a/., 2007)
The melanocortin 1 receptor, M clr, is thought to maintain a basal “resting” level o f  
activation, leading to the production o f  cAMP. This activates a signalling pathway, 
resulting in the synthesis of the black pigment, eumelanin. This pigment is also 
strongly induced upon the binding of Mc l r  by its agonist a-MSH. However, in the 
presence o f  the Agouti protein, a-MSH is displaced and the production o f  
pheomelanin (yellow pigment) is driven.
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1.6 THE ZEBRAFISH AS A MODEL FOR P-DEFENSIN STUDIES
1.6.1 The zebrafish as a model organism
The zebrafish, Danio rerio , is a valuable model organism. As a small vertebrate 
teleost, it possesses many of the developmental and molecular pathways seen in 
mammals while maintaining the advantages gained from using small invertebrate 
models, such as low maintenance costs. In addition to being more closely 
phylogenetically related to mammals than other invertebrate models, the zebrafish 
also possesses a number of additional qualities which makes it amenable to scientific 
research.
Firstly, zebrafish are small in size and large numbers can be maintained in modest 
aquariums at a fraction o f  the cost of a mammalian facility. In addition, zebrafish 
breed very efficiently and each breeding pair can be expected to produce 200-300 
embryos weekly. This provides large sample sizes for experiments, to allow greater 
degrees of statistical power to be achieved when analysing data.
A further benefit of employing zebrafish is their ex utero development (see Figure 
1.14). Zebrafish embryogenesis is completed within five days o f  development and 
the permeability o f  early embryos means they can be treated with drugs merely by 
adding these to the embryonic growth medium. Early embryos can also be easily 
manipulated by micro-injection o f  DNA, RNA or morpholinos. The embryos remain 
transparent throughout embryogenesis, allowing structures to be examined under a 
light microscope, and are amenable to fluorescence imaging.
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Figure 1.14 The first 24 hours of zebrafish development (adapted from 
Kimmel et al., 1995)
The zebrafish embryo develops rapidly and ex vivo. Initially, the one-cell embryo (B) 
rapidly divides to form a cluster of cells on top of the yolk sac after 2.25 hours of 
development (C-F). Following this, gastrulation begins with cells migrating around 
the yolk, reaching the “shield” stage after approximately 6 hours (G). The somites 
then start to develop and the patterning, with a distinct eye and tail forming by 12 
hours post fertilisation (hpf)(H). Following 24hpf (J), the embryo has developed 
sufficient nervous ability to react to external stimuli. Pigmentation occurs at 
approximately 28hpf (K) and the majority o f  the organs have fully developed by 
72hpf (L).
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Finally, the zebrafish genome sequencing project has been completed and updated 
assemblies are freely available online, with the next major genome release due in 
2012. Although the genome assembly is still categorised as “preliminary” , publically 
available data is frequently updated. The ZFIN Zebrafish Model Organism Database 
contains up-to-date details on wild type and mutant/transgenic lines available, mutant 
phenotypes and gene expression data, as well as details on anatomy, zebrafish care 
and information on other laboratories worldwide who are also working with 
zebrafish.
Due to its rapid, transparent embryogenesis, zebrafish have traditionally been used as 
developmental models. However in more recent years, the zebrafish model has 
started to be used for the study o f  a variety o f  systems, including the immune system.
1.6.2 The zebrafish immune system
The zebrafish presents a valuable model for the study o f  disease and the immune 
response, and holds the major advantage o f  possessing both an innate and adaptive 
immune system. Since the adaptive immune system is thought to have coincided with 
the emergence o f  jawed vertebrates (Laird et al., 2000), prior to the divergence o f  the 
teleost from other vertebrates, zebrafish share this system with mammals. However, 
the zebrafish has the additional advantage of functioning only with basic innate 
immunity up until at least 4dpf (days post fertilisation) when the first adaptive 
immunity markers become detectable (Allen and Neely, 2010). This presents the 
opportunity to study the innate immune system independently o f  the adaptive within 
the embryonic and larval zebrafish.
In order to comprehensively display the variety and complexity o f  the zebrafish 
immune system, a comparison of the zebrafish and human systems is depicted in 
Figure 1.15. A number o f  studies o f  zebrafish haematopoiesis have revealed that the 
majority o f  human immunity cells have corresponding zebrafish cells, although the 
functionality o f  all these cells has not yet been established.
As shown in Figure 1.15, the zebrafish immune system possesses a well-developed 
complement system with conserved inflammatory proteins including TNFa, various
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interleukins and other chemokines. In addition, the circulating cells include 
neutrophils and macrophages, both o f  which have been genetically engineered as 
GFP fusion proteins, which can be easily visualised in early embryos (Lawson and 
Weinstein, 2002; Mathias et a l., 2006).
The zebrafish has been used as a model to study a number o f  diseases, however the 
modelling o f  Mycobacterium  infections (first described in Prouty et a/., 2003) is 
particularly relevant. Utilising M. marinum  species, it was shown that zebrafish form 
caseating granulomas resembling those seen in humans, following infection. 
Strikingly, the pathology o f  this disease in zebrafish has been claimed to be a better 
model of human tuberculosis than mouse (Phelps and Neely, 2005). In more recent 
work, a comparison between M. marinum  and M. tuberculinum  (human pathogen) 
revealed significant conservation o f  host-pathogen interactions (Tobin and 
Ramakrishnan, 2008), highlighting the relevance o f  the model to tuberculosis studies. 
A recent study also marked the importance of the zebrafish model to tuberculosis 
studies when the study of granulomas caused by M  .tuberculinum  revealed a novel 
mechanism by which mycobacteria can induce the formation o f  granulomas to 
facilitate growth (Volkman et al., 2010).
Zebrafish also possess several additional immune components that make them viable 
for the study o f  (3-defensin function: they have been reported to express homologues 
of both CCR6 (Liu et al., 2009) and its ligand CCL20, as well as an array o f  Toll-like 
receptors. This provides the potential for the study o f  defensin-induced chemotaxis, 
as well as the induction o f  the immune system via the Toll-like receptors. 
Interestingly, the existence of three P-defensin-like genes showing expression in the 
adult zebrafish have also been reported (Zou et al., 2007).
1.6.3 The zebrafish defensins
Zou el al., 2007 reported the expression o f  three zebrafish P-defensin-like genes, 
d e jb ll , defbl2 and defb/3 in various adult tissues, along with a number o f  additional 
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Figure 1.15 A comparison of the human and zebrafish immune systems
(taken from Meeker and Trede, 2008)
This comparative table illustrates the vast similarities between the human and 
zebrafish immune systems. Almost every area o f  the human system has a zebrafish 
counterpart, with the fish system displaying a well-developed innate and immune 
response.
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residues typical o f  the defensin family and following computational analysis, were 
predicted to fold to form three p-sheets, adopting a folding pattern similar to that of 
the P-defensins in plants and mammals (Zou et al., 2007)(Figure 1,16a).
In addition, the zebrafish defensins were shown to share a similar synteny to the 
human P-defensin locus at 8p23.1; defb ll and defbl2 are both located at the same 
locus on chromosome 21, between SPAG1 1 and the olfactory pseudogene 
OR7E157P, as is seen in the human genome (Figure 1.16b).
The expression o f  the zebrafish defensins was originally shown to be varied, with 
defb ll and defbl3  being detected in an number of adult tissues including the gut, skin 
and gills, and defbI2 only in the gut (Zou et al., 2007, Figure 1.16c). Subsequent 
work has reported an increasing anterior-posterior gradient o f  zebrafish defensin 
expression along the adult gut, along with more specific expression o f  defb ll in the 
larval skin and swim bladder (Oehlers et al., 2011).
Beyond these initial studies, however, no functional characterisation o f  the zebrafish 
defensins has been carried out.
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Figure 1.16 The zebrafish p-defensin-like genes (taken from Zou et al., 
2007)
(a) Computational analysis predicted that d e fb ll, defbl2 and defbl3 fold similarly 
to the mammalian (3-defensins, with apparent conservation o f  the triple­
stranded antiparallel p-sheet observed.
(b) The synteny surrounding defb ll and defbl2 on zebrafish chromosome 21 
shows some conservation with the human 8p23.1 defensin cluster.
(c) Expression analysis using RT-PCR revealed the differential expression o f  the 
zebrafish defensins. defb ll and defbl3 were detected in all tested adult tissues, 
whereas defbl2  was detected only in the gut.
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1.7 THESIS AIMS
In this thesis, I have investigated the function o f  vertebrate defensins, by looking in 
detail at specific zebrafish and murine defensins.
The broad aims of the thesis are as follows:
1. To observe how both the primary and tertiary structure o f  murine Defb 14 
affect the peptide’s antimicrobial activity against both gram positive and 
gram negative bacteria.
2. To characterise the previously reported zebrafish (3-defensin peptides, 
particularly with a view to elucidating antimicrobial functions and any other 
potential roles
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Chapter 2: The Structure-Activity Relationship of Murine  
Defb14
"Almost all aspects o f  life are engineered at the molecular level, and without 





The emergence o f  antibiotic-resistant pathogens is a growing concern due to our 
ever-increasing dependence on antibiotics in medicine, veterinary medicine and 
agriculture. A number of classes o f  antibiotic were discovered in a “golden era” of 
antibacterial drug discovery beginning in the 1940s, and pathogens were unable to 
build up a robust resistance to the vast array o f  drugs being produced. However a 
combination o f  more widespread use o f  antibiotics and the difficulties associated 
with bringing novel drugs to market and their subsequent financial viability has led 
to a decrease in the number of novel antibiotics being developed. In a 2004 report, 
the World Health Organisation (WHO) identified antibiotic resistant bacteria as the 
largest worldwide pharmaceutical gap (Kaplan and Laing, 2004).
The 1950s and 1960s saw the development o f  a huge number o f  novel antibiotics, 
belonging to a number of different chemical categories (Coates et al, 2002; Wenzel 
2004). Different categories of antibiotic target different bacterial processes, for 
example the (3-lactams inhibit bacterial cell wall synthesis (Izaki et a!, 1968), 
whereas the aminoglycosides and tetracyclines target protein synthesis (Brock,
1963). The possession of antibiotics which target different processes is an important 
strategy in combating bacteria which have mutated to develop resistance. However, 
since the 1960s, only two new categories of antibiotic have been developed; the 
oxazolidinones (Linezoid, first approved in 2 001 )(Moellering ,2003) and a cyclic 
lipopeptide Daptomycin (first approved in 2003)(Woodworth et al, 1992). Instead, 
novel antibiotics since the 1960s have largely consisted o f  derivatives o f  the existing 
classes o f  antibiotics.
The use o f  peptides derived from the innate immune system, such as the (3-defensins, 
represents a potential source from which to develop novel antibiotics. Not only are 
the peptides small (which translates to lower production costs and faster synthesis), 
but their mechanism of action is general, targeting the entire bacterial cell membrane 
of both gram positive and negative species. This presents an inviting economic 
model, as the non-specific nature lowers the risk o f  bacterial resistance emerging 
quickly, since this would require major changes to the entire cell membrane structure 
(as opposed to the mutation of a single protein for more specific drugs). In addition,
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the [3-defensins have the further advantage o f  being largely bactericidal, as opposed 
to many other conventional antibiotics which are bacteriostatic. There is some data 
that suggests that bactericidal drugs are more effective in vivo and correlate to higher 
survival rates for endocarditis than bacteriostatic (Finberg, 2004). On an economic 
level the (3-defensins are inviting, as bactericidal activity presents less o f  an 
opportunity for bacteria to evolve resistance. This effectively extends the “shelf-life” 
o f  the drug, making it a more attractive option for development.
The defensins are such a great area o f  interest that two new defensin-inspired drugs 
have been produced and have progressed through to the clinical trials stage o f  
development. Encouragingly, in September 2010, PolyMedix Inc began Phase 2 
clinical trials o f  their new compound PMX-30063 (Scott el a /., 2008), a synthetic 
defensin biomimetic which targets both gram positive and negative bacteria. This 
drug has the financial advantage of being non-protein (the molecule is based on a 
carbon backbone), as well as crucially being tolerated systemically.
A second defensin-like antibiotic in clinical trials is Novozymes and Sanofi 
Aventis's Plectasin NZ21 14 (Ostergaard et a!., 2009). This peptide is derived from 
the fungus P.nigrella  and has been selected as a high performing variant against 
vancomycin-resistant S.aureus ( VRSA). This peptide has already had promising 
results in a Phase I clinical trial, where it has been shown to be tolerated at high 
doses.
In order to investigate defensin-derived peptides which might be of further clinical 
relevance, research emphasis has been placed on the analysis o f  the origin of 
defensin antimicrobial activity. Although the underlying basis o f  defensin function is 
still not yet known, investigations have been canned out to elucidate the effects of 
altering both the structure and charge of antimicrobial peptides.
A number o f  studies focussed on the role of the characteristic cysteine:cysteine 
disulphide bonding in antimicrobial activity. Wu et a!., 2003, used synthetic 
analogues o f  human (3-defensin 3 (HBD3) to change the intramolecular disulphide 
bonding pattern and showed that it was not necessary for antimicrobial activity. 
Moreover, an analogue containing no cysteines also remained antimicrobially active.
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Hoover et al., 2003 reported similar findings and also showed that a fully linear 
HBD3 peptide retained its antimicrobial activity.
Since full cysteine connectivity does not appear to be vital for antimicrobial activity, 
studies have also concentrated on the role o f  charge and structure in activity. Hoover 
el a/., 2003 showed that fragments of the N- and C- termini o f  HBD3 were 
bactericidal to gram positive and negative bacteria, respectively. The tested 
fragments were all positively charged and those with a higher charge were shown to 
have higher antimicrobial activity. However, there was no correlation between 
changes in charge and the observed differential activity against bacteria of different 
gram stains, leading to the conclusion that although charge is important for activity, 
structure must play a role too (Hoover et a l 2003). Krishnakumari et a l., 2006 also 
demonstrated the importance of structure when they showed that three synthetic C- 
terminal fragments of HBD1, HBD2 and HBD3 retained antimicrobial activity 
against both gram positive and negative bacteria when in their dimeric forms. 
However, when the peptides were reduced, they only retained activity against gram 
negative E.coli. Circular dichroism spectra showed that the dimeric peptides retained 
structures similar to the native peptide, whereas the reduced monomeric spectra 
indicated a loss o f  structure, which was suggested to be responsible for the reduced 
antimicrobial potential (Krishnakumari et a!., 2006).
While an abundance o f  studies have focussed on the human |3-defensins, their murine 
orthologues hold the added potential for in vivo studies. Although they can provide 
insight into the molecular function of antimicrobial peptides, in vitro antimicrobial 
assays are taken entirely out o f  biological context. The in vitro study o f  murine 
defensins, however, could lead to the discovery o f  highly active peptides or peptide 
fragments whose findings could then be applied directly to relevant in vivo studies.
Previous work in this group investigated the antimicrobial activity o f  murine Delb8, 
finding it to be poor against all tested species. However, Defrl, an allele o f  Defb8 in 
C57B1/6 mice was shown to be strongly antimicrobial (Morrison et al., 2002). The 
sequences o f  the two alleles are shown in Table 2.1.
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Peptide Sequence Ant imicrobia l?
Defrl DPVTYIRNGGICQYRCIGLRHKIGTCGSPFKCCK +++
Defb8 EPVSCIRNGGICQYRCIGLRHK1GTCGSPFKCCK -
Table 2.1 Sequences of Defrl and Defb8 peptides (data from Morrison et 
al., 2002)
Although the sequences of these alleles only differ by three amino acids, the 
antimicrobial activity of Defrl has potent antimicrobial activity, whereas Defb8 does 
not.
It was shown that due to its odd number o f  cysteine residues, the native state of 
Defrl was as a covalent dimer, while Defb8 is monomeric. The restoration o f  six 
cysteines to Defrl (resulting in monomerisation) leads to the abrogation of 
antimicrobial activity (Taylor et al., 2007), indicating that dimérisation was 
responsible for the increased antimicrobial activity in this peptide. This finding, 
along with the similar findings o f  Krishnakumari et a l., 2006 in HBD1-3 led to the 
decision to investigate the role of dimerism in antimicrobial activity in murine 
Defbl4.
D efbl4 is the murine orthologue o f  HBD3 (Semple et al., 2006) and is a highly 
effective, salt-insensitive bactericidal agent against an array o f  both gram positive 
and negative bacteria. DefbM is monomeric, so a synthetic analogue (D efb l4 - lC  ') 
containing just one cysteine residue at canonical position V was produced, to 
determine whether a dimeric peptide would show even better antimicrobial activity 
(Figure 2 .1 a, Taylor et al., 2008). Dimérisation did not improve the activity o f  full 
length D efb l4 - lC v, however an investigation into the antimicrobial activity of 
D efb l4 - lC v-inspired peptide fragments indicated that the amino acids responsible 
for antimicrobial activity in this molecule reside in the N-terminal (Figure 2.1b). In 
further work, an additional two active fragments o f  interest, Defb 14-1 Cv( 1-10) and 
Defb 14-1 Cv(6-17) (Figure 2.2) were identified (Reynolds et al., 2010), following 
screening of a number o f  N-terminal fragments for antimicrobial activity against a 
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In this chapter I continue the analysis o f  the bactericidal activity of D e fb l4 - lC v and 
investigate further the origin o f  its activity using a library o f  progressive truncated 
peptides. The use o f  a deletion series allows for the continuation o f  investigation into 
the activity o f  the peptide fragments, but within the context o f  a full length molecule. 
1 look at the effects of dimerisation, charge and primary sequence on the bactericidal 
activity against a panel o f  gram positive and negative bacteria. In order to introduce 
higher clinical relevance to the study, the panel o f  bacteria tested included strains 
relevant to the current crisis o f  antibiotic resistance, including M RSA , A.baumannii 
and E.coli.
Sections 2.3.1 -  2.3.5 o f  this chapter were published in Reynolds et al., 2010 and  
Tyrrell et al., 2009. Appropriate permissions were obtained prior to including the 




The aims o f  this work were to:
1. Assess the bactericidal properties o f  a panel o f  DefbM-inspired synthetic 
peptide fragments in order to further dissect the residues important for 
activity
2. Observe and identify the regions of Defbl 4 critical for bactericidal activity
3. Further investigate the effect o f  dimérisation on bactericidal activity
4. Investigate the bactericidal activity o f  the peptide panel under more 
physiological conditions containing serum and salt
5. Utilise the data from these analyses to draw conclusions about the role of 
charge in antimicrobial activity
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2.3 ANTIMICROBIAL ACTIVITY OF A DEFB14-INSPIRED  
PEPTIDE DELETION SERIES
Synthetic Defb 14-inspired peptide fragments containing sequential peptide deletions
of three amino acids were obtained (Derek Macmillan, UCL), as shown in Table 2.2.
These fragments were based on the D efb l4 - lC v peptide which has all its cysteines
(apart from cysteine V) mutated to alanine residues. This was done to enable the
formation of dimeric peptides (via disulphide bridges between the remaining cysteine
residues) and has previously been shown to have no effect on the parent peptide’s
antimicrobial activity (Taylor et a/., 2008).
The activity o f  the peptide deletion series was determined by recording the minimum 
bactericidal concentration (MBC) for each of the peptides against a panel o f  gram 
positive and negative bacteria at 37°C. This peptide concentration is defined as the 
minimum concentration required to kill 99.99% bacteria incubated with the peptide 
and is therefore o f  high clinical relevance. An alternative test which could have been 
employed is the minimum inhibitory concentration (MIC). The MIC determines the 
minimum concentration o f  peptide at which bacterial growth is inhibited and thus 
bacteriostatic compounds would yield a positive result. In a clinical setting, 
bacteriostatic antibiotics will prevent bacterial growth until the infection can be 
managed by the host immune system. However, such compounds are not effective in 
treating immunodeficient patients or for the treatment o f  infections affecting 
immune-incompetent regions (for example, meningitis)(Booth, 2 0 0 1), in which case 
a bactericidal agent is necessary. For this reason, MBC values were determined for 
all tested compounds.
2.3.1 The bactericidal efficiency of the monomeric Defb14 deletion 
series varies according to bacterial gram status
During synthesis, the deletion peptides spontaneously form dimers due to their single
free cysteine residue. The deletion series was reduced with dithiothreitol (DTT) to
produce monomeric peptides which maintained this state throughout the assay
(verified by mass spectrometry, Martin De Cecco, data not shown). As the amino
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increase, indicating a reduction in bactericidal activity (higher concentrations of 
peptide are required to maintain the same level o f  killing).
The data indicates that the effect o f  the deletions varies dependent on the gram status 
of the strains being tested, with the peptides’ activity against gram negative bacteria 
being largely more robust than that against gram positive bacteria. This effect can be 
observed by noting how much o f  the parent peptide can be deleted before 
antimicrobial activity is lost.
In the gram negative species, P.aeruginosa and A.baumannii, no MBC could be 
determined at any tested peptide concentration with the fragment Defbl4-1CA A(l- 
14), indicating that significant bactericidal activity is lost (Figure 2.3a,b). This is a 
striking contrast to the Defb 14-1 C vA( 1 -11 ) peptide, which achieves an MBC 1.7 
(±0.0) pM and 2.5 (±0.0) pM against P.aeruginosa  and A.baumannii respectively. In 
contrast, a broader effect is seen in the tested gram positive species; notably an MBC 
was not achieved at any tested concentration o f  Defb 14-1C A( 1-11) in M RSA , and 
the MBC achieved for the same peptide against S.aureus was significantly higher 
than the parent peptide (Figure 2.4a,b). In addition, a more pronounced effect is seen 
in the analysis o f  E fa eca lis , which is not killed by deletion peptides beginning with 
D efb l4 - lC vA(l-8) (Figure 2.4c).
However, the trend of increased robustness o f  peptides against gram negative 
bacteria is not clear cut. as illustrated by E.coli, which is unaffected following the 
deletion o f  just the first eight amino acids (D efb l4 - lC vA(l-8), Figure 2.3c).
2.3.2 Dimérisation does not improve bactericidal activity in full length 
Defb14-1Cv, but preserves the activity of the deletion series
Although previous work showed no improvement in bactericidal activity o f  Defb 14-
1CV in comparison to Defb 14 (Taylor et a/., 2008), allowing the D e fb l4 - lC v peptide
deletion series to dimerise has a dramatic effect on their bactericidal activity against
both gram positive and negative strains. Strikingly, bactericidal activity is fully
recovered for both dimeric Defbl4-1CVA(1-14) and Defb 14-1 C x A( 1-17) against
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D efb l4de le tion  peptide
(a) MBC values achieved against P.aeruginosa
(b) MBC values achieved against A.baumannii
(c) MBC values achieved against E.coli
Graphs show the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM) and are based on at least three independent 
biological repeats. Where no error bar is shown, SEM = 0.0.
**p<0.01 (vs D efbl4-1CN). Where no MBC was achieved, significance was 
calculated based on highest tested concentration. Red bars denote peptides did not 
achieve a MBC at the described concentration
Figure 2.3 M onom eric peptide antim icrobial activity against gram
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D efbl4 deletion peptide










(a) MBC values achieved against S.aureus
(b ) MBC values achieved against MRSA
(c) MBC values achieved against E.faecalis
Graphs show the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM) and are based on at least three independent 
biological repeats.
**p<0.01, *p<0.05 (vs D efb l4 - lC x). Where no MBC was achieved, significance 
was calculated based on highest tested concentration.
Red bars denote peptides did not achieve a MBC at the described concentration. No 
data is provided for D e fb l4 - lC vA(l-5) tested against E.faecalis (c) due to lack of 
peptide stocks.
Figure 2.4 M onom eric peptide antim icrobial activity against gram
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D e f b l4  d e le t io n  p e p tid e
Figure 2.5 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against P.aeruginosa
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
***p<0.0005 (monomer vs. dimer). Where no MBC was achieved, significance was 
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D e fb l4  dele tion  peptide
Figure 2.6 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against A.baumannii
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
*p<0.05 (monomer vs. dimer). Where no MBC was achieved, significance was 
calculated based on highest tested concentration.
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dimer records an MBC of 2.6 (±1.0) pM, compared to an inactive monomer. 
Similarly, dimeric D efbl4-1CVA(1-17) has an MBC of 3.3 (±0.8) pM against 
A.baum annii, where the monomeric peptide did not achieve an MBC (Figure 2.6).
Although dimérisation does not fully recover the activity o f  all the deletion peptides 
against E.coli, it does recover the activity o f  D e fb l4 - lC xA(l-8), which gives an 
MBC of  2.5pM (±0.0)(Figure 2.7).
A similar effect was observed with gram positive bacteria, although it was less 
striking than the gram negatives; although dimerising D efb l4-1C VA(1-14) and 
Defbl4-1CN A( 1-17) did not confer activity against S.aureus, dimerising Defbl4- 
1 C x A( 1 -1 1) recovered an MBC of  0.9 (±0.3) pM (Figure 2.8). Similarly, dimeric 
Defbl4-1C'N A( 1-17) had no activity against MRSA, and dimerising D efbl4-1CVA( 1- 
14) only recovered a low level of activity at 6.7 (±3.3) pM. A more striking recovery 
o f  activity occurred upon dimerising D efbl4-1CVA(1-11), which recovered an MBC 
of 1.5 (±1.1) pM against MRSA (Figure 2.9). Dimérisation had no effect on the lack 
of antimicrobial activity o f  Defb 14-1 Cx A( 1 -11 ), D efbl4-1CVA( 1-14) and Defbl4- 
1 C xA( 1-17) against E faecalis, however dimerising D e fb l4 - lC vA(l-2) and Defbl4- 
lC xA(l-8) resulted in a significantly improved (p<0.05) antimicrobial activity, with 
MBCs o f  1.0 (±0.2) pM and 1.9 (±0.6) pM being recorded respectively (Figure 
2.10). A summary of the D efb l4-lC V  deletion series MBC values for both 
monomers and dimers is shown in Table 2.3.
2.3.3 N-terminal substitutions have no effect on peptide activity
Previous work has shown that the loss of just two N-terminal amino acids abolishes 
Defbl4 chemoattraction of CD4± T cells (Tyrrell et al., 2009). This study also 
showed that the mutation of the highly conserved leucine residue at position 2 (to 
glycine, lysine and isoleucine) resulted in differential activity changes, suggesting 
that this residue is crucial for chemotactic ability. It was therefore decided to 
investigate whether these changes would also affect the bactericidal activity o f  the 
parent peptide.
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Figure 2.7 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against E.coli
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error of mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
*p<0.05 (monomer vs. dimer). Where no MBC was achieved, significance was 
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Figure 2.8 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against S.aureus
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
*p<0.025, **p<0.0001 (monomer vs. dimer). Where no MBC was achieved, 
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D e fb l4  deletion peptides
Figure 2.9 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against MRS A
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ± standard error o f  mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
*p<0.05 (monomer vs. dimer). Where no MBC was achieved, significance was 
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Figure 2.10 Comparison of the antimicrobial activity of monomeric and 
dimeric forms of the Defb14-1Cv deletion series against E.faecalis
This graph shows the minimum bactericidal concentration (MBC) achieved for each 
peptide ±  standard error of mean (SEM). Bars faded to a lighter shade denote 
peptides that did not achieve an MBC at the depicted highest concentration tested 
(MBC > xpM). Values are based on figures for at least three independent 
experimental repeats.
*p<0.05 (monomer vs. dimer). Where no MBC was achieved, significance was 
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D efb l4 -lC V  Defbl4-1CVL2G Defbl4-1CVL2K Defbl4-1CVL2I








D efb l4 -lC V  Defbl4-1CVL2G Defbl4-1CVL2K Defbl4-1CVL2I
D e fb l4 - lC v variant
Figure 2.11 Antimicrobial activity of three Defb14-1Cv peptides with 
substitutions at position 2
(a)This graph depicts antimicrobial activity against gram negative P.aeruginosa. 
Data is based on three replicate experiments and error bars depict the standard error 
of the mean
(b) This graph depicts antimicrobial activity of the peptides against gram positive
S. aureus.
None of the peptides showed a statistical difference in activity in comparison to the 
parent D e fb l4 - lC v peptide.
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The three D efb l4 - lC v substitution peptides (Table 2.4) were tested for antimicrobial 
activity against P.aeruginosa  as a representative gram negative species and S.aureus 
as a representative gram positive species. It was found that in their dimeric state, no 
statistically significant difference was observed between the peptides’ activities 
against both P.aeruginosa and S.aureus (Figure 2.11).
2.3.4 The Defb14-1Cv deletion series lose their salt insensitivity 
as the peptide shortens
Defbl4 has been shown to be salt insensitive in its activity (Taylor et al., 2008).
Importantly, the peptide fragments D e fb l4 - lC v(l-lO) and D e fb l4 - lC v( 6 - l7) have
previously been shown to also be salt insensitive (Reynolds et al, 2 0 10). In order to
test the salt sensitivity o f  the deletion series peptides, antimicrobial assays were
performed against P.aeruginosa  in the presence o f  increasing concentrations of
sodium chloride salt, ranging from 0-200mM.
Analysis revealed a general tendency for salt sensitivity to increase as peptide length 
decreased. Although D efb l4 - lC vA(l) showed no significant difference in activity 
across the whole range of salt concentrations (Figure 2 .12), this was the only deletion 
series peptide to behave in this way. D efbl4-l CvA( l -2) showed a significant 
decrease in activity at the highest tested salt concentration (200mM), with an MBC 
increase from 0.5 (±0.2) pM at OmM salt to 2.5 (±0.0) pM at 200mM (Figure 2.12). 
Flowever, although the activity was reduced, both D efbl4-1CVA( 1-2) and Defbl4- 
1C nA (1-5) retained bactericidal activity at 200mM.
A deletion of more than five amino acids proved to have a greater effect on 
bactericidal activity; D e fb l4 - lC vA(l-8) showed a significantly lower MBC of  6.7 
(±2.0) pM (p<0.05) at only 50mM salt, with no activity at lOOmM and 200mM. 
Flowever, this trend toward inactivity appeared to level off at lower salt 
concentrations, with the largest deletion peptide Defbl41CvA( 1-17) still maintaining 
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2.3.5 Improving the antimicrobial activity of Defb141Cv(6-17): 
serum sensitivity, cyclicisation and stereoisomers
Since D efb l4 - lC v(6-l7) had previously been identified as a short antimicrobially
active fragment o f  D e fb l4 - lC v (Reynolds et al., 2010), 1 decided to investigate the
activity o f  this peptide in the presence of serum and see whether the antimicrobial
activity could be made more robust by cyclicisation. Tang et al., 1999 suggested that
linearised (both with and without serum), suggesting that cyclicising D efb l4 - lC v(6-
17) may improve its activity.
The ability o f  a peptide to function in the presence of serum is clinically relevant if 
the peptide is to be developed as a systemic antibiotic. However, since antimicrobial 
activity appears to be largely independent of exact 3D peptide structure, one strategy 
which can be used to make a peptide more stable in vivo is the production o f  a 
stereoisomer. Translated cellular peptides contain amino acids in the “ L” 
conformation, however due to the chirality o f  carbon, stereoisomer “mirror images” 
o f  these amino acids can be made in the “D” conformation (reviewed in Martinez- 
Rodriguez et a/.. 2010). It is possible that a peptide made of D-amino acids would be 
able to resist degradation by specific proteases better than the L-form.
A series o f  four peptides were synthesised (by Derek Macmillan. UCL) to test 
whether cyclicisation and isomérisation have an effect on the antimicrobial activity 








Table 2.5 The sequences of Defb14-1Cv(6-17) derivatives
This table shows the sequences of four synthetic derivatives o f  D e fb l4 - lC v(6-17) in 
comparison to the original D efb l4 - lC v(6-l 7). A cysteine residue was added to the 
N-terminal o f  the peptides to facilitate cyclicisation. The superscript “L!N” refers to aG’yc
linear molecule and “ ” denotes a cyclic peptide. The final two peptides, followed
by the letter “D” denote stereoisomers, containing only D-amino acids.
A new preparation of Defbl4-lCA(6-l7) was tested for antimicrobial activity against 
P.aeruginosa as a representative gram negative organism, where it achieved a MBC 
of 1.6 (±0.3) pM. However, when tested in 5% (v/v) foetal calf serum (FCS) 
antimicrobial activity was abrogated (MBC > 20pM). A similar observation was 
made with the D efb l4 - lC v(7-17)LIN peptide, which achieved a MBC of  2.4 (±0.1) 
pM in 0% serum, but lost activity (MBC > 18pM) in just 5% (v/v) serum. The
V C YCcyclicisation o f  the D efb l4 - lC  (7-17) peptide did not improve the antimicrobial 
activity in either serum-free or 5% serum (Figure 2.13).
Instead, the peptide showed lowered antimicrobial activity in serum-free tests 
(MBC=3.6±0.7pM) and lost activity in 5% serum (MBC > 19pM).
Interestingly, although the D efb l4 - lC v(7-17)LIND peptide did not display 
antimicrobial activity as potent as D e fb l4 - lC v(6-17), the activity appeared to be 
more robust. Figure 2.13 shows that D efb l4 - lC v(7-17)LIND maintains antimicrobial 
activity even in 10% FCS, although the concentration of peptide required to kill 
99.99% inoculum is significantly increased. The DetF>14-lCv(7-17)o c  D peptide 
shows a similar level of activity to D e fb l4 - lC v(7-17)LIND, although the MBC
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achieved at 10% FCS was not significantly different to that achieved at 0% FCS (6.9 
± l.6pM vs 10.0 ± O.OpM, respectively). This suggests that the cyclicisation o f  the 
D-amino acid stereoisomer may act to further preserve the antimicrobial activity of 
the linear peptide.
The analysis was repeated using S.aureus as a representative gram positive organism. 
As seen with the P.aeruginosa analysis, cyclicisation had no effect on improving the 
antimicrobial activity of D e fb l4 - lC v(7-17)LiN either in serum-free or 5% FCS 
reactions (Figure 2.14). However, the D-amino acid isomérisation improved the 
D efbl4-1CN(7-17)LIND at all serum concentrations and a MBC was recorded even at 
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isomérisation also appeared to improve the peptides activity in serum-free medium. 
The D efb l4 - lC v(7-17)LIN linear peptide achieves a MBC of  18 ±0.0pM in 0% 
serum, however Defb 14-1 C v(7-17)' IND showed 99.99% kill o f  the initial inoculum 
at just 6.7±1.4pM. The cyclic isomer showed further improvement over the linear, 
with antimicrobial activity at 10% FCS increasing in this peptide to lead to a 
recorded MBC of 10 ± O.OpM, nearly half the value o f  the linear peptide.
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2.4 DISCUSSION
This work has continued the analysis o f  the D efbl4 peptide with the ultimate aims of 
elucidating the origins of antimicrobial activity and assessing its suitability for 
development as a potential novel antibiotic. To approach the question o f  the 
importance o f  primary amino acid sequence to bactericidal activity, I tested a 
deletion library o f  Defb 141 C x -derived peptides against a panel o f  clinically relevant 
bacterial strains. This deletion library has the collective power o f  illustrating the 
importance o f  fragments o f  peptide within the context o f  a full-length molecule, thus 
maintaining a conformation as close to the physiological parent peptide as possible.
1 also investigated the effects of cyclicisation and isomérisation on antimicrobial 
activity within the context o f  a single D e fb l4 - lC v fragment, D e fb l4 - lC v(6-17).
2.4.1 Primary peptide sequence has a crucial role in the determination 
of bactericidal activity against different bacterial strains
In this work, 1 showed that as the D efb l4 - lC v peptide deletions increased, that
monomeric MBCs increased in a strain dependent manner. This analysis highlighted
the importance o f  specific amino acid sequences to the bactericidal activity against
different strains; based on the MBC values obtained, amino acids 6-8 (LRK) appear
to be critical in monomeric activity against E.co/i and E.faecalis (Figures 2.3c, 2.4c),
amino acids 9-14 (FFAR1R) in activity against S.aureus (Figure 2.4a) and amino
acids 15-17 (RIR)in activity against P.aeruginosa and A.baumannii (Figures 2.3a,b).
This finding suggests that multiple sequences are important for the broad spectrum 
bactericidal activity seen in Defb 14, but highlights in particular residues 6-17 as 
amino acids that are critical to the response against the organisms tested in this study. 
This is concordant with work previously carried out in this group, which showed that 
peptide fragments D efb l4 - lC x( 1-10) and D efb l4 - lC v(6-17) display potent 
bactericidal activity (Reynolds et al, 2010). The increased activity o f  Defb 14-1 Cv(6- 
17) over Defb 14-1 Cv( 1-10) is also supported by this data, since 1 have shown that 
residues 1-5 can be removed from the parent peptide without significant effects on 
the bactericidal activity. This indicates that the bactericidal activity o f  D etb l4 -  
lC v( 1-10) may derive mainly from amino acids 6-10 (LRKFF). Flowever, the data
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would also support amino acids 1-17 having individual additive effects to the 
bactericidal activity.
The highlighting o f  amino acids 6-8 as important in bactericidal activity (against 
E.coli and E faeca /is) is also concordant with a previous study on HBD3, which 
showed that the sequence NTLQK has been subject to negative selection forces 
throughout primate evolution (Semple et al, 2005). The sequence NTLQK 
corresponds to KTLRK in D efbl4 (Figure 2.1), and its conservation in primates 
might be indicative o f  its importance in bactericidal activity.
These observations indicate that primary sequence is important in determining 
bactericidal activity, but do not differentiate between sequence and the overall 
molecular charge and hydrophobicity. Hydrophobicity is a measure o f  the proportion 
o f  hydrophobic residues present in a peptide and a higher hydrophobicity (less 
negative AG value) is thought to confer a greater ability for membrane integration 
and disruption.
Through their structure-function work on HBD3. Klüver et a l., 2005, argued that the 
most important factors for maintaining bactericidal activity were a combination of 
high positive charge and hydrophobicity, where decreases in charge could be 
compensated for by increases in hydrophobicity (Klüver et a!, 2005). While, the 
work described in this chapter suggests that primary sequence affects activity 
independently of these factors, it also supports these claims. Figure 2.15 depicts the 
antimicrobial activity o f  deletion series against P.aeruginosa graphically, showing a 
progressive reduction of charge as the peptide deletions increase. The monomeric 
peptides D efbl4-1CVA( 1-17) and D efb l4 - lC v(6 - l7) have the same charge, yet only
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Figure 2.15 The relationship between charge and antimicrobial activity
(taken from Reynolds et at., 2010)
The above graph depicts the net charge (pH 7) o f  the D efb l4 - lC x deletion series 
monomers and dimers. Monomers are denoted by a square, dimers by a circle. Active 
peptides are marked with black shading.
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the latter is a good antimicrobial against P.aeruginosa. Although charge cannot 
explain this increased activity, Table 2.2 reveals that D e fb l4 - lC v(6-l7) has a much 
higher hydrophobicity than Defb 14-1 CVA( 1 -17), supporting the assertion by Klüver 
et a /., 2005 that increased hydrophobicity can compensate for lowered charge to 
improve antimicrobial activity.
2.4.2 Peptide dimerisation protects bactericidal activity
1 have shown that the dimerisation o f  the deletion series is enough to recover some 
bactericidal activity against all tested bacterial strains. Since dimeric peptides have 
double the charge o f  monomeric peptides, this might initially suggest that the 
increased activity is largely down to charge, providing support for the claims of 
Klüver el a/., 2005. While this is the case, again the data also suggests that charge 
alone cannot explain the complexity o f  the situation. When comparing the dimeric 
forms o f  Defb 14-1CA A( I-17) and D efb l4 - lC vA(l-23) in Figure 2.15, it can be seen 
that the peptides possess the same charge. However, while both peptides are inactive 
against P.aeruginosa  in their monomeric forms, Defbl4-1C'VA(1-17) alone acquires 
activity as a dimer (Figure 2.5). Since the peptides possess similar hydrophobicities, 
it would be reasonable to expect D e fb l4 - lC vA(l-23) to behave in a similar way, if 
charge and hydrophobicity were the only considerations to be made. Since the 
peptides’ activities are so vastly different, it leads to the conclusion that the addition 
of amino acids AAVLNA in Defb 14-1 Cv( 1-17) confer additional bactericidal 
activity. Interestingly, the peptide AAVLNA is inactive (and unable to form 
dimers)(data not shown), so the extra sequence is only relevant within the context of 
the larger molecule. This finding supports our experimental technique of 
investigating the activity of amino acid sequences within the context o f  a larger 
parent peptide.
The dimerisation data described in this chapter is not the first observation o f  its kind. 
It supports the recent work o f  Antelleva et a i., 2009, who conducted a study on an 
artificial (f-defensin, synthesised based on the shared characteristics o f  more than 80 
defensins. Their work suggested that dimerisation could improve bactericidal activity 
o f  the peptide, although no comment was made about the influence o f  molecular
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charge on this activity (Antcheva et a/., 2009). Neither the findings of Antcheva et 
a/., 2009 nor the findings reported in this chapter explain why D efb l4 - lC  is no more 
active than Defbl4, despite being a dimer. It perhaps suggests that there is a ceiling 
to the bacterial killing efficiency a peptide can have, or otherwise it may indicate that 
activity is being limited by another independent factor.
2.4.3 Salt sensitivity increases as the N-terminal deletions of Defb14- 
1CV increase
D efbl4 and Defbl4-1CA are salt insensitive peptides and maintain a high level of 
antimicrobial activity at high (200mM) concentrations. The salt concentration in 
physiological isotonic saline solutions is approximately 150mM (0.9% NaCl), so 
maintaining antimicrobial activity at these levels is crucial for any peptide which 
may be developed for future use as an intravenous medicine. In addition, Goldman et 
al., 1997 found that fluid from the airways of cystic fibrosis patients contained salt at 
a concentration of l20mM. Resistance to high levels o f  salt may allow for the 
development of an antibiotic inhaler to treat cystic fibrosis patients.
Figure 2.12 shows that at 200mM NaCl, a significant decrease in D e fb l4 - lC v 
antimicrobial activity against P.aeruginosa  is observed following the deletion o f  just 
two N-terminal amino acids. Moreover, the removal of the first eight N-terminal 
amino acids abrogates antimicrobial activity at this salt concentration. This data 
suggests that the N-terminal region is highly important for the retention o f  salt 
insensitivity and that this property is more sensitive than antimicrobial killing in salt- 
free solutions.
It is possible that the N-terminal confers additional stability to D e fb l4 - lC v under 
high salt conditions and is thus required for antimicrobial activity. Alternatively, 
since the mechanism of  defensin activity is thought to derive from initial electrostatic 
interactions with the negatively charged bacterial cell wall, it could be that the 
presence of Na+ cations disrupts this electrostatic balance. Since the D e fb l4 - lC v 
deletion series progressively decreases in charge (Figure 2.15), this might explain the 
observed effects.
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2.4.4 The serum sensitivity of Defb14-1Cv(6-17) derivatives can be 
manipulated by chiral isomerisation
In this chapter, I showed that the chiral isomerisation o f  D e fb l4 - lC v(7-17) by
substitution o f  L-amino acids for D-amino acids results in a marked increase in
antimicrobial performance in the presence o f  serum. This improvement was observed
in both gram positive and negative bacteria and resulted in resistance in up to 10%
serum (Figures 2.13, 2.14). In addition, cyclicisation o f  the chiral isomer further
improved the antimicrobial activity, in particular against gram positive S.aureus.
Since the majority of cellular proteins are synthesised using L-amino acids, it is 
possible that D-form peptides are resistant to proteolytic degradation in vivo , if  they 
can no longer be recognised enzymatically. Similarly, even a reduction in proteolysis 
might result in an improvement in antimicrobial activity. Although the stability o f  the 
peptides were not tested in this study, this could be carried out using mass 
spectrometry in future work.
Tang el a /., 1999 postulated that the 0-defensin RTD-1 maintained a higher level of 
antimicrobial activity due to its cyclic nature. The findings in this chapter do not 
suggest that the same applies for D e tb l4 - lC v(7-17)o c . While this observation 
might be simply explained by the artificial nature of the tested peptide, there are a 
number o f  other explanations.
The lack o f  correlation to Tang et al., 1999 might be explained by the difference in 
peptide sizes. Since RTD-1 is a full length 18 amino acid peptide, when Defbl4- 
1CV(7-17)C 'tC is simply a 10 amino acid fragment o f  a much larger peptide, it may
have reduced overall stability and therefore lowered antimicrobial activity.
v d'yeAlternatively, it may be that the cyclicisation of D efb l4 -lC  (7-17) alters the 3D 
structure o f  the peptide too much for it to maintain its antimicrobial activity. In 
Figures 2.13 and 2.14 it is apparent that the cyclic peptides do not function as well as 
the linear in serum-free solutions, which may indicate a partial steric shielding of 
positively charged residues, critical for microbial membrane interactions.
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While the cyclicisation o f  D e fb l4 - lC v(7-17) did not appear to dramatically improve 
the antimicrobial activity o f  the peptide, creating chiral D-form isomers did. This 
presents an interesting avenue for future research and indicates that when designing 
future antibiotics, D-form isomers should be considered and tested, to ensure 
maximum drug efficiency. However, since D-amino acids are found naturally in the 
peptidoglycan o f  bacterial cell walls (reviewed in Cava et a!., 2011), extra care 
would need to be taken to first determine whether the peptides would induce an 
immune response.
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2.5 CONCLUSIONS AND FUTURE DIRECTIONS
In this chapter I have shown that as the D efbl4-1CN peptide truncates from the N- 
terminal, its MBC increases, indicating a poorer bactericidal activity. However, 
while this general trend was seen in all tested strains, the number of amino acids that 
can be lost before the peptide becomes inactive varies between organisms. 
Interestingly, the bactericidal activity against gram negative species appeared to be 
more robust than that of the gram positives.
In this work, I also showed that dimerisation improves the activity o f  deletion 
peptides and that changes in charge and hydrophobicity are insufficient to fully 
account for these large changes in activity.
Finally, I evaluated a series o f  cyclic and stereoisomeric peptides based on the 
antimicrobially active fragment Defb 14-1 CV(6-17). I found that while cyclicising 
peptide fragments has a limited effect on the antimicrobial activity, creating 
stereoisomers using D-amino acids appears to confer an increased activity in the 
presence o f  serum (compared to L-form peptides). However, this increased activity 
was only observed in the presence o f  serum and not in serum-free reactions. This 
finding is especially relevant in the light of a recent study by Maisetta et a!., 2011 
which showed that P.gingivci/is can produce proteases which help resist antimicrobial 
peptide function. The finding that the D-fonn cyclic peptide tested in this study is 
resistant to serum, suggests the peptide is resistant to specific proteases, which may 
be important in tackling bacteria like P.gingiva/is.
This study is interesting from two points o f  view. Firstly, it adds to the growing 
literature on the origins o f  antimicrobial activity in the P-defensins, and secondly, it 
has implications for the creation and modification o f  defensin-based antibiotics. 
However, this is not a fully comprehensive study and indicates a number o f  areas in 
which additional work could be carried out. A selection of these studies is suggested 
below.
A major limitation of this study is that it has been canned out using synthetic, 
modified peptides in an in vitro setting. Since the study was earned out on murine 
peptides, it would be interesting to mutagenise Defb 14 and carry out in vivo studies
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to determine whether my in vitro observations are replicated. In particular, it would 
be interesting to observe the effect of deleting triplet peptide sequences within the 
D efbl4 molecule, to firstly observe any differences in disease clearance and 
susceptibility. Alternatively, primary mutant airways could be cultured and observed 
for differences in ability to fight controlled infections.
A second area o f  future work could be to investigate the amphiphilicity o f  the 
D efbl4-1CN deletion series. Although this study considered primarily the effect of 
charge and amino acid sequence on antimicrobial activity, work by Pathak et ah, 
1995, suggested that amphiphilicity is the most important characteristic o f  an 
antimicrobial peptide (above hydrophobicity and helicity). Since this study only 
briefly considered the effects o f  hydrophobicity on antimicrobial activity, it may 
prove interesting to consider the changing amphiphilicity as the deletion series 
progresses. Amphiphilic peptides possess both hydrophobic and hydrophilic 
peptides, enabling them to interact with both charged and uncharged residues. Given 
the amphiphilic nature o f  cell membranes, this property is thought to allow (3- 
defensins to efficiently insert into and disrupt membranes.
In order to further the interesting findings from the cyclic stereoisomer work 
described in this chapter, it would be of great value to cany  out in vivo analysis of 
the D efb l4 - lC v(7-17)c vc D. Since the antimicrobial activity of this peptide was so 
promising in vitro, it would be interesting to observe whether administering the 
peptide to mice suffering from acute infection would alleviate the disease. 
Demonstrating that the peptide could work effectively in vivo would be an important 
step in identifying it as a potential novel antibiotic.
Finally, to further the in vitro analysis carried out in this study, it would be 
interesting to cany  out a reciprocal study looking at the effects o f  deleting the C- 
terminal o f  D e fb l4 - lC v. Since the N-terminal of D efbl4 seems to be the most 
important for antimicrobial activity, it would be interesting to take the active Defbl4- 
1 C v( 1 -23) and progressively truncate it. This would identify whether the active 
sequences identified in this chapter are only active within the context o f  a full-length 
molecule or whether they are independently highly active peptides, suitable for 
development as novel antibiotics.
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Chapter 3: The Antim icrobial Function of the Zebrafish  
Defensins
"I know the human being and fish can co-exist peacefully ” 
Presidential candidate George W. Bush
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3.1 PREFACE
The zebrafish, Dcmio rerio, is a proven and clinically relevant organism on which to 
model immunological studies. In recent years, the study o f  infection and 
inflammation in zebrafish and other teleosts has become more widespread. These 
organisms have proved to be important in the study of the pathogenesis o f  bacterial 
infections, notably providing a relevant model for mycobacterial disease (Prouty et 
al., 2003), as well as being useful in the study o f  viral infections, like the Herpes 
simplex virus (Burgos el al., 2008).
As described in Chapter 1, antimicrobial peptides are important constituents o f  the 
mammalian innate immune system and directly provide protection against a range o f  
microbes. The situation in aquatic species is less extensively studied than that o f  
mammals, however there is growing evidence that antimicrobial peptides serve a 
similar purpose in a variety o f  fish and a recent review identified more than 80 
antimicrobial peptides in various fish species (Rajanbabu and Chen, 2011). Some of 
the peptides do not have clear mammalian homologues; the antimicrobial peptide, 
pleurocidin (a piscidin), purified from skin mucal secretions o f  the winter flounder. 
Pleuronectes americana  has been shown to have potent activity against both gram 
positive and negative species o f  bacteria (Cole, 1997). Similarly, other piscidins have 
been demonstrated to be potent haemolytic and antimicrobial peptides in the 
Perciformes teleosts (Silphaduang, 2001).
In addition, orthologues o f  the major categories of mammalian antimicrobial peptides 
have also been identified in fish and in the past five years, new genes have been 
rapidly identified. Notably, functional cathelicidins have been reported in the 
Rainbow Trout (Oncorhynchus mykiss), Atlantic Salmon (Sa/mo salar) (Chang el al., 
2006) and cod (Gadus morhua) (Broekman et al., 2011) and defensin homologues 
have been identified in zebrafish (Danio rerio) and other teleosts (Zou et al., 2007) 
and rainbow trout (Falco et al., 2008; Casadei et al., 2009). Recently, novel and 
antimicrobially active hepcidins have also been identified in orange-spotted grouper 
(Epinephelus coioicles)(Zhou et al., 2011).
As described in Chapter 1, three (3-defensin-like peptides were reported by Zou et al., 
2007. Recently, Oehlers et al., 2011 mapped the expression of these defensins across
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the length o f  the intestine of both adult zebrafish and larvae, showing an increasing 
anterior-posterior gradient o f  expression. In this chapter, I describe the further 
characterisation o f  these (3-defensin-like peptides, with a view to defining the role 
that these genes might play in the immunity of zebrafish as well as investigating their 
potential for development as novel antibiotics. The work includes a search for 
additional zebrafish (3-defensins and observations on the expression of the genes in 
both embryos and adult fish. In addition, the antimicrobial properties o f  the peptides 
against a range o f  human and zebrafish pathogens are explored in vitro.
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3.2 AIMS
The aims o f  this chapter were to:
1. Search the zebrafish genome for additional novel P-defensin-like genes
2. Investigate the expression and inducibi lity o f  these genes to form a better idea 
o f  their role in zebrafish immunity
3. Investigate the antimicrobial activity o f  the published zebrafish defensin-like 
peptides against a panel o f  microbes, including gram positive and negative 
bacteria and fungi
4. Investigate any antimicrobial activity under differing salt and serum 
concentrations to evaluate the potential for development as novel therapeutics
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3.3 THE GENOMIC ORGANISATION OF THE ZEBRAFISH DEFENSINS
3.3.1 Searching for novel members of the zebrafish defensin family
Since the human (3-defensins have undergone rapid gene duplication and 
diversification events throughout evolution (Semple et a /., 2005), it is reasonable to 
suppose that their zebrafish counterparts might have undergone the same processes. 
This supports the case for the presence of more than three defensin genes being 
present in the zebrafish genome. To address this, a comprehensive search o f  the 
genome was carried out, with the aim to further the initial discoveries reported in 
Zou et a/., 2007.
More than 100 (3-defensin peptide sequences were collected from chicken, mouse, 
human and zebrafish using the Ensembl web server. These sequences were used to 
construct a Hidden Markoff Model which was then applied to the zebrafish genome 
using Genewise (with the assistance o f  Dr Colin Semple). Due to the large number of 
hits, this analysis was repeated (by Dr. Colin Semple), applying the model to the 
known zebrafish ESTs (Ensembl release 48, December 2007), to narrow the hits to 
genes that are expressed. This analysis produced 38 gene predictions, o f  which only 
14 scored as highly as the known zebrafish defensins (which were also detected, 
providing a positive control for the analysis). O f the remaining 14 predictions, five 
were chosen for analysis (in the first instance) based on their sequences not 
overlapping other known non-defensin genes and having some sequence homology 
with other fish defensins. The sequences of these peptides, along with their 
alignment to the annotated zebrafish defensins are shown in Table 3.1.
Primers were designed to detect mRNA transcripts o f  the genes by PCR from 24hpf 
embryonic cDNA, however no expression was detected (data not shown). To avoid 
overlooking any adult-specific expression, the analysis was also repeated using 
cDNA harvested from whole adult fish, however transcripts were still not detected.
Due to time constraints, this work was not pursued any further. However, the 38 
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3.3.2 d e fb ll and de fb l2  have reported paralogues in an adjacent 
gene cluster
Since the publication of the Zou el a /., 2007 paper, paralogues to both defb ll and 
dejbl2  have been annotated in Ensembl (Zebrafish Zv8, Aug 2010). These genes are 
located adjacent to the zebrafish defensin cluster on chromosome 21 (Figure 3.1). To 
differentiate between these genes, 1 will refer to the 5' defbl1 /defbl2  cluster as 
“defbl 1.1 and defbl2.1" and the 3 ’ cluster ''''defbl 1.2 and defbl2.2” (see Figure 3.1).
In order to gain insight into whether these genes are real paralogues or simply errors 
in the zebrafish genome assembly, their synteny was analysed. Supporting the notion 
that these are genuine sister genes (as opposed to an error in the assembly) is that the 
synteny surrounding the two gene clusters is different. Although both sets o f  genes 
are flanked by a cluster of sialidase genes, the number of genes annotated within 
these clusters varies (Figure 3.1), suggesting that divergence may have occurred 
following a duplication of this area. Figure 3.1 shows the presence o f  three sialidase 
{nen) genes 5 ’ o f  dejbl2 at position 23.20Mb. compared to just one 5 ’ to the second 
defbl2  at position 23.40Mb. Paralogous genes can be expected to show some 
divergence (unless their founder duplication event occurred very recently). Although 
the transcribed sequences of defbl2.1 and defbl2.2 were identical, some evidence of 
divergence can be seen when comparing the sequences of defbl 1.1 and d e fb ll.2. 
There are seven single nucleotide changes between the two gene transcripts (Figure 
3.2a), however only two o f  these lie within the translated region o f  the gene. One of 
these two mutations is silent and the other leads to a point mutation in the signal 
sequence of the Detbll peptide (leaving the mature peptides identical)(Figure 3.2b). 
Since these changes were only single amino acids, it was not possible to 
differentially amplify the individual transcripts using RT-PCR. In addition, 
sequencing the gene yielded a single sequence identical to d e fb ll.2, with no duplicity 
being detected at the point mutation areas. This could indicate that defbl 1.1 is an 
error in the zebrafish assembly, but might also indicate differential expression o f  the 
genes.
The defbll. f  defbl2.1, defbl2.2 and dejbl3 genes have all been removed from the 
new zebrafish assembly (Zebrafish Zv9, November 2010), leaving just defbl 1.2 














£  CD -=
Q *A






















£  CD CD ¿j 4¡ <
■2Za . OC
I .  Z II
w g 









fT3 1) ■*—< x:
b ß
-C  c/3
b ß  £>
I G32 <ubß

















'■H r l  ^  
§  <N U
8 «&^ cu- 
co "Q <N eg 
<U g








c  ^  ,2 ni_H CO
£ g) r~ uj o 
£  o  w o



































































3  tcD 
§ -S
O G 




C  Ü  Ofl 
O  -C N
'5b -Eû
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since experimental data have shown that defbl2  and de/b/3 are transcribed and both 
the Zv8 and Zv9 assemblies are categorised as “preliminary” , I will utilise the 
Zebrafish Zv8. August 2010 release of the genome in this thesis. Moreover, since I 
have not proven the existence o f  d e fb ll.l and defbl2.1 and the mature peptide 
sequences are similar (de/b //) and identical (defbl2), the analysis in this thesis refers 
to a single de/b// and de/b/2, based on the 3 ’cluster (at 23.40Mb).
3.4 EXPRESSION OF THE ZEBRAFISH DEFENSINS
Zou et a/., 2007 previously demonstrated the expression (at the RNA level) o f  d e jb ll , 
dejb/2  and de/b/3 in various tissues o f  the healthy zebrafish adult. In order to 
investigate whether expression levels were inducible in response to infection (as is 
seen with many mammalian defensins, see Section 1.4), it was decided to observe 
RNA levels in both healthy and infected zebrafish embryos.
3.4.1 Expression of zebrafish defensins in embryos
Zebrafish embryos presented an inviting model for this study, in particular because 
this would eliminate the need to perform invasive techniques on adult fish, reducing 
breeding stocks. In addition, since the defensins are part of the innate immune 
system, it is reasonable to expect them to be expressed in zebrafish embryos (which 
possess innate but not adaptive immunity at this stage).
RT-PC’R was used to investigate the expression levels o f  the three genes in embryos 
aged 24hpf (hours post fertilisation) (Figure 3.3a). de/b/1 was the only gene detected 
in the early embryo, so to ascertain when defb/2 and de/b/3 are first expressed, a 
panel o f  cDNA taken from larvae aged 3dpf, 5dpf, 6dpf and 7dpf and RT-PCR was 
performed again (Figure 3.3b). defb /i was present in all the tested stages, whereas 
defbl2  and de/h/3 could only be detected in 6dpf and 7dpf embryos (faint bands for 
defb/3  were verified by sequencing).
Since these experiments were performed on healthy embryos, it was reasoned that 
defb/2  and defb/3 might be inducible following embryonic/early larval infection.
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a Adult 24hpf Embryo
-ve 1 2 3 1 2 3 -ve
300bp
200bp
defb ll defbl2 defbl3
3d 5d 6d 7d -ve 3d 5d 6d 7d -ve 3d 5d 6d 7d -ve
Figure 3.3 Embryonic expression of the zebrafish defensins
(a) shows the results o f  RT-PCR analysis looking for defbl 1, defbl2 and defbl3 in 
cDNA from 24hpf embryos. A panel showing adult expression was included as a 
positive control. Bands were verified following gel purification by sequencing 
analysis (data not shown).
(b) depicts RT-PCR analysis carried out in larval embryos at 3dpf. 5dpf, 6dpf and 
7dpf. The lower band in these gels represents primer dimer and the upper bands 
(white arrows) were verified by sequencing.
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48hpt larvae were treated with lOng/ml LPS for a period of 6 hours and were then 
sacrificed and RNA was extracted. RT-PCR analysis revealed that defb!2 and de/b/3 
were still undetectable in these embryos (Figure 3.4a), however, since LPS-treated 
larvae showed no outward signs o f  infection and did not have decreased viability 
compared to controls (data not shown), it is unclear whether any immune response 
was effected by the LPS-treatment.
Zebrafish embryos commonly succumb to infection when their incubation medium is 
not cleaned out regularly. To investigate whether the defb/2  and defbl3 could be 
induced in larvae in response to these natural fish pathogens, embryo medium and 
embryos were cultured for 48 hours without cleaning out or refreshing the medium. 
48hpf fresh larvae were then harvested, dechorionated and incubated for a further 6 
hours in the cultured “dirty” medium, which showed clear fungal and bacterial 
infection. Larvae were harvested at 54hpf and RT-PCR was performed for defb ll, 
defbI2 and defbl3. No expression for defbl2 and dejbI3 was detected (Figure 3.4b). 
Survival o f  treated larvae was again, no different to the survival of the control treated 
larvae (data not shown), so it is unclear whether lack of infections was the reason 
that no induction was seen. This study suggests that a more robust method of 
infection should be optimised prior to repeating the investigation.
3.5 ANTIMICROBIAL ACTIVITY OF THE ZEBRAFISH DEFENSINS
The defining characteristic o f  the (3-defensin family is the ability to kill or inhibit the 
growth o f  a broad spectrum of microbes. To address whether Defbll, Defbl2 and 
Defbl3 are antimicrobial, synthetic preparations o f  the mature peptides (synthesised 
by collaborator Derek Macmillan, UCL) were tested in vitro against a panel of 
pathogens (Table 3.2). This panel was chosen to include a range o f  gram positive and 
negative bacteria and the fungus Candida albicans. The panel also included a 
number of opportunistic human pathogens (e.g. Acinetobacter baumannii) to dually 
investigate whether any of these peptides would have potential value as base peptides 
for the development of novel antibiotics. Finally, Edwardsiella tarda was also 
included as an established natural zebrafish pathogen to address the idea that the 
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Figure 3.4 The inducibility of the zebrafish defensins
(a) shows the detection, by qRT-PCR of  actin and the zebrafish defensins in 54hpf 
embryos following a 6 hour incubation with lOng/ml LPS.
(b) shows the detection, by qRT-PCR of  actin and the zebrafish defensins in 54hpf 
embryos following a 6hr incubation in bacteria and fungi-contaminated embryonic 
medium
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previously been shown that E. tarda provokes an inflammatory response in zebra fish 
(Pressley et al., 2005), so it was reasoned that natural zebrafish defences may be 








S. a u reus Positive
C. albicans Fungus
Table 3.2 List of organisms used in zebrafish defensin antimicrobial 
assays
3.5.1 Antimicrobial activity of the zebrafish defensins against human 
and zebrafish pathogens
Mature peptide sequences, as reported by Zou et al., 2007 (Table 3.3) were 
synthesised “in-house” (Defbll, Defbl3; Derek Macmillan, UCL) or were purchased 
from United Peptide Corporation. Peptides were not folded following the reports (as 
summarised in Section 2 .1) that antimicrobial activity is not dependent on 3D 
structure.
In vitro antimicrobial analysis was performed using Defbll, Defbl2 and Defbl3 
against a panel of microbes at 37°C (Figures 3.5-3.8). Minimum bactericidal 
concentration (MBC) values were determined to assess the minimum concentration 
of peptide required to kill 99.99% initial microbial inoculum.
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Peptide Sequence AG Charge
Defbll ASFPWSCASLSGVCRQGVCLPSELYFGPLGCGKGFLCCVSHFL +4.01 + 2
Deft) 12 AEVQIQNWTC-GYGGLC-RRFCFDQEYIVAHHGCPRRYRCCAVRF - 6 .7 6 + 5
Detbl3 NDTDVQRWTC- GYRGLC-RKHCYAREYMIGYRGCPRRYRCCALRF -5.12 + 8
Table 3.3 Sequences of the mature zebrafish defensins
This table depicts the mature peptide sequences (following cleavage of the signal 
sequence) o f  the zebrafish defensins, as predicted in Zou et a!., 2007.
3.5.2 Antimicrobial activity of the zebrafish defensins against human 
and zebrafish pathogens
Detbll showed no activity against any o f  the strains tested at the highest tested 
concentration o f  lOpM (Figures 3.5-3.8). In contrast, Defbl2 showed weak 
antimicrobial activity (MBC = lOpM) only against P.aeruginosa (Figure 3.5), 
whereas Defbl3 showed notable activity against all tested strains, with MBCs 
ranging from 3.1 (±0.6) pM (P.aeruginosa, Figure 3.5) to 10 (±0.0) pM (E.tarda, 
Figure 3.7). No striking pattern in the specificity o f  activity o f  Defbl3 was observed 
and the peptide showed a moderate level o f  activity against both gram positive and 
negative bacteria, E.tarda and the fungus, C.albicans. A summary o f  the MBC 











Figure 3.5 Bactericidal activity of the zebrafish defensins against gram 
negative bacteria
The graph depicts the antimicrobial activity (measured as MBC, pM) of the zebrafish 
defensins, as compared to the very potent murine D efbl4 (described in Chapter 2). 
Data is based on three independent experimental repeats and error bars represent the 
standard error o f  mean (SEM). Where no error bar is depicted, SEM = 0.0.














Figure 3.6 Bactericidal activity of the zebrafish defensins against gram 
positive bacteria
The graph depicts the antimicrobial activity (measured as MBC, pM) o f  the zebrafish 
defensins, as compared to the very potent murine D efbl4 (described in Chapter 2). 
Data is based on three independent experimental repeats and error bars represent the 
standard error o f  mean (SEM). Where no error bar is depicted, SEM = 0.0.
Faded out bars (Defbll and Defbl2) denote peptides which did not achieve a MBC at 







m Defbl4 zDefbll zDefbl2 zDefbl3
Peptide
Figure 3.7 Bactericidal activity of the zebrafish defensins against the 
gram negative fish pathogen, E.tarda.
This graph depicts the bactericidal activity o f  the zebrafish defensins against a 
pathogen known to infect fish, E.tarda. Faded out bars indicate the peptide failed to 
achieve a MBC at the depicted concentration. Murine D efbl4  has been shown to 
illustrate the MBC achieved by a very potent antimicrobial.
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Figure 3.8 Antimicrobial activity of the zebrafish defensins against the 
fungus, C.albicans
This graph depicts the antimicrobial activity (measured using MBC,pM) o f  the 
zebrafish defensins against the fungus C.albicans. Faded out bars (Defbll and 
Defbl2) imply that the peptide did not achieve a MBC at the depicted concentration. 
Murine D efbl4  has been included as an example o f  the MBC which can be expected 
when treating with a highly potent antimicrobial.
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3.5.3 Serum and salt sensitivity of the antimicrobial activity of Defbl2 
and Defbl3
To investigate the antimicrobial activity o f  Defbl2 and Deth>13 under more 
physiological conditions, in vitro antimicrobial assays were performed with the 
addition o f  serum and sodium chloride at varying concentrations. Defbl2 lost all 
activity (no MBC could be obtained) against P.aeruginosa  when incubated in the 
lowest concentration o f  sodium chloride (50mM) and 1% (v/v) foetal calf serum 
(data not shown), indicating its activity is both salt and serum sensitive.
DefbD was tested for serum sensitivity against P.aeruginosa, as a representative of 
gram negative bacteria, S.aureus as a representative o f  gram positive bacteria and 
C.albicans. Although the addition of 5% and 10% serum significantly affected the 
MBC against all three strains (Figure 3.9a-c), lower level activity (MBC = 10 ± 0.0 
pM ) was still retained at 10% serum against both P.aeruginosa  and C.albicans 
(Figure 3.9a,c), although activity was lost against gram positive S.aureus at serum 
concentrations o f  5% upwards (Figure 3.9b).
The activity of Defbl3 alone was tested for salt sensitivity against P.aeruginosa  as a 
representative gram negative organism and S.aureus as a representative gram 
positive organism. The bactericidal activity of DefbD showed a higher sensitivity to 
salt levels than serum, and its activity against P.aeruginosa was affected significantly 
upon incubation with lOOmM NaCl (MBC = 10 ±0.0 pM) and activity was lost in 
200mM NaCl (Figure 3.10a). Mirroring the results from the serum sensitivity 
experiments, DefbD activity against S.aureus showed an increased sensitivity, with 
significantly higher MBCs arising with the addition o f  just 50mM NaCl (MBC = 




This figure illustrates the sensitivity of the antimicrobial activity of Defbl3 in varying 
concentrations o f  foetal calf serum (% value refers to v/v mixture) against:
(a) gram negative P.aeruginosa
(b) gram positive S.aureus
(c) C.albicans (fungus)
Data is based on three independent experimental repeats and error bars depict SEM 
values. Where bars have been faded out, the peptide did not achieve a MBC at the 
depicted highest tested concentration.
* p<0.05, where no MBC was achieved, significance was calculated using the 
highest tested MBC value.
Figure 3.9 Serum  sensitiv ity o f the antim icrobial activity o f Defbl3 (figu re
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Figure 3.10 The salt (NaCI) sensitivity of the antimicrobial activity of 
Defbl3
This figure illustrates the sensitivity o f  the antimicrobial activity o f  Defbl3 in varying 
concentrations o f  NaCI salt against:
(a) gram negative P.aeruginosa
(b) gram positive S.aureus
Data is based on three independent experimental repeats and error bars depict SEM 
values. Where bars have been faded out, the peptide did not achieve a MBC at the 
depicted highest tested concentration.
* p<0.05, where no MBC was achieved, significance was calculated using the 
highest tested MBC value.
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3.6 DISCUSSION
3.6.1 Novel members of the zebrafish p-defensin-like family
In this study, a genome-wide search was performed in order to discover new (3- 
defensin-like genes, in addition to the original three genes reported in Zou et al., 
2007. A shortlist o f  five candidate genes was identified, however no transcripts could 
be detected for any of these genes in either embryonic or whole adult cDNA.
While this search did not identify any novel zebrafish defensins, it presents the 
opportunity for further work in the area and does not necessarily imply that there are 
only three defensins in the zebrafish genome. Since it is known that human p- 
defensins are induced in response to infection (Harder el al., 1997; Garcia et al., 
2001; reviewed in Section 1.4), it may be that the five candidate transcripts tested in 
this study would be detectable in cDNA taken from diseased adult fish.
Since the time available to investigate this aspect o f  the project was limited, this 
analysis was not pursued; however the study could be completed in future work. 
Repeating the analysis described in this chapter using the new zebrafish assembly, 
Zv9 might bring new insights to the study however, the issue of the deletion o f  the 
d e fb l l . l , defbl2.1, defbl2.2 and dejbl3 genes would first need to be addressed. O f 
particular interest would be the study o f  the d e jb ll.l  and defb ll.2  paralogues. 
Although the genes are very similar and the predicted mature peptides are identical, 
the point mutation in the signal sequence may result in the peptides being secreted in 
different subsets of cells. Alternatively, the regulation o f  the genes might vary, 
providing alternative roles for the genes. A further explanation could be that 
zebrafish show copy number variation (CNV) at this locus. Copy number variation 
has been reported at the human 8p23.1 locus (Hollox et al., 2003) and this type of 
variation is notoriously difficult to sequence accurately. Since the zebrafish genome 
sequence is not based on the sequence of a single homogenous zebrafish, it is 
possible that the confusion arising in this area is down to copy number variation at 
this locus between the different fish sampled.
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3.6.2 Expression of the zebrafish defensins
Prior to tliis study, Zou et al., 2007 found that d e fb ll , dejbl2 and defbl3 are expressed 
in a variety o f  healthy adult tissues. Oehlers et al., 201 1 extended this study and 
detected the expression of all defb ll and defbB  in zebrafish larvae. In the work 
described in this chapter, I have shown that defb ll can be detected in the early 24hpf 
embryo and that defbl2  and defb!3 can be detected in 6-7dpf larvae.
1 reasoned that although defbl2 and defbl3 were not detectable in the early embryo, 
they might still be inducible in the 24-48hpf embryo following exposure to microbial 
stimuli. To investigate this, embryos were first treated with a lOng/ml LPS solution 
and expression was examined. Watzke et al., 2007 demonstrated that immersion of 
zebrafish larvae in LPS could induce the key genes in the innate immune response 
including IL-1|3 and TNF-a, so this experimental technique was used. Again, defbl2 
and defhl3 were not detected in cDNA from these larvae, however analysis o f  
expression o f  1L-1 (3 and TNF-a (using the primers from Watzke et al., 2007) 
revealed expression o f  these genes in both control and treated larvae (data not 
shown). Bleaching and dechorionating control early embryos and growing in sterile, 
autoclaved medium did not remove the presence of these bands (data not shown). 
Since it was not possible to prove that the LPS induced any response in the treated 
larvae, it is not possible to assert that defbl2 and defbl3 are uninducible at this stage. 
Since the Watzke et al., 2007 study was earned out in younger (24hpf) embryos, it is 
possible that a higher concentration of LPS would be required for this experiment to 
be informative.
The induction o f  defbl2 and defb!3 was also investigated following treatment of 
48hpf larvae with a mixture of bacteria and fungi cultured from contaminated 
embryo medium. As seen with the LPS study, no induction of defbl2 and defbl3 was 
observed. This experimental technique was chosen so that “natural” (within the 
confines o f  the fish facility) fish pathogens could be tested. I hypothesised that these 
microbes would be more likely to induce an immune response than any cultures of 
lab strain bacteria, however no induction was observed.
While these two studies indicate that defb ll and defb/3 are not inducible in young 
larvae, it is possible that they are inducible in response to a specific, as yet untested
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stimulus. For example, Proud et a/., 2004 demonstrated that HBD2 is inducible in 
epithelial cells in vivo in response to rhinovirus infection. It is possible that defbl2 
and defbl3 could be virally induced, in which case this study would not have 
identified the induction. The work described in this thesis should therefore be viewed 
as preliminary findings which could be expanded in future studies.
A major weakness o f  this work was the inability to confirm infection using infection 
markers. Analysis o f  the EST Profile of both 1L -113 and TNF-a using Unigene 
suggests the genes are normally expressed in the zebrafish embryo and larva. To 
resolve the problem of infection confirmation, a number o f  steps could be taken. 
Although IL-1 (3 and TNFa may normally be expressed at low levels in developing 
larva, Watzke et a /., 2007 have shown the genes to be inducible. It is therefore 
probable that any changes in gene expression could be examined quantitatively using 
qRT-PCR. Analysing expression o f  treated embryos in comparison to control 
embryos would result in a fold change which could be used to identify any induction 
of the immune response.
Alternatively, Stockhammer et a /., 2009 published a transcriptome modelling study, 
analysing changes in expression of innate immunity genes in response to Salmonella  
species infection. A set of genes could be chosen from this analysis to create a panel 
of genes known to be induced following bacterial infection.
Finally, the infection of larvae GFP-tagged bacteria would allow for time course 
experiments to be carried out. This would allow the infection to be visualised within 
the larval tissues before RNA extraction and analysis.
An alternative approach to examining the role of defb ll, defbl2 and defblS in 
zebrafish embryos and young larvae would be to employ morpholino technology. 
This would allow for the observation of the effects of a transient knockdown o f  the 
genes on fish survival in the presence of a variety of organisms. This could give 
insight into the in vivo immune function of these genes.
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3.6.3 Antimicrobial activity of the zebrafish defensins
This analysis used a series o f  in vitro assays testing synthetic preparations o f  the 
zebrafish defensins against a panel o f  microbes. The work indicated that Defbl 1 is 
inactive against all tested strains and that Defbl2 shows a low level activity specific 
to P.aeruginosa, whereas DefbB shows moderate antimicrobial activity against the 
full range o f  tested microbes.
The inactivity o f  Defbl I may be explained in a number o f  ways. It is possible that the 
peptide is not antimicrobial and that instead, it has takes on another role in zebrafish 
immunity, for example, a role in the chemoattraction o f  immune cells to sites of 
infection, as is the case with Defbl4 (Taylor et al., 2008). Since defbl 1 mRNA was 
previously detected in a number o f  zebrafish tissues frequently exposed to bacteria, 
for example the gut and gill (Zou et al., 2007), this presents a viable option for the 
peptide’s function. Alternatively, the peptide may have evolved specific activity to 
one type of microbe, untested and therefore undetected in this assay. In particular, it 
should be noted that the organisms tested in this study were grown and assayed at 
37°C. It may be more informative in future studies to test fish-specific organisms at 
the physiological zebrafish temperature of 28°C.
However, it is equally possible that Defbl 1 is antimicrobial, but that the activity has 
not been detected in this in vitro experiment. A recent paper on the human p-defensin 
HBD1. showed that its low level activity can be drastically improved against a range 
o f  commensal bacteria and fungi under reducing conditions (Schroeder et al., 2011). 
This work illustrates the importance of the chemical conditions required for 
antimicrobial activity. It is possible, therefore, that Defbl 1 could display 
antimicrobial activity in vivo and that its inactivity in my assays is a product of 
testing in vitro. However, since many vertebrate peptides are antimicrobially active 
under in vitro conditions, it is impossible to predict whether Defbl 1 is truly inactive 
or not without further experimentation (potentially in vivo).
In addition, the inactivity o f  Defbl 1 might be explained by the fact that the peptide 
tested in this assay is synthetic. The test peptide was not folded post-production, and 
in addition is lacking any posttranslational modifications which might occur in vivo. 
Since the full requirements and mechanisms of antimicrobial activity are unknown,
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this may have contributed to the inactivity o f  Defbll. However, given the combined 
low charge and hydrophobieityof Defbll, it is also arguable that the peptide is 
antimicrobially inactive in vivo.
Defbl2 showed singular weak activity against P.aeruginosa. While the same issues 
encountered with Defbl I o f  synthetic structure and in vitro testing also apply to this 
peptide, it may also highlight another problem with the concept o f  synthesising 
peptides chemically. All three defensin peptides analysed in this study were 
synthesised as mature peptides, based on the signal sequence predictions made by the 
software Signal P 3.0. While the sequences for Defbll and DefbB showed clearcut 
signal sequence cleavage sites, Defbl2 contained two potential cleavage sites (Figure 
A 1.1, A 1.2). For the purposes of this study, the shorter peptide was chosen due to its 
similarity to the sequence o f  Defbl3 and previous publication in Zou et al., 2007. 
However, since this decision was based on homology and probability, it is entirely 
possible that the synthetic Defbl2 peptide tested in this assay was shorter than the 
physiological mature peptide. In Chapter 2, I illustrated the importance short amino 
acid sequences can have on bactericidal activity within the context o f  a larger 
molecule, so it may be that the addition of the missing N -terminal amino acids o f  the 
Defbl2 mature peptide would improve its in vitro antimicrobial activity.
In order to definitively determine the correct sequence o f  Defbl2, it would be 
necessary to purify the peptide from adult zebrafish. Work aimed at isolating 
antimicrobial peptides from whole zebrafish extracts is currently ongoing (D. 
Campopiano, personal communication), and this work may uncover the true structure 
of Defbl2.
Supporting the notion that Defbl2 has more potent antimicrobial activity in vivo is 
the observation that the gene could only be detected in the gut o f  healthy adult 
zebrafish (Zou et a l., 2007). Since the gut is heavily laden with antimicrobial 
commensals, it is possible that Defbl2 is expressed in this region in response to and 
in order to control the microbial load.
DefbB showed moderate activity in vitro when compared to other potent mammalian 
antimicrobials such as HBD3. However, it is again possible that the in vivo activity
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of  this peptide might be improved over the results observed in this analysis. One 
major reason for this is the discrepancy between the temperature at which the 
antimicrobial assays were carried out (37°C) and the temperature at which Defbl3 
would function in vivo (28°C). It might be that the peptide’s activity becomes more 
(or less) potent at this lower temperature. There has been some evidence to suggest 
that bacteria alter the chemical composition o f  their cell membranes in response to 
different temperatures, with P.aeruginosa being reported to alter its membrane 
hydrophobicity following a reduction to 28°C (Hori et a /., 2009). Since the P- 
defensins’ mode o f  action appears to be dependent on a delicate balance o f  charge 
and hydrophobic interactions with the membrane, then it is reasonable to suppose 
that altered cell wall composition could alter antimicrobial activity. In order to gain 
better insight into this, the antimicrobial assays could be repeated in vitro at 28°C and 
any differences in activity could be observed. In addition, this repeated assay could 
provide interesting insights to the issues o f  serum and salt sensitivity. For example, 
the serum sensitivity observed may have occurred due to direct inhibition o f  the 
peptide, or alternatively degradation. Peptide degradation might be less efficient at a 
lower temperature, resulting in a lower serum sensitivity. The issue of peptide 
degradation could be addressed in further work by analysis of the peptides in a, post­
antimicrobial assay using mass spectrometry.
In summary, this analysis revealed that Defbl3 has broad spectrum antimicrobial 
activity, suggesting that the zebrafish defensin family may have an important role in 
zebrafish immunity. Although the peptide is not as potent an antimicrobial as HBD3, 
it still possesses solid, broad spectrum antimicrobial activity. The peptide may, 
therefore, provide insights for future work in the field of antibiotic development. In 
particular, its consistent activity against a range of different types o f  microbes 
suggests that it might be useful to studies aiming to produce novel broad-spectrum 
antibiotics.
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3.7 CONCLUSIONS AND FUTURE DIRECTIONS
In this chapter, the expression and antimicrobial role of the zebrafish defensins was 
investigated. While this work did not result in the identification o f  any novel 
zebrafish defensin family members, it was shown that defb ll is expressed in early 
zebrafish embryos, whereas defbI2 and defbl3 are only expressed in older larvae. 
Furthermore, this work suggested that defhl2 and defbB  may not be inducible in 
response to the stimuli tested in larval fish.
In addition, a detailed analysis of the in vitro antimicrobial activity o f  synthetic 
zebrafish defensin preparations was performed, suggesting that Defbl3 has potent 
antimicrobial activity against a range of different bugs.
The findings in this chapter are of value in two different areas. Firstly, the findings 
support the mounting evidence that the defensins are important in the immune 
system of zebrafish, and by association, other teleosts. In addition, the work 
described has identified DefbB as a broad spectrum antimicrobial peptide which may 
have relevance to future studies attempting to develop non-human defensins for use 
as clinical antimicrobial drugs.
Both o f  these areas o f  interest present interesting avenues for future research. In 
order to further understand the role of the defensins in zebrafish immunity, studying 
the action of the peptides in vivo might prove to be beneficial. Producing knock out 
transgenics for the three genes would allow for detailed infection studies to take 
place, where increased illness, or increased recovery times might indicate the 
importance of the genes in the pathology of disease. However, since it is unknown 
whether there are additional members of the defensin family in the zebrafish genome, 
this study might become ambiguous if unknown redundant members of the family 
are able to compensate for the lack of antimicrobial activity a knockout might 
produce.
To study further the question of whether the zebrafish defensins are inducible, 
detailed studies could be carried out in adult fish. A fully controlled experiment 
could involve tank mates being separated and groups being subjected to 
intraperitoneal injections of varied preparations of different classes of known fish
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pathogens and commensals. It could then be ascertained whether the infections 
produced higher levels of defensin expression with respect to healthy, untreated 
tankmates. Alternatively, some success has been observed in infection studies where 
single scales are removed from the skin of adult fish, allowing fish to be infected via 
the wound upon immersion in a solution containing various microbes (Pressley el a/., 
2005). This would present a less invasive method to approach the experiment.
In conclusion, the w'ork in this chapter presents an interesting introduction to the 
zebrafish defensins, investigating both their suitability as candidates for novel
therapeutics as well as beginning to define their role in the innate immunity of
zebrafish. Ultimately, gaining a better understanding of zebrafish immunity might 
have implications as far reaching as the fishing industry, where an improved 
knowledge o f  fish immunity might lead to genetic engineering to produce
commercial fish more resistant to disease.
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Chapter 4: The Role of d e f b l l  in Developm ent in D a n io  r e r io
“One sometimes finds what one is not looking f o r ’’ 
Sir A lexander Fleming
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4.1 PREFACE
In Chapter 3, the antimicrobial properties of the [i-defensin-Iike peptides were 
investigated. The study indicated that defbll is the only member o f  the defensin 
family expressed in zebrafish embryos, yet a synthetic preparation failed to show any 
antimicrobial activity in vitro. In this chapter, I investigate the role o f  defb ll in 
greater depth, in order to establish its role in the early zebrafish embryo, with 
particular emphasis on establishing whether the peptide has a potential role in early 
zebrafish development.
4.1.1 Zebrafish development: an overview of the first 24 hours
Zebrafish embryonic development occurs rapidly, in well-documented stages as 
described in Kimmel et al., 1995. An overview o f this comprehensive study is 
described below.
Eggs are fertilised ex vivo and begin as a single cell attached to a large yolk mass 
(Figure 4 .1 a). This initially undergoes rapid, synchronous cell divisions, with 
divisions occurring roughly every 15 minutes (Kimmel et al., 1995). From 
approximately 2.25hpf onwards (Figure 4.1c), the group o f  cells (the “blastodisc” ) 
begin to lose their cell cycle synchrony. This marks entry into the midblastula 
transition (MBT) where the cells become motile and embryonic transcription initiates 
(Kimmel et al., 1995). Epiboly (Figure 4. Id), one o f  the first cellular rearrangements, 
begins in the late blastula stage, where the cells of the blastodisc thin and radiate 
over the surface of the embryonic yolk, until the whole surface is covered.
When the embryo reaches 50% epiboly, it enters the gastrula period o f  development 
(Figure 4.1e), where the first large-scale morphogenic events occur. During 
gastrulation, the undifferentiated blastula cells undergo a series of movements and 
rearrangements in order to form three embryonic germ layers (the endoderm, 
ectoderm and mesoderm) which ultimately give rise to a fully patterned embryo 
(reviewed in Rohde and Heisenberg, 2007). The cell movements driving vertebrate 
gastrulation are evolutionarily conserved (Solnica-Krezel, 2005) and result in the 














50% -epiboly 75% -epiboly 90% -epiboly bud
5.3 h 8 h 9 h 10 h
6-som ite 14-somite 21-somite
12 h 16 h 19.5 h
Figure 4.1 Zebrafish developmental stages (edited from Kimmel et al., 
1995)
This figure depicts “camera lucida” sketches of the developing embryo at various 
stages. Embryos are orientated are shown from the lateral side, with the dorsal side 
on the right. Embryonic stages are labelled according to their anatomical stage and 
the timepoint at which this developmental stage is reached.
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During gastrulation, cells from the lateral and ventral edges o f  the embryo converge 
on the dorsal, leading to a thickening o f  the dorsal side of the embryo (Figure 4 . If). 
At the same time as these convergence movements occur, extension o f  cells along 
the anterior-posterior axis occurs along the dorsal side of the embryo (Figure 4.1 h).
Following gastrulation, the embryo enters the segmentation period whereupon 
somitogenesis begins (Figure 4. li,j) and the tailbud extends and elongates to form 
the embryonic tail depicted in Figure 1.41 at 24hpf. Organogenesis occurs in post 




The main aim o f  this chapter was to investigate the role of defb ll in zebrafish 
embryos in the light of the findings o f  Chapter 3, where I could not detect an 
antimicrobial function for the Defbl 1 peptide, despite detecting expression in the 
early embryo. In order to gain insight into the role o f  the gene, it was decided to 
investigate:
1. the effects o f  transiently knocking down dejb ll expression using morpholino 
oligonucleotides
2. wholemount in situ hybridisation (WISH)
3. genome-wide expression analysis in defbl knockdown mutants
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4.3 DEFBL1  EXPRESSION
4.3.1 d e fb ll is expressed in the early embryo
As described in Chapter 3, analysis using RT-PCR revealed defb ll is the only 
documented zebrahsh defensin to be expressed in the early embryo at 24hpf. To 
investigate the expression pattern in further detail, RT-PCR was performed on 
embryos harvested between 8hpf and I8bpf. Transcripts for defb ll were detectable 
from I2hpt (in this case, I2hpf embryos were staged at tail bud stage), and 
expression was detected continuously after this time point (Figure 4.2). In order to 
determine the location o f  the transcripts, in situ hybridisation was performed on fixed 
I3hpf and 24hpf embryos. Expression of defb ll was difficult to observe at 13hpf and 
no difference was observed between embryos stained with a defb ll probe and the 
corresponding sense probe (data not shown), indicating that expression levels are too 
low to detect. However, at 24hpf, defb ll appeared to localise to the embryonic head. 
From a lateral view, the staining is situated just outside (dorsal) of the developing 
eye (Figure 4.3b,c), appearing to localise to the diencephalon. When viewed from 
directly above the embryonic head, it can be seen that the staining localises to two 
symmetrical sites seemingly at the border of the telencephalon and the eye (Figure 
4.3a,d).
4.3.2 Transient knockdown of de fb ll causes multiple developmental 
defects
To gain insight into the function of defbll in the early embryo, transient knockdowns 
were performed using morpholino technology. Morpholino oligonucleotides are 
short, single-stranded nucleotides possessing a modified DNA backbone comprising 
a six-carbon “morpholine” ring to replace the pentose ring observed in the nucleic 
acids. In addition, the oligomerising phosphate bonds seen in DNA are substituted 
with non-ionic, lower-charged phosphodiamidate links in the morpholino (Figure 
4.4a) (Summerton, 2007). Morpholinos are widely used to transiently knock down 
gene expression in zebrafish and other organisms by binding mRNA transcripts (by 
Watson-Crick base pairing) to physically (sterically) block either translation or 
correct splicing, in a sequence-dependent manner. The modifications to the 
morpholino backbone enhance the stability of the oligomers in vivo and minimise
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defbll 6-actin
12h 14h 15h 18h I2h 14h 15h 18h
Figure 4.2 Expression of d e fb ll at different developmental stages
Embryos harvested at 12,14,15 and 18hpf were analysed for defb ll and ß-actin  
expression (positive control). Embryos were staged prior to sacrificing and 12hpf 
corresponded to the tailbud stage o f  development (as described in Kimmel et al., 
1995)
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Figure 4.3 Wholemount in situ hybridisation staining for d e fb ll in 24hpf 
embryos
(a) embryo depicted from dorsal anterior view. Arrows point to two areas o f  defb ll 
staining. The contrast in this picture has been digitally altered to better reflect 
observations made “by eye” .
(b)/(c) defb ll staining viewed in lateral orientation
(d) Depicts a section through the zebrafish embryonic brain at 48hpf (dorsal view), 
showing the location o f  the diencephalon with respect to other neural tissues, (taken 
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Figure 4.4 defb/1 morpholino sequences
(a) Morpholino structure is based on that o f  DNA and is such that morpholino 
oligonucleotides can sterically block complementary DNA sequences. Morpholinos 
consists o f  a modified six-carbon “morpholino” ring linked by phosphodiamidate 
bonding. Picture taken from Eisen and Smith, 2008.
(b) This section depicts the positioning of the defbll morpholinos used in this study 
in the defb ll sequence.
Tl = translation block one morpholino, T2 = translation block 2, SI = splice block l, 
T1/T2 = area where the Tl and T2 morpholinos overlap.
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off-target effects since their synthetic nature minimises their interactions with 
cellular proteins (Summerton, 2007).
A translation block morpholino (“T l ”, Figure 4.4b) was first used to knockdown 
dejb ll. Translation block morpholinos prevent the assembly of the translation 
initiation complex at the 5 ’UTR of  the target mRNA sequence. Embryos were 
observed throughout the first 24 hours o f  development to determine the effects o f  the 
transient knockdown. As shown in Figure 4.5, morphants appeared to develop 
normally until the tailbud stage, where they began to show a marked developmental 
delay in comparison to control embryos. This delay was highly penetrant, affecting 
98% (n=152) morphant embryos. It became more pronounced as development 
progressed resulting in a shortened anterior-posterior axis by 24hpf.
Since convergence and extension cellular movements drive the elongation and 
narrowing o f  the embryonic anterior-posterior axis during development, it was 
reasoned that the observed delay might be caused by a defect in these morphogenic 
cell movements. To quantify this delay, the distance between the head and tail o f  the 
morphants was measured, to gauge any difference in anterior-posterior axis 
elongation. Measurements were taken at both 13hpf and 14hpf, and it was found that 
the axis elongation was significantly decreased in morphants (compared to controls) 
at 14hpf (2-4 somites) (Figure 4.6). The shortened anterior-posterior axis can be 
observed clearly in 24hpf morphants (Figure 4.7a,b).
To gain further insight into the convergence-extension defect, wholemount in situ 
hybridisation (WISH) was carried out to visualise the location o f  a number o f  key 
cell movement markers. Embryos were firstly stained for hggl and dlx3. h g g l , a 
marker of the anterior-posterior axis and dix3, a convergence marker which localises 
to the edge o f  the neural plate (either side o f  the developing notochord; Schulte- 
Merker et al., 1994) were stained in 14hpf (4-somite) control and morphant embryos. 
In the defb ll morphants, hggl showed more diffuse staining than control embryos, 
whereas the dix3 showed a dramatic change, with staining indicating the neural plate 
was wider than in wild types. This suggested that convergent cellular movements 
were retarded in the morphant embryos (Figure 4.8). The movement defect was 
quantified and found to be statistically significant (Figure 4.9).
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Control defb ll MO
Figure 4.6 Head-tail distance in 14hpf control and d e fb ll morphant 
embryos
Head-tail distance was measured (pm). The difference between morphants and 
control-injected was significantly different (p<0.0005).
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Figure 4.7 The de fb ll morphant phenotype at 24hpf
This figure presents the defb ll morphant phenotype. The upper panel shows a wild 
type embryo, with a close up image showing brain and eye structure at higher 
magnification. The lower panel depicts a representative defbll morphant at 24hpf. 
The anterior-posterior axis is strikingly shortened and the brain shows no 
compartmentalisation (upper arrow) as seen in the control embryo. The developing 
eye is also an aberrant shape (lower arrow).
Scale bars = 100pm
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Control defb ll
Figure 4.8 Wholemount in situ hybridisation (WISH) on 14hpf d e fb ll 
morphants
Control-injected and defb ll morphant 14hpf (2-4 somite) embryos were stained for a 
number o f  developmental markers. The above shows representative pictures o f  the 
phenotypes observed. Sample numbers are provided next to gene names. For 
hggl/d lx3  staining, 31/33 stained embryos showed the aberrant phenotype depicted 
in the upper panel (data pooled from three independent injection sets).













Ctrl 14h D e fb ll 14h
Figure 4.9 Measurements of the neural plate in control and d e fb ll 
morphant embryos
14hpf (2-4 somite) hggl/dl.x3 stained control and defbll morphant embryos were 
collected and neural plate width was measured. The differences depicted in this 
graph were found to be statistically significant, p<0.001.
136
4.3.3 d e fb ll morphants develop brain and eye abnormalities
In addition to the developmental impairment, morphants developed an abnormally 
shaped head and eyes (Figure 4.7b). A near complete lack of brain 
compartmentalisation can be clearly observed at 24hpf in morphant embryos. In 
addition, the shape o f  the leading edge o f  the developing embryonic head appears 
more rounded and less defined in the morphants (Figure 4.7). Finally, the morphant 
eyes are observed to be smaller than wild type and differ in shape, adopting a more 
oval appearance. Sections through the eyes o f  4dpf morphant embryos showed the 
eyes were smaller in size than wild type (Figure 4.10), and lacked any evidence of 
differentiation to form the stratified layers observed in wild type embryos. This 
indicates a suspension o f  optical development prior to 48hpf when the layers first 
differentiate. The morphant lens, while remaining a similar size to the wild type, also 
contained nuclei (Figure 4.10), not seen in wild type embryos. No normal eyes were 
observed in morphant sectioned eyes slides (n=22).
4.3.4 Verifying the de fb ll morphant phenotype
Non-specific “off-target” effects are a possibility when using any knockdown 
technique. In zebrafish, these effects can include developmental delay and 
widespread neural necrosis and, in many cases, have been attributed to p53 activation 
(Danilova et a!., 2010). To ensure that the observed defb ll morphant phenotype was 
not due to non-specific p53 activation, defb ll “T l ” morpholino was injected into 
p 5 3 M2l4K'M2l4K embryos (these embryos encode a non-functional, dominant negative 
p53). Embryos were observed at 24hpf and 48hpf and still maintained the same 
mutant phenotype as described previously (data not shown), so p53  activation was 
ruled out as a primary cause of the mutant phenotype.
In order to further confirm the specificity of the observed defbll phenotype, a second 
translation block morpholino, “T2” was designed (Figure 4.4b) and injected into 
embryos. 80.9% injected embryos (119/147) were observed to show a developmental 
delay beginning at 13-14hpf, along with abnormal brain and eye structure at 24hpf 
(Figure 4.1 I), replicating the “T l ” morpholino phenotype. However, since “T2” has 
a 10 base overlap with “T l ” and therefore is not unique, the morphant phenotype w'as
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Figure 4.10 Sections through eyes of defb/1 morphants, compared to 
controls
(a) shows haematoxylin and eosin staining of sections through a control morpholino- 
injected embryonic eye (4dpf)
(b),(c) a representative image o f  a typical defb ll morphant eye at 4dpf (n=22). Arrow 
points out the presence of a persistent nucleus in the lens
Images captured at x20 magnification, scale bar = 100pm.
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also replicated using a splice-block morpholino, “S I” . The splice-block morpholino 
was designed to bind the 5 ’ regions o f  intron 1 and its adjacent exon to result in 
intron inclusion and a transcript containing a premature stop codon (Figure 4.4b, 
4.12a). As observed with morpholinos “T l ” and “T2”, 71% “S I ” morphants (n=l 12) 
showed a slowing o f  development, resulting in a reduced anterior-posterior axis at 
22hpf (Figure 4.12b). A higher concentration o f  “S I ” morpholino was required to 
achieve the same phenotype as “T l ”, and the penetrance was reduced (71% (80/112) 
morphants showed phenotype), however aberrantly spliced defb ll mRNA was 
detected in RNA from affected morphant embryos (Figure 4.12c). Sequencing 
revealed that the “S I ” morpholino allowed for the inclusion o f  both introns o f  the 
defb ll transcript (due to sequence similarity at the 5 ’ end o f  introns 1 and 2) and the 
presence of this aberrant transcript corresponded with the presence o f  mutant 
phenotype.
4.3.5 Rescue of d e fb ll morphants
In order to prove the specificity of the defb ll “T l ” morpholino, morphants were 
rescued using defb ll mRNA. The “T l ” morpholino was chosen to rescue due to the 
severity and high penetrance o f  the phenotype. Originally, mutations were introduced 
into the 5 ’UTR of the synthesised mRNA in order to prevent the morpholino from 
binding it. However, these mutants proved difficult to transcribe in adequate 
concentrations for injection, so it was decided an excess volume o f  wild type mRNA 
should have the effect of diluting the morpholino phenotype. As shown in Figure 
4.13, the co-injection o f  “T l ” morpholino and defb ll mRNA resulted in the recovery 
o f  a normal phenotype for 26.6% (25/94) injected embryos. In addition, a “dilution 
effect” was observed, with 22.3% (21/94) (embryos exhibiting a “mild” phenotype 
(classed as having either an eye or brain phenotype, not both), leaving only 28.7% 
(27/94) co-injected embryos showing the full defb ll morphant phenotype (vs 89.1% 
(1 14/128) injected with morpholino alone). In addition, sections through the eyes of 
rescue morphants at 4dpf revealed a similar statistic (Figure 4.14); while 25% (7/28) 
co-injected embryos exhibited a severe morphant phenotype, a further 46.4% (13/28) 
exhibited a “mild” phenotype, where the eyes maintained their reduced size but
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M orpholino Translated sequence Expected 
band, bp
C o n tro l/T l/T 2 MKPQSIFILLVLWLALHCKENEAASFPWSCASLSGVCRQGVCLPSELYFGPLGCGKGFLCCVSHFLStop 181
S I (in tron 1) MKPQSIFILLVLWLALHCKFRMFAFGDISVLELCStop 409
S I (in tron 2) MKPQSIFILLVLWLALHCKENEAASFPWSCASLSGVCRQGVCLPSELYFGPLGCGKGFLStop 275
S I (in tron 1+2) MKPQSIFILlVLWLALHCKFRMFAFGDISVLELCStop 503
Control defbll T1 defbll S I
--------------------- A ct in      D e fb ll
•ve C o n tro l T1 T2 S I  -ve  C o n tro l T1
Figure 4.12 de fb ll S1 morpholino phenotype
(a) This table shows the predicted translated peptide sequences following embryonic 
injection with defbll SI morpholino. The far left column details the morpholino 
details and which introns is targeted. Expected diagnostic RT-PCR band sizes are 
depicted in the far right column.
(b) The defb ll SI phenotype is similar to the T1 phenotype. Pictures taken at 22hpf, 
scale bar = 100pm. SI morphant picture is a representative picture based on three 
independent experimental repeats containing a combined total o f  112 embryos.
(c) Diagnostic RT-PCR to detect defbll transcript size changes. Control, T1 and T2 
embryos have a band at 181 bp, indicating wild type splicing. cDNA from SI-injected 
morphants have an aberrant transcript size of 503bp, indicating inclusion o f  both 
introns. For additional clarity, the identity of bands from these gels were confirmed 
by sequencing (data not shown)
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showed some evidence of differentiation to form stratified layers, and had a lens free 
from nuclei. In addition, 28.6% (8/28) embryos showed normal eye development, 
indistinguishable from wild type. This indicates that co-injection o f  defb ll 
morpholino with defb ll mRNA is able to rescue both the developmental and optical 
defects previously described.
4.4 MICROARRAY ANALYSIS OF DEFBL1  MORPHANTS
4.4.1 Microarray analysis of de fb ll morphants compared to controls
In the absence o f  an antibody to Defbl 1, microarray analysis was performed on 
morphant embryos in order to gain insight into the global gene expression changes 
resulting from defb ll knockdown. RNA was harvested from morphant and control- 
injected embryos at 12.5hpf, just after the first defb ll transcripts can be detected by 
RT-PCR. Samples were sent for hybridisation using Agilent Whole Zebrafish 
Genome Oligo Microarrays (Miltenyi Biotec GmbH) on two independent biological 
repeats.
Analysis o f  the data revealed 6553 statistically significant (p<0.05) differentially 
expressed genes between control and morphant embryos. This included an up- 
regulation o f  3164 genes and a further down-regulation o f  3389 genes. In order to 
assess any patterns in these genes, the Database for Annotation Visualization and 
Integrated Discovery (DAVID) (Huang el a/., 2009a, Huang el a !., 2009b) was used 
to group the genes according to their area o f  expression in the zebrafish 
(ZFIN ANATOMY search, Table 4.1). Concordant with the abnormal brain and eye 
structures seen in defbl 1 morphants, a large proportion o f  the differentially expressed 
genes are located in the embryonic eye and brain. Moreover, the structure associated 
with the highest grouped percentage of differentially expressed genes reported was 
the retina (Table 4.1). Table 4.1 shows a heavy representation o f  neural structures, 
including the diencephalon as the structure showing the most significantly affected 
subset of genes. Key developmental structures are also highlighted, including the 
neural crest, corresponding to the developmental defects observed in the defb ll 
morphants. The highlighting of the brain, eye and developmental tissues is in 
accordance with the observed defbll morphant phenotype.
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Anatomical Structure % genes p value Anatomical Structure % genes p value
retina 8.29 7.41E-07 neural plate 4.39 1.02E-10
optic tectum 6.08 6.55E-06 pronephric duct 3.82 0.001968
optic vesicle 3.54 5.43E-08 YSL 3.49 0.002863
lens 2.86 0.003204 tegmentum 3.37 6.48E-04
lens vesicle 2.56 6.79E-04 epiphysis 3.16 4.79E-05
retinal ganglion cell layer 2.24 0.001553 olfactory placode 3.04 9.35E-06
retinal inner nuclear layer 1.66 7.24E-04 periderm 3.01 6.17E-06
presumptive neural retina 0.9 0.00398 ventral mesoderm 2.74 7.89E-07
optic primordium 0.83 0.006977 ventricular zone 2.56 4.35E-05
hindbrain 7.84 1.64E-06 adaxial cell 2.46 3.99E-04
spinal cord 6.86 7.55E-07 otic placode 2.34 7.11E-04
diencephalon 6.65 2.59E-11 neural crest 1.73 1.75E-06
midbrain 6.23 3.70E-05 trigeminal placode 1.68 6.46E-06
central nervous system 6.05 1.03E-06 heart tube 1.58 6.89E-04
telencephalon 5.4 2.48E-07 margin 1.53 0.001542
neural tube 5.22 1.39E-09 heart rudiment 1.41 0.001437
forebrain 3.77 5.81E-05 pectoral fin bud 1.33 0.002769
neuron 3.62 1.81E-06 forerunner cell group 0.88 0.00382
cranial ganglion 3.06 5.52E-06 lateral plate mesoderm 0.8 0.005669
alar plate midbrain region 2.69 0.004994 hypaxial myotome region 0.8 0.006734
basal plate midbrain region 2.24 3.53E-05 pancreas primordium 0.65 0.003134
head 1.71 4.25E-04 anterior lateral plate mesoderm 0.48 6.75E-04
midbrain hindbrain boundary 1.71 0.005164 posterior lateral plate mesoderm 0.45 0.002044
rhombomere 1.63 5.63E-05 gut 3.89 9.83E-05
neural rod 1.58 6.89E-04 pectoral fin 3.77 0.001083
hindbrain neural plate 1.53 4.63E-06 pharyngeal arch 3.74 9.34E-10
midbrain neural keel 1.33 2.73E-06 heart 3.21 9.16E-04
primary neuron 0.83 1.93E-04 epidermis 2.86 4.89E-06
rhombomere 5 0.68 8.23E-04 ovary 2.06 2.60E-04
hindbrain neural keel 0.63 1.15E-04 musculature system 1.93 2.12E-04
midbrain neural rod 0.55 5.55E-04 cleithrum 0.6 0.005054
neuroectoderm 0.53 0.004618 slow muscle cell 0.43 7.28E-04
rhombomere 3 0.5 0.001711 caudal fin 0.43 0.009699
presumptive rhombomere 3 0.23 0.001927 trunk vasculature 0.38 0.002525
somite 7.63 1.87E-08 pharyngeal pouch 0.35 0.001129
otic vesicle 5.02 1.24E-05 fast muscle cell 0.35 0.001756
myotome 4.8 1.03E-05 opercle 0.28 0.009753
notochord 4.42 0.006475 angioblastic mesenchymal cell 0.23 0.003659
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Table 4.1 Clustering of genes differentially expressed in de fb ll 
morphants with respect to control embryos (table shown on previous 
page)
“ DAVID” software (Huang et al., 2009a; Huang et al., 2009b) was used to cluster 
genes according to their anatomical location (as described by the Zebrafish 
Information Network, ZFIN). Only structures significantly enriched (p<0.01) were 
included.
Structures highlighted in yellow represent genes predominantly expressed in the 
adult or developing eye; structures in blue are associated with the adult or developing 
brain and neural structures; structures i n H J  are associated with developmental 
structures not found in the adult and ^ ^ B P s tru c tu re s  are those which cannot be 
grouped into any of the above categories.
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To investigate further any enrichment (p<0.01) in the differentially expressed genes, 
the group was analysed according to biological function gene ontology (GO) terms. 
The search revealed a wide variety of biological processes affected (Table 4.2) with 
processes ranging from vital cellular processes such as transcription and protein 
signalling, to more specific growth and development pathways. In particular, genes 
affecting embryonic morphogenesis and organogenesis were enriched, along with 
those involved in cell motion and migration.
The GO term analysis revealed a number o f  pathways which may be key in the 
pathology o f  the defb ll morphant phenotype and these were not all predicted from 
based on the defb ll morphant knockdown. For example, transcription and regulation 
o f  transcription were highly enriched, suggesting that defb ll might have a role which 
directly or indirectly interacts with transcription factors. As with the anatomy 
clustering, developmental processes were also enriched, with regulation of 
neurogenesis and embryonic morphogenesis being identified as being significantly 
enriched. Interestingly, regulation of cell migration and regulation o f  cell motion 
were both detected, which may be illustrative o f  the convergence defects observed in 
the defb ll morphants.
Although these analyses identified the gene expression locations and processes 
which are enriched within the microarray, the results obtained were wide-ranging 
and there was often overlap between clustering terms (for example “regulation o f  
growth”, “regulation o f  cell growth”, Table 4.2). To narrow the processes affected, 
the differentially expressed gene group was analysed again, grouping genes 
according to a set o f  keywords. Each keyword covers a number o f  GO terms, 
therefore the resulting number o f  categories were narrowed, which would possibly 
allow for more trends to be observed. The analysis (Table 4.3) revealed a number of 
processes observed in the GO term analysis; again, changes in expression o f  genes 
involved in transcription and regulation o f  transcription were highly enriched as were 
the categories o f  “developmental proteins” and homeobox genes. Interestingly, this 
analysis also detected a significant enhancement in the Wnt signalling pathway 
(Table 4.3). The Wnt-PCP signalling pathway has a crucial role in the mediation o f  
convergence and extension movements during gastrulation (reviewed in Roszko el
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GO Term % p value GO term
regulation of transcription 8.51 3.76E-11 G0:0045449
regulation of transcription, DNA-dependent 6.96 7.93E-14 G0:0006355
transcription 3.82 3.16E-04 G0:0006350
regulation of RNA metabolic process 7.01 1.05E-13 G0:0051252
carbohydrate catabolic process 0.7 0.0022 G0:0016052
alcohol catabolic process 0.63 6.94E-04 G0:0046164
cellular carbohydrate catabolic process 0.63 6.94E-04 G0:0044275
glucose metabolic process 0.63 0.0059 G0:0006006
glucose catabolic process 0.55 0.0027 G0:0006007
hexose catabolic process 0.55 0.0027 G0:0019320
monosaccharide catabolic process 0.55 0.0027 G0:0046365
glycolysis 0.5 0.0016 G0:0006096
pattern specification process 2.03 2.13E-04 G0:0007389
embryonic morphogenesis 1.83 0.0011 G0:0048598
regionalization 1.43 0.0073 G0:0003002
cellular component morphogenesis 1.36 5.74E-04 G0:0032989
embryonic organ development 1.31 6.94E-04 G0:0048568
cell morphogenesis 1.08 0.0046 G0:0000902
cell part morphogenesis 0.88 0.0035 G0:0032990
cell projection morphogenesis 0.85 0.0038 G0:0048858
embryonic organ morphogenesis 0.75 0.0083 G0:0048562
muscle cell differentiation 0.6 0.0051 G0:0042692
cell fate commitment 0.58 0.0014 G0:0045165
striated muscle cell differentiation 0.58 0.0055 G0:0051146
muscle cell development 0.5 0.003 G0:0055001
regulation of neurogenesis 0.48 7.72E-04 G0:0050767
regulation of nervous system development 0.48 7.72E-04 G0:0051960
striated muscle cell development 0.48 0.0043 G0:0055002
regulation of cell development 0.48 0.0016 G0:0060284
notochord development 0.4 0.0092 G0:0030903
regulation of growth 0.63 3.55E-05 G0:0040008
regulation of cell growth 0.55 1.09E-04 G0:0001558
regulation of cell size 0.4 0.0092 G0:0008361
negative regulation of growth 0.2 0.0045 G0:0045926
regulation of cell motion 0.28 0.0045 G0:0051270
regulation of cell migration 0.28 0.0045 G0:0030334
cell projection organization 1 0.0044 G0:0030030
melanosome localization 0.2 0.0086 G0:0032400
pigment granule transport 0.2 0.0086 G0:0051904
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Table 4.2 Clustering of differentially expressed genes by biological 
function gene ontology
“ DAVID” software (Huang et al., 2009a; Huang et al., 2009b) was used to cluster 
genes according to their biological function GO terms. Only structures significantly 
enriched (p<0.01) were included.
Processes highlighted in B Q  are related to transcription, processes in blue related to 
catabolism, processes in yellow relate to embryonic development (in various tissues) 
and processes highlight in relate to cell growth.
Term % genes p value
dna-binding 6.33 9.18E-19
Homeobox 2.89 3.88E-14
developmental protein 3.62 4.93E-14
nucleus 8.74 1.09E-08
Transcription 4.09 6.91E-08
transcription regulation 4.12 9.48E-08
glycolysis 0.43 2.75E-04
DNA binding 0.43 4.39E-04
signal 2.06 0.0034
glycoprotein 2.31 0.0092
egf-like domain 0.98 0.0098
wnt signaling pathway 0.63 0.0099
Table 4.3 Genes differentially expressed in the microarray are sorted 
according to PIR_KEYWORDS
“ DAVID” software (Huang et al., 2009a; Huang et al., 2009b) was used to cluster 
genes according to the PIR KEYWORDS database. Terms enhanced at a probability 
o f  p<0.01 are listed.
al., 2009). It is, therefore, interesting that the genes involved in this process are 
significantly differentially expressed in the defbll morphants, compared to the 
control embryos. Figure 4.15 illustrates the Wnt pathway and the genes identified as 
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4.4.2 Validation of microarray data using quantitative RT-PCR
In order to begin to validate the microan-ay data, a panel o f  genes were selected for 
analysis using qRT-PCR. The panel of genes chosen included some from the Wnt- 
Pep pathway (as representatives of a pathway o f  interest), as well as other random 
genes found to be significantly altered between control and morphant embryos. A 
selection o f  genes outwith the Wnt-Pcp pathway was included in this analysis to 
broaden the range o f  genes tested so as not to introduce bias into this testing.
Embryos were injected with either control or defb ll morpholino and RNA was 
harvested at 12.5hpf for analysis. Genes from the Wnt-PCP pathway (w n tl l ,  wnt8, 
frizz!ed2) were included in the analysis to reflect the relevance o f  the pathway to the 
convergence-extension phenotype observed in the defb ll morphants.
O f the twelve genes tested, ten genes showed expression trends similar to those 
observed in the microarray data (Figure 4.16). Although the fold-changes obtained 
by qRT-PCR did not exactly replicate the microarray data, a trend in the same 
direction (positive or negative) was seen as verification o f  the up- or down- 
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Figure 4.16 qRT-PCR validation of microarray data
Quantitative RT-PCR was used to validate the expression changes o f  twelve genes 
identified as being differentially expressed in the microarray analysis. Data is based 
on three independent repeats earned out on three biological samples. Fold changes 
are measured relative to control embryos.
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4.5 DISCUSSION
In this chapter, I described a novel role for defb ll in early zebrafish development, 
suggesting a role in cell movement as well as in early eye and brain development. In 
addition, I implicated a number of pathways in the pathology o f  the morphant 
phenotype by comparing genes differentially expressed between control and 
morphant embryos using microarray analysis.
While the involvement o f  defensins in development is a role far from their traditional 
role in innate immunity, it is not unheard o f  for genes to take on vastly different 
roles. Famously, in 1985, Toll was identified in the Drosophila melanogaster embryo 
as a key determinant of dorsoventral patterning (Anderson et al., 1985). However, 
the gene was later identified as being a key player in the anti-fungal response o f  adult 
Drosophila  (Lemaitre el a/., 1996). The Toll-like receptors in mammals retain only 
the immunological role.
There have been recent reports which also link the mammalian defensins to varied 
developmental processes. It has been reported that a knockdown o f  epididymis- 
specific D efh l5  in R.norvégiens causes decreased adult fertility and developmental 
failure in offspring (Zhao et al., 201 1). Murine D efh l9  has also been implicated in 
testis development (Menke and Page, 2002). Interestingly, the Eurexpress database (a 
transcriptome atlas for the mouse embryo) also shows specific expression of murine 
D efb50  in the developing brain and spinal cord at E l4.5 (Richardson et a/., 2009).
4.5.1 The de fb ll morphant phenotype
The defb ll “T l ” morphant phenotype was explored by imaging morphant embryos 
throughout the first 24 hours of development to visualise the defects caused by 
transient defbll knockdown. The observed convergence extension cellular movement 
delay was quantified by measuring the anterior-posterior axis o f  morphants, as well 
as by measuring the neural plate width in embryos stained using WISH for hgg l and 
dlx3.
In order to prove the specificity of the “T l ” translation block morpholino, it was 
shown that its phenotype is replicable with two additional morpholinos “T2” and the
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splice-block morpholino “S I” . The splice block morpholino was selected because the 
morphant phenotype could be correlated to an aberrantly spliced d efbl 1 mRNA 
transcript, detectable by RT-PCR. This helped to discount the notion that the 
observed phenotype might be attributable to non-specific interactions, particularly 
since the “T l ” and “T2” morpholinos shared a 10 base overlap. However, it should 
be noted that the presence of aberrant defb ll transcript does not preclude the embryo 
from also suffering an additional non-specific response.
The defb ll morphant phenotype was also shown to be partially rescued upon the 
introduction of full length wild type defb ll mRNA. While the observed rescue was 
robust, showing recovery of both the developmental and eye and brain phenotypes, 
28.7% co-injected embryos did not rescue. However, this observation was somewhat 
expected due to the wild type nature o f  the mRNA. The morpholino would have been 
able to bind and silence this mRNA (in addition to the endogenous transcripts), so 
the rescue depended on a “flooding” effect, whereby excess wild type transcript was 
introduced to provide larger volumes of unbound transcript which could be translated 
appropriately. A mutated mRNA transcript would have avoided morpholino binding 
and would therefore have been preferable and may have produced a better rescue. 
However, a PCR fragment containing full length defb ll with introduced mutations in 
the 5 'UTR was not compatible with translation (data not shown), indicating that the 
mutations interfered with the translation process.
It would be interesting to observe whether the Defbll peptide is capable o f  producing 
a better rescue than defbll mRNA. Although this was attempted (data not shown), no 
rescue was observed using the synthetic, unfolded Defbll peptide described in 
Chapter 3. However, this was a mature peptide (missing its signal sequence) and 
therefore may not have been secreted, and was also unfolded which may have led to 
a loss o f  functionality.
The work described in this chapter suggests that defb ll has multiple roles dependent 
on the developmental stage o f  the zebrafish. Zou et ah, 2007 showed that defb ll is 
expressed in a number o f  adult tissues where its role would presumably differ from 
the embryonic role in convergence extension. In addition, Oehlers et al, 2011 showed 
specific expression of defbll in the post 24hpf embryonic and adult gut as well as
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strong expression in the swim bladder. This work led to the hypothesis that Defbll is 
important in antimicrobial defence within these organs. This work would support the 
notion that the gene takes on different functions at different stages.
The specific WISH expression pattern showing dejb ll in the embryonic head at 
24hpf suggests that the gene can have tissue-specific functionality. However, it 
should be noted that at 24hpf, defb ll expression may not be limited to the head and it 
is likely that instead it shows low level expression across the embryo. This is 
supported by the observation that no WISH staining pattern could be determined at 
13hpf (data not shown), when the mRNA is still detectable by RT-PCR. The 
detection o f  defb ll transcripts in the early embryo was not replicated in the Oehlers 
et al., 201 1 study, however this data was not shown or expanded upon. It is possible 
that since this study was focused on antimicrobial activity and expression in the gut, 
that earlier expression analyses were not prioritised. Due to the time at which the 
study was published, there was not sufficient time for the WISH and RT-PCR 
analysis described in this study to be repeated with the same primers and probes 
described in Oehlers et a l., 2011. However, performing these analyses in the future 
may provide insight into the reported discrepancies. In addition, obtaining a Defbll 
antibody would also provide insight into whether the observations o f  defb ll mRNA 
transcripts correspond to the protein levels.
The notion that defbll has multiple roles highlights the lack o f  clarity as to whether 
the eye and brain phenotype observed in defb ll morphants are related to the earlier 
developmental delay. It is possible that the defect in convergence extension 
movements brings about defects in brain and eye development by affecting the 
migration o f  neuronal and optical precursor cells from the ectoderm. However, it is 
equally possible that defbll has additional roles in eye and brain development. It has 
previously been shown that macrophages play a crucial role in tissue remodelling in 
the developing mouse eye (Lang and Bishop, 1993). The macrophages are reported 
to be responsible for the regression of two ocular layers normally only transiently 
present in early optical structures. Since defb ll morphant eyes never undergo 
remodelling to develop stratified cell layers, it is possible that macrophages might 
play a role in this phenotype. It has been shown that macrophages invade the
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cephalic mesenchyme o f  developing zebrafish embryos and migrate into the tissues 
o f  the developing brain and retina (Herbomel et a l., 2001), although it is unknown 
what role they fulfil. This, coupled with the finding that mammalian defensins are 
chemoattractants for macrophages (Soruri el al., 2007) suggests that the interaction 
of defb ll with macrophages in the developing eye and brain is a candidate process 
which may, when disrupted, cause a phenotype independent o f  the earlier observed 
developmental delay. This role is supported by the fact that primitive macrophages 
are first observed in the developing embryo from 14-16hpf, far later than the first 
defect observed in defb ll morphants. It was observed, by injecting defb ll morpholino 
into FliA-GFP transgenic fish), the defbll morphants do not lose their macrophages 
(data not shown)(FliA acts as a marker for vasculature and macrophages (Lawson 
and Weinstein, 2002)). This function could be investigated in future studies.
4.5.2 d e fb ll and convergence extension movements
The work in this chapter implies that convergence and extension cell movements are 
disrupted in the defbll morphants. This leads to a developmental delay which leaves 
the embryos with severe eye and brain phenotypes and a decreased anterior-posterior 
axis.
The phenotype observed in defb ll morphants is similar to that seen in the knypek 
mutant, which has been reported to mediate convergence extension cellular 
movements in the same pathway as vw7///(Topczewski et al., 2001). kny knockout 
embryos show a shortened anterior-posterior axis at 24hpf, along with broadened 
neural plate staining (as indicated by dlx3 staining). However, these mutants do not 
appear to develop the same eye defects observed in defb ll morphants. The shared 
aspects o f  these mutant phenotypes suggest that defb ll may be involved in 
convergence extension control, however further investigation would be required to 
confirm this.
Recent work has suggested that the morpholino knockdown of cell essential genes 
often results in a non-specific phenotype similar to the defb ll morphants, 
characterised firstly by early brain necrosis (at 24hpf) followed by small eyes and a
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developmental delay (Danilova el aI., 2010). As with the dejb ll morphants, these cell 
essential knockdowns result in an up-regulation of p53  which has been shown to 
mediate the non-specific response. While this may suggest that the observed dejb ll 
phenotype is non-specific, it has been shown that where p53  is mediating a non­
specific response, the phenotype can be reversed in the presence o f  p53  morpholino 
(Danilova et til., 2010). Since the defbll morphants retain their phenotype in the 
absence o f  functional p53 (data not shown), it can be deduced that although p53  
activation may contribute to the phenotype o f  the mutants, that it is not the causative 
element, nor is it necessary for the persistence of the phenotype.
4.5.3 Genome-wide analysis of defb/1 morphants
The 12.5hpf timepoint was chosen to harvest morphant and control embryos for 
microarray analysis. This was chosen because the earliest time at which I could 
detect defb ll transcripts was at 12hpf and I hoped to utilise the array to capture a 
“snapshot” of the earliest expression changes to affect the morphant embryos. The 
presence of more than 6000 significantly differentially expressed genes in the 
morphants (with respect to control-injected embryos) implies that embryos could 
have been harvested at an earlier timepoint in order to omit some o f  the later 
downstream responses to the defbll knockdown. In addition, the volume o f genes 
affected suggests that although defb ll is undetectable by RT-PCR in embryos 
younger than 12hpf, that low, localised very low levels o f  expression might be 
occurring in younger embryos.
The microarray data represents a preliminary, broad attempt to identify any pathways 
that defb ll might be working in. Encouragingly, the data supported the 
developmental nature o f  the morphant defect and predictably showed an 
enhancement of expression changes in genes involved in neurological and optical 
development. Interestingly, the absence o f  large numbers of significantly affected 
infection and inflammation pathways also suggests that the observed morphant 
phenotype is not likely to be attributable to any decrease in immunity that defbll 
might convey. This in turn, supports the findings in Chapter 3 that Defbll is not a 
potent antimicrobial peptide. This suggestion is also supported by the finding that
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mildly bleaching embryos prior to morpholino injection has no effect on the 
morphant phenotype (data not shown), suggesting that microbial invasion is also not 
responsible for the morphant phenotype.
One drawback o f  the array is that it is impossible to determine whether the 
differential gene expression observed is a direct effect o f  the defb ll knockdown or 
merely one o f  many downstream effects. Although the keyword analysis (Table 4.3) 
suggests that the Wnt pathway is enriched amongst the changed genes, this still does 
not answer the question o f  whether defb ll works within this pathway or simply acts 
on it indirectly. Given the enrichment in changes of transcription factor expression 
(Table 4.2-3) and the high likelihood that defb ll is a secreted peptide, it may be that 
it affects a single (or multiple) cell surface receptor with multiple cellular targets. 
This would be concordant with the GO term analysis (Table 4.2) which identified 
transcription regulation as being highly enriched in morphants. The observation that 
defb ll appears to act in different ways at different developmental stages supports the 
idea that it binds more than one protein.
Finally, it should be noted that while the array provides interesting insights into the 
effects o f  defb ll knockdown, any concrete observations should be supported with an 
appropriate validation technique. In this study, a small cohort o f  affected genes were 
verified using qRT-PCR. However, since the qRT-PCR validation o f  one gene 
cannot validate a second unrelated gene in the array, extrapolating from any o f  the 
findings of this analysis would only be justifiable following validation o f  the specific 
genes involved.
4.5.4 d e fb ll and the Wnt-PCP pathway
As shown in Figure 4.15, a number of genes involved in the canonical and Wnt-PCP 
pathways were found to be differentially expressed, via microarray analysis, in 
defb ll morphants with respect to controls. Since the Wnt-PCP pathway has been 
implicated in the control o f  convergence extension (reviewed in Roszo el a/., 2009), 
it is intriguing that genes within this pathway were enriched in the microarray 
analysis, in particular with writ 11 being confirmed (by qRT-PCR) as being down-
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regulated in dejbll morphants. Table 4.4 lists all the Wnt-PCP pathway genes found 
to be differentially expressed in the defb ll morphants array (analysis carried out by 
Claire Smillie).


















Table 4.4 Genes involved in the W nt-PCP pathway with altered expression in 
dejb ll morphants (reproduced with permission from Claire Smillie) 
This table includes a selection of genes involved in the Wnt-PCP pathway whose 
expression was found to be altered in defbll morphants. The fold change in gene 
expression depicted in this table is low (<2 fold changes), however these fold 
changes were reported to be significantly different (p<0 .0 1 ) to control-injected 
embryos.
As described previously, the dejb ll morphant phenotype shares features o f  the 
knypek knockout mutant, however it also shares features of the trilobite (.strabismus)
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knockdown. Jessen et al., 2002 reported a morpholino knockdown resulted in 
embryos with a convergence extension defect, resulting in a reduced anterior- 
posterior axis at 24hpf. While this is a similar phenotype to that observed in dejb ll 
morphants, the eye defect is not replicated, indicating that while defb ll morphants 
may be involved in the Wnt-PCP pathway, that it may also influence other pathways.
An additional finding of relevance to the observed defb ll morphant phenotype is the 
report that wnt7  transcripts (wnt7aa , wnt7ab, wnt7ba, wnt7bb) are expressed in the 
early zebrafish brain (Beretta et al., 2011). The expression patterns reported in this 
study suggest a role for the wnt7 genes in neural specification and a role in early 
patterning is suggested as well. Since wnt7ba has been shown (and validated) to be 
down-regulated in defb ll morphants (Figure 4.16), it is possible that defb ll could 
function within the same pathway as wnt7b to effect both the observed 
developmental and neural phenotypes.
However, whether the identification o f  expression changes o f  genes present in the 
Wnt-PCP is a result of an earlier defect, or is itself the causal event in the mutant 
phenotype, is unknown.
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4.6 CONCLUSIONS AND FUTURE DIRECTIONS
To conclude, in this chapter 1 have shown strong evidence supporting a novel role for 
zebrafish defensin defbll in early development. Given the highly conserved nature of 
developmental genes at the gastrulation level, this work presents an interesting 
avenue for future work which could potentially be relevant to studies in other 
vertebrates and mammals.
Although there are many different approaches that could be taken to progress this 
work, I believe the most interesting data will yield from biochemical studies. The 
production o f  a Defbll antibody would facilitate highly informative pul! down 
experiments to identify binding partners and any complexes that Defbll may form. 
Work o f  this nature would assist greatly in placing defb ll within a pathway. In 
addition, the presence o f  an antibody would allow for a detailed analysis o f  the 
expression pattern of defb ll to take place. While the study described in this chapter 
was informative, its main weakness is that the expression studies focussed on 
expression at the RNA level. Since RNA transcript changes do not always translate 
to a change in protein levels, antibody analysis on both whole embryos and 
embryonic and adult sections would be very useful, particularly in the earliest stages 
o f  defb ll expression. An antibody to Defbll is currently being produced in 
collaboration with another laboratory.
Further microarrays could also be carried out earlier in development, at the 11.5- 
12hpf timepoint to minimise the detection o f  downstream effects. This kind of 
analysis could be accompanied by whole cell quantitative proteomic assays to 
simultaneously detect the changes in protein levels associated with the mRNA 
transcript changes. Not only would the analyses serve to validate each other, but they 
would also provide interesting insight into global protein changes induced by defb ll 
knockdown.
The production o f  defb ll knock out fish would also provide insight into the function 
o f  the gene. This would comprehensively address the question of the effects o f  a 
complete knockdown in the morphant embryos and would also show whether the 
gene is essential for viability.
161
Finally, to gain further insight into the pathways within which defb ll functions, a 
chemical screen could be carried out on morphant embryos. The addition o f  small 
molecules from known kinase and phosphatase inhibitor libraries could be added to 
injected morphant embryos to observe whether topical application of the drug could 
reverse the earliest observed developmental phenotypes. Identifying a small 
molecule that could rescue the phenotype would place defb ll within a known 
pathway and could concentrate future studies into a relevant area.
Overall, this work provides a starting point for future studies into the molecular 
function of d e fb ll. It is unclear why or how a developmental function arose for a 
defensin-like gene, however the findings o f  further study may prove to be important 
in other vertebrate and mammalian defensin and development studies.
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Chapter 5: Concluding Remarks
"The whole strenuous intellectual work o f  an industrious research worker would  
appear, after all, in vain and hopeless, i f  he were not occasionally through some 
striking fa c ts  to f in d  that he had, at the end o f  all his criss-cross journeys, at last 
accom plished at least one step which was conclusively nearer the truth ”
¡Max Planck
163
Antimicrobial resistance to current therapies is an increasing and dangerous problem. 
In my literature review in Chapter 1, I described how both opportunistic (for example 
MRSA) and pathogenic (for example, TB) microbes have acquired a worrying level 
o f  resistance to modern medicines. As illustrated by Swartz, 2004 in his depiction o f  
the mortality rates o f  meningitis both before and after the introduction o f  antibiotics, 
effective antibiotic care is vital to maintaining basic standards of human health. The 
consequences, for example, of a multidrug resistant meningitis-causing 
S.pneumoniae, causing 100% mortality in those infected would be disastrous, but if 
bacteria keep evolving antibiotic resistance faster than dings are produced, such 
situations could become a reality. The introduction o f  antibiotics revolutionised 
public health and their integrity must be preserved.
One potential source of novel antibiotics is the (Tdefensin family. This ancient set of 
antimicrobial peptides has adapted to fight various pathogens across evolution and a 
testament to their importance is their widespread conservation across organism as 
far-ranging as humans, platypus, zebrafish, fruit flies and even plants.
In Chapters 1 and 2 1 outlined how the positive charge o f  the |3~defensins. along with 
their hydrophobicity are thought to facilitate a mechanism whereby holes are 
punctured in microbial membranes. The nature of this proposed mechanism is such 
that microbes have to make significant changes to their cell membrane structure in 
order to gain resistance to the P-defensins, or alternatively some form o f  inhibitory 
mechanism would need to be acquired, thus reducing the likelihood o f  resistance 
emerging. In addition, since the P-defensins are bactericidal, few (if any) viable cells 
would be left behind following treatment, leaving little time for mutation or 
insensitivity to quickly occur.
Bearing these factors in mind, 1 began this study investigating murine Defbl4, with a 
view to understanding more about the origins o f  its antimicrobial activity. Through 
my antimicrobial assays on the D efbl4-1CN deletion series, I showed that multiple 
N-terminal amino acid residues contribute to the antimicrobial activity of the 
molecule. In addition, my data indicated that a combination o f  dimerisation, charge 
and primary sequence are important for the maintenance o f  antimicrobial activity.
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In order to further this study, 1 investigated how small peptide fragments could be 
modified in order to improve their antimicrobial activity. Since the D efbl4  peptide 
fragment Defbl 14-1 Cv(6- 1 7) was previously identified as being highly active 
(Reynolds et a /., 2010), I looked at the effects o f  cyclicisation and stereo 
isomérisation (by substituting L-amino acids for D-amino acids) on the peptide, with 
a view to improving its activity in the presence o f  serum. I found that while 
cyclicisation alone did not improve the antimicrobial activity, that stereoisomerism 
caused the peptide to perform significantly better under high serum conditions 
(Figure 2.14). This study suggests that a possible method o f  improving the 
antimicrobial activity of peptide antibiotics would be to investigate further the effects 
o f  D-form amino acids, and in particular, their resistance to serum proteases.
My work on the antimicrobial activity o f  D etb l4  led to my interest in the zebrafish 
defensins, since at the beginning of this study, the genes were newly reported and 
had not been investigated beyond their initial reporting. I began investigating the 
zebrafish defensins with a primary aim to understand their role within the zebrafish 
immune system. However, at the same time I evaluated their suitability as 
antimicrobial agents and hoped they could tell us more about the nature of 
antimicrobial peptides.
In the work described in Chapter 3, using synthetic peptides, I identified the Defbl3 
peptide as being a broad-spectrum antimicrobially active compound, whereas Defbl2 
showed more specific low level activity solely against gram negative P.aeruginosa. 
Although 1 could detect the transcripts of all three zebrafish defensins in adult tissues 
(as was reported in Zou et al., 2007 and Oehlers et al., 2011), I also identified early 
expression of defbl2  and defbl3 from 6-7dpf, while defblI was detected much earlier 
in 1 2 hpf embryos.
The work presented in this thesis on antimicrobial activity presents a number of 
interesting directions in which new research could be carried out. With the D efbl4 
story, arguably the most exciting lead is the finding that D e fb l4 - lC v(7-l 7)C'YCD
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peptide is highly antimicrobially active against P.aeruginosa  in the presence o f  high 
levels o f  serum. This work could be quickly turned into an in vivo study whereby 
mice with infected wounds or systemic infections could be treated using the DefbI4- 
1Cv(7-17)CYCd as an antibiotic. If this peptide were to maintain its activity under 
physiological conditions, it could prove to be of great interest in the antibiotic 
development field.
My work on zebrafish antimicrobial activity also suggests that further work would be 
appropriate in this model to determine the role o f  the defensins within the zebrafish 
immune system. For example, it would be informative to investigate any role defbl2 
and defbl3 have in the chemotaxis of adaptive immune cells (especially given that 
zebrafish express CCR6 , a chemotaxis receptor in mammals, (Yang et a/., 1999)). 
Since the zebrafish is still being established as a relevant immunological model 
system, discovering more similarities between the zebrafish and mammalian immune 
systems would be beneficial and may yield interesting mammalian insights.
Finally, the antimicrobial inactivity o f  Defbll in combination with its early 
expression during development led to the proposal that defb ll has a role in early 
zebrafish development. The data presented in Chapter 4 indicated that defb ll directly 
or indirectly affects the convergence and extension cell movements beginning in 
gastrulation. A transient knockdown of defb ll was shown to result in a shortened 
anterior-posterior axis and brain and eye abnormalities which were rescuable upon 
co-injection o f  defb ll morpholino and mRNA.
This work is interesting because it identifies another unexpected role for the defensin 
superfamily. It also presents interesting evolutionary questions -  for example, why 
and how did a defensin evolve a developmental role? In addition, is this 
developmental role confined to zebrafish and other teleosts, or is it conserved 
through to mammals? The reports of the involvement of murine D efb l9  in testis 
development (Menke and Page, 2002) and D efb l5  in R.norvégiens having a role in 
fertility and the survival o f  offspring (Zhao et al., 2011) further suggest that a 
developmental role may exist for the defensins.
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Elucidating a pathway for defb ll will be vital in understanding the observations 
reported in Chapter 4. Carrying out biochemical analysis on the peptide interactions, 
to uncover any binding partners and complexes formed would be infonnative, as 
would observing the peptide localisation within the embryo.
In conclusion, this thesis presents a wide-ranging study on the function o f  vertebrate 
defensins using both zebrafish and mouse defensins in order to gain further 
understanding of the larger defensin family. I have studied peptides from an applied 
point o f  view and have presented promising data on a highly antimicrobial and 
serum-resistant peptide fragment. I have also studied the (3-defensins within the 
context o f  the whole organism and have demonstrated an important and varied 
endogenous role for the defensins discovered in zebrafish. The work in this thesis 
demonstrates the wide-ranging activity o f  the defensin superfamily and confirms 
their exciting applications to human medicine as well as their fascinating applications 
in vivo.
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Chapter 6: Materials and Methods
nullius in verba 
Nothing upon trust
Motto of the Royal Society
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6.1 MOLECULAR METHODS
6.1.1 List of Solutions
Chemicals were obtained from Sigma-Aldrich unless otherwise stated. Dry 
chemicals and solutions were stored at room temperature unless otherwise stated.
Loading dye
20% Ficoll, l%  Orange G and lOOrnM EDTA 
PC'R, RT-PCR and qPCR primers
All primers were designed using Primer 3.0 software (Rozen and Skaletsky, 2000) 
and were purchased from Sigma-Aldrich. 10mM stocks were prepared by dissolving 
in TE buffer and lOpM working stocks were prepared by diluting in distilled water. 





Buffer was made up to 500ml to make a 20X stock. 20X stock was diluted to a IX 
working stock with distilled water.
TE buffer (obtained from the Human Genetics Unit Core Services) 
lOmM Tris.Hcl. ImM EDTA
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6.1.2 Polymerase chain reaction (PCR)
PC’R reactions for sequencing and genotyping were performed using Recombinant 
Taq DNA polymerase from Invitrogen™. PCR for cloning was performed using high 
fidelity Phusion™ DNA polymerase (New England Biolabs).
PCR was carried out according to manufacturer’s instructions with lx reaction 
buffer, 4mM M gC f, 0.2pM forward and reverse primerslOmM dNTPs, ~50ng DNA 
( I pi stock) and l unit Taq in a final volume of 25pl (made up with dFEO).
High fidelity PCR was carried out in lx HF buffer (New England Biolabs), lOmM 
dNTPs, 2pM  MgCE, l pM forward and reverse primers and 1 unit o f  DNA 
polymerase made up to 50pl with dH^O.
PCR reactions were cycled according to a standard programme o f 3 minutes 
denaturation at 94°C followed by 30 cycles o f  45 seconds at 94°C, 30 seconds 
annealing at 58°C and 1 minute elongation at 72°C. A final elongation set was earned 
out for 10 minutes at 72°C.
High fidelity PCR reactions were cycled at 98°C, 30 seconds, and then on a two-step 
cycle (40x) 98°C for 10 seconds and 72°C' for 45 seconds. A final elongation at 72°C 
was carried out for 10 minutes.
Sequences o f  primers used in this study are shown in Table 6.1.
6.1.3 RNA extraction
Tissue was homogenised in Trizol (Ambion) and transferred to screw-cap tubes. 
lOOpl chloroform was added per ml Trizol. and tubes were shaken and incubated for 
5 minutes. Samples were centrifuged at 13000 rpm, for 15 minutes and the upper, 
clear aqueous phase was transferred to a fresh tube. An equal volume o f  isopropanol 
was added and tubes were stored on ice for 15 minutes. RNA was precipitated by 
centrifugation at full speed for 15 minutes. The pellet was washed in 75% ethanol 
and resuspended in 3 0-50 pi DE PC-treated dHjO. RNA preparations were stored at - 
























































































































































































6.1.4 Reverse-transcription polymerase chain reaction (RT-PCR)
Freshly prepared or frozen RNA was used to prepare cDNA using the First Strand 
cDNA Synthesis (AMV) kit from Roche Applied Sciences, as per the manufacturer’s 
instructions, using l pg RNA. RT-PCR was then carried out as per the standard 
protocol for PCR.
6.1.5 Quantitative reverse-transcription polymerase chain reaction 
(qRT-PCR)
Quantitative RT-PCR was carried out using Brilliant II SYBR Green (Stratagene) 
mastermix according to the manufacturer’s instructions. Samples were cycled in 20pl 
volumes according to the following general programme: 95 °C for 10 minutes 
followed by 40 cycles of95°C for 10 seconds, followed by 60°C for 45 seconds.
Cycling reactions were carried out in 384-well optical plates on an HT7900 
lightcycler (Applied Biosystems). Data analysis to calculate relative fold change was 
earned out using 2 'AAC1 conversions to convert CT values into the appropriate fold 
change. Calculations were can'ied out in Microsoft Excel.
6.1.6 Gel electrophoresis
PCR products were run on a 1.5% (w/v) (1.5g agarose in 100ml lx  TBE) agarose 
gel, supplemented with 1 pi ethidium bromide and viewed over a UV illuminator. 
Samples were loaded with 1 pi loading dye.
To extract bands for sequencing, gels were excised over a UV illuminator and 
samples were purified using a Qiagen gel extraction kit, following the 
manufacturer’s instructions.
6.1.7 Sequencing
PCR reactions shown to have clear, single product bands were gel extracted (Section 
6 . 1.6) and sent for sequencing by the MRC HGU Core Facility. Here, samples were
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run on an ABI Prism 3730 Genetic Analyser using Big Dye v3.1 sequencing 
technology (kit obtained from Applied Biosystems). For consistency, sequencing 
samples were carried out in duplicate.
6.1.8 Cloning of de fb ll
As described in Section 6 . 1.2, PCR for defb ll was carried out on whole embryo 
cDNA to amplify the transcript (primers shown in Table 6 . 1). PCR products and a 
pBluescript II SK+/- plasmid were digested using Sacl and Rsrll restriction enzymes 
(New England Biolabs) according to manufacturer’s instructions. Digested fragments 
were ligated using T4 DNA ligase (Promega). A molar ration o f  1:5 vector: insert 
DNA was incubated in lx ligase buffer with 1 unit DNA ligase, made up to lOpl 
with dFEO for 3 hours at room temperature. Ligated products were then transformed 
into competent cells (DH5a E.coli).
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6.2 MICROBIOLOGICAL TECHNIQUES
All chemicals were obtained from Sigma-Aldrich unless otherwise stated.
6.2.1 List of Solutions
Ampicillin (A9393, Sigma-Aldrich)
Foetal calf serum (FCS) (Siema-Aldrichl 
Isosensitest agar (Oxoid)
250ml stocks were made up by dissolving 7.85g agar powder in 250ml dFLO and 
sterilising by autoclaving.
Isosensitest broth (Oxoid)
250ml stocks were made up by dissolving 5.85g powder in 250ml dH20  and 
sterilising by autoclaving.
L agar (prepared by MRC HGU Core Services)
15g Difco agar 
l Og Bacto-tryptone 
lOgNaCl
5g yeast extract, made up to II with dFFO
Luria broth: As supplied by MRC Human Genetics Unit Technical Services
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1 Og Bacto-tryptone 
lOgNaCI
5g yeast extract, dissolved in 11 dH20
Phosphate buffer ( I OmM)
4.01ml IM K2HPO4 
0.99ml KH2P 0 4
0.5g glucose, dissolve in 500ml dH20
6.2.2 List of category 2 strains
Acinetobacter baumannii ATCC 19606
Candida albicans J2922
Edwardsie/la tarda ATCC 15947
Escherichia coli ATCC 25922
Enterococcus fa eca l is ATCC 700802
Pseudomonas aeruginosa  P A O 1
Staphylococcus aureus ATCC 25923
MethicilI in-resistant Staphylococcus aureus, MRSA J2918
6.2.3 Preparation, maintenance and growth of microbial stocks
Microbial stocks were stored at -80°c in 50% glycerol. For antimicrobial assays, 
microbes were streaked onto Isosensitest agar plates and grown overnight at 37°C. 
Plates were stored at 4°C for up to one week. Single colonies were inoculated into
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10ml Isosensitest agar and incubated, with shaking at 225rpm at 37°C overnight. To 
ensure microbes were growing exponentially. 1 ml overnight culture was inoculated 
into 10ml fresh Isosensitest broth and incubated for four hours prior to antimicrobial 
assays.
All strains were cultured in a level 2 biological containment suite.
6.2.4 In vitro antimicrobial assays
Approximately l x l 0 6 cells in exponential growth phase were incubated with various 
P-defensin derivatives in a lOmM phosphate buffer for 3 hours at 37°C (225rpm) 
(final volume, lOOpl). Incubations were then spread onto Isosensitest agar plates and 
grown overnight. Plates were inspected for colonies the following morning and the 
percentage o f  organisms killed by the peptide was calculated. MBC values were 
taken as the lowest concentration that killed 99.99% initial inoculum.
All antimicrobial assays were performed at least in triplicate in independent 
experiments. For DTT treatments, peptides were incubated overnight in lOmM DTT 
to disrupt any dimers, prior to antimicrobial testing. The non-parametric Mann- 
Whitney U test was used to calculate statistical significance and data analysis was 
carried out using Microsoft Excel.
All peptides for antimicrobial assays were obtained from Derek Macmillan, UCL, 
where they were synthesised “in house”.
6.2.5 Serum and salt sensitivity assays
To assess serum and salt sensitivity, antimicrobial assays were earned out using 
phosphate buffer supplemented with either 50mM, lOOmM or 200mM NaCl or 1%, 
5% or 10% foetal calf serum.
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6.2.6 Transformation of competent cells
DH5« competent E.coli were obtained from Invitrogen and transformed according to 
the manufacturer’s instructions. Briefly, 50pl cells were incubated with lOOng DNA 
on ice for 30 minutes. Cells were then heat-shocked at 42°C for two minutes and 
allowed to recover on ice for a further two minutes. Cells were then incubated in L 
broth for 1 hour and the entire culture was spun down and plated on selective 
(100pg/ml Ampicillin) L-agar plates overnight.
6.2.7 Isolation of plasmid DNA
Single colonies were picked off o f  selective agar plates and cultured for 12-16 hours 
overnight at 37°C, (5ml for minipreps, 50ml, maxipreps) in L broth supplemented 
with 50pg/ml L-ampicillin. Samples were shaken at 225rpm. Plasmid DNA was then 
extracted using Qiagen maxiprep or miniprep kits, according to the manufacturer’s 
instructions. DNA was eluted in 30pl elution buffer.
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6.3 ZEBRAFISH TECHNIQUES
6.3.1 List of Solutions
All solutions were obtained from Sigma-Aldrich unless otherwise stated.
E3 embryo medium (60x stock)
8 .6g NaCl
2.45g M g S 0 4.7H20
1.45gCaCl2.2dH20
0.38g KCl. dissolved in 500ml dH20  and stored at 4°C 
Eosin




S212 , PolyScientific R&D
4% paraformaldehyde
2g paraformaldehyde dissolved in 50ml PBS, heated to 65 °C until dissolved
6.3.2 List of Strains
p53M2l4K7M2l4K (dominant negative mutant) (described in Berghmans et a/., 2005)
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AB wild type
6.3.3 Zebrafish maintenance and husbandry
Male-female pairs o f  fish were placed in mating tanks and were separated by a 
barrier overnight. The following morning, the barriers were removed and eggs were 
collected and washed in Ix E3 embryo medium. Fertilised eggs were washed in E3 
embryo medium and incubated at 28°C.
To continue on fish lines, 5dpf (days post fertilisation) larvae were grown up in 
nursery tanks before being transferred to the adult system at 28dpf.
Embryos for sterile experiments were washed in a 0.07% bleach solution for five 
minutes before rinsing thoroughly in E3 embryo medium and repeating the process. 
At 24hpf, these embryos were dechorionated into autoclaved, sterile E3.
6.3.4 LPS and microbial treatment of zebrafish larvae
48hpf larvae were incubated in autoclaved E3 embryo medium containing lOng/ml 
LPS for 6 hours at 28°C. Larvae were then sacrificed for RNA extraction.
For larvae treated with microbes, pre-incubations of embryos were cultured without 
cleaning at 28°C for 48 hours. This contaminated culture was then used to inoculate 
fresh 48hpf larvae for 6 hours at 28°C prior to sacrificing.
6.3.5 Morpholino and RNA injections
Embryos were collected (as above) and injected using glass capillary needles driven 
by nitrogen gas. Approximately lnl DNA was injected directly into the cell (RNA) 
or yolk (morpholino) of single cell-stage embryos. Embryos at the two cell stage or 
greater were not injected. Injected embryos were incubated at 28 °C and cleaned out 
regularly.
Morpholino oligonucleotides were designed by and obtained from Genetools. 






Table 6.2 M orpholino sequences
6.3.6 In vitro transcription of mRNA for morpholino rescue
In vitro transcription was carried out using the defb tl cloned into the Bluescript II 
plasmid as described in Section 6.1.8. In vitro transcription was carried out using the 
mMessage mMachine® T7 Ultra kit (Ambion), according to manufacturer’s 
instructions. This created capped transcripts with poly-A tails for additional stability.
RNA concentration was determined using a NanoDrop 1000 Spectrophotometer 
(Nanodrop) and 5pl 40ng/pl aliquots were stored at -80°C prior to use.
For the morpholino rescue experiment, 1 pi stock RNA was mixed with 1 pi 30pM T1 
morpholino and injected directly into the embryonic cell. Control embryos injected 
with just morpholino were also injected into the cell (rather than the yolk) for 
consistency.
6.3.7 Imaging zebrafish embryos
Whole embryos were imaged using a Nikon stereo microscope and image data was 
captured and processed using IpLab spectrum software (Scanalytics corporation).
Embryonic sections were observed on a Zeiss Axioplan II microscope and data was 
processed on IpLab spectrum software.
Scripts to stamp scale bars onto images (written by Paul Perry, Human Genetics 
Unit) were used on this software.
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6.3.8 Zebrafish embryo histology
Embryos were fixed in 4% paraformaldehyde (PFA) overnight at 4°C'. Embryos were 
dehydrated in methanol and then transferred to a series o f  three 100% ethanol 
washes. Embryos were then washed in xylene at room temperature, followed by 
xylene at 60°C prior to embedding in molten wax. Embryo blocks w'ere allowed to 
harden overnight and were then 5 pm sections were cut onto slides.
Slides were stained using haematoxylin and eosin. Embryos were first dewaxed in 
3x5 min xylene washes and rehydrated in a series o f  decreasing alcohol baths 
(2x100%, 70%, 50%, 30% for 5 minutes each). Slides were washed thoroughly in 
running water and then stained in haematoxylin for 3 minutes. Excess dye was 
thoroughly rinsed off and slides were then differentiated in acid/alcohol, followed by 
lithium chloride. Eosin staining was then performed for 3 minutes. Slides were 
dehydrated in xylene and mounted using DePeX (BioChemika) and cover slips.
6.3.9 Zebrafish wholemount in situ hybridisation (WISH)
PCR primers were designed to amplify myoD  with a T7 site placed at the 5 ’ flank of 
the gene and T3 at the 3 ’ to allow for both sense and antisense transcripts to be 
generated.
Probes for hggl and dlx3 were obtained from Susan Lynas, Human Genetics Unit 
and the ntla probe was obtained from Niki Wyatt, Human Genetics Unit.
In vitro transcription was carried out using T7 and T3 RNA polymerases (Promega) 
according to manufacturer’s instructions, using Digoxygenin-11-UTPs (Roche 
Applied Science). Probes were then diluted 1:200 for use in wholemount in situ 
hybridisation. This procedure was canned out according to the widely used protocol 
described in Thisse et a l., 2008.
Anti-digoxygenin-AP Fab fragments (Roche Applied Science) was used as an 
antibody and following washing, embryos were stained in BM Purple (Roche 
Applied Science) for 1-2 hours.
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Stained embryos were mounted in 70% glycerol and imaged under a 
stereomicroscope.
6.3.10 Zebrafish microarrays and analysis
Control and Tl morpholino-injected embryos were snap frozen at I2.5hpf for RNA 
extraction using Trizol, as described previously. Samples were then sent to Miltenyo 
Biotec for gene expression profiling using a one-colour Agilent Whole Zebrafish 
Genome Mieroarray.
Data obtained was arranged in a list o f  genes significantly up- or down-regulated in 
defb ll morphants with respect to controls. Data is based on the pooled microarray 
analyses obtained from two independent biological replicates.
The full list o f  genes differentially expressed in the array are included in the CD at 
the rear of this thesis.
The data sets obtained were analysed using DAVID software 
(http://david.abcc.ncifcrf.iiov/') (Huang et a!., 2009a,b).
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6.4 BIOINFORMATIC AND COMPUTATIONAL TECHNIQUES
6.4.1 List of programs and databases used
Blast
This was utilised with default settings, as described by Tatusova and Madden, 1999. 
Clustal W (multiple sequence alignment)
Available at: http://www.ebi.ac.uk/Tools/msa/clustalw2/ (March 2011). As described 
by Higgins et a l., 1996.
6.4.2 Defensin gene prediction
Gene prediction was carried out using a UNIX interface. Multiple alignments of 
chicken, human and mouse f3-defensins were performed using ClustalW and were 
then used to create a Hidden Markov Model using the HMMer program. A further 
program, Genewise was then used to systematically search the zebrafish genome 
(July 2007 version) for novel (3-defensin-like genes. Hits were narrowed by their 
homology to known zebrafish ESTs to produce a shortlist of five genes. This work, 
including the running of Genewise was performed by Dr Colin Semple.
6.4.3 DAVID analysis (as described in Huang et al., 2009a,b)
The Database for Annotation, Visualization and Integrated Discovery (DAVID) was 
used to analysis the data obtained in the microarray. Data was run through the “Gene 
ID Conversion” program to create a gene list which was run through a series of 
functional annotation tools. Genes were analysed according to the following 
annotation categories: Gene Ontology: Biological Function, K eggPathw ays, 
PIR Keywords and ZFIN Anatomy.
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Figure A l . l  Signal P peptide predictions for Defbll (upper panel) and Defbl3 
(lower panel)
Signal P predictions were run to confirm the observations o f  Zou et a/., 2007. Defbll 
and Defbl3 show clear predicted signal sequence cleavage sites, as depicted by the 
red “cleavage probability” line.
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Figure A1.2 Signal P peptide cleavage prediction for Defbl2
Signal P predicted two potential signal sequence cleavage sites for Defbl2, with 
approximately equal cleavage probability at each.
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P-I)efensins are known to be both antimicrobial and able to chem oattract various immune cells. Although 
the sequences of paralogous genes are not highly conserved, the core defensin structure is retained. D efb l4-lC ' 
has bactericidal activity sim ilar to that of its parent peptide (murine p-defensin Defbl4) despite all but one of 
the canonical six cysteines being replaced with alanines. The 23-amino-acid N-terminal half of D efbl4-lC v is 
a potent antimicrobial while the C-term inal half is not. Here, we use a library of peptide derivatives to 
dem onstrate that the antimicrobial activity can be localized to a particular region. Overlapping fragments of 
the N-terminal region were tested for their ability to kill Gram-positive and Gram-negative bacteria. We 
dem onstrate that the most N-terminal fragments (amino acids 1 to 10 and 6 to 17) are potent antim icrobials 
against Gram-negative bacteria whereas fragments based on sequence more C term inal than amino acid 13 
have very poor activity against both Gram-positive and -negative types. We further test a series of N-terminal 
deletion peptides in both their monomeric and dimeric forms. We find that bactericidal activity is lost against 
both Gram types as the deletion region increases, with the point a t which this occurs varying between bacterial 
strains. The dimeric form of the peptides is more resistant to the peptide deletions, but this is not due ju s t to 
increased charge. O ur results indicate that the primary sequence, together with structure, is essential in the 
bactericidal action of this P-defensin derivative peptide and importantly identifies a short fragment from the 
peptide that is a potent bactericide.
P-Defensins are believed to be important components in 
innate immunity. They are expressed predominantly at muco­
sal surfaces and the reproductive tract. They are a multigene 
family which has —40 m em bers  spread over five genomic loci 
in humans (18). They possess a strong, broad-spectrum anti­
microbial action in vitro and also have been shown to be che- 
moattractants for various immune cells (23, 24). Some p-de- 
fensins are rapidly induced by exposure to lipopolysaccharide 
or Till cytokines, while human p-defensin 1 (h B D l)  expres­
sion is mostly constitutive (14). Recently, increased copy num ­
ber of the p-defensins at the chrom osome 8 locus has been 
associated with an increased risk o f  psoriasis (7). Conversely, 
decreased copy num ber of this cluster has been associated with 
an increased risk o f  inflammatory bowel disease (5).
Defensins have a canonical six-cysteine motif, but the remain­
ing sequence of these short peptides is not highly conserved. The 
consensus is X 2. mC X V7(G/A)XCX,.4( X M ,CX47CCX„, where 
X is any residue, G/A is glycine or alanine, and C is cysteine. The 
spacing and connectivity o f  the six cysteines separate a-de- 
fensins from p-defensins, and  although highly conserved 
throughout evolution, the canonical six-cysteine motifs in ei­
* C orresponding  au thor. M ailing address: M R C  H um an G enetics 
Unit, W estern  G en era l H osp ita l. E d inburgh  E H 4  2X U , U n ited  King­
dom. Phone: (44) 131 467 8411. Fax: (44) 131 467 8456. E-m ail: 
julia.dorin@ hgu.m rc.ac.uk. 
t  N.L.R. and M .D .C. co n trib u ted  equally  to the  study.
' Published ahead  o f  p rin t on 22 F ebruary  2010.
ther defensin class are not required  for antimicrobial activity 
(2, 11, 20, 23). The canonical disulfide bridges may be im por­
tant for protection o f  the peptide in vivo, as has been dem o n ­
strated for a-defensins (11).
Evolutionary studies of  the mouse and human genomes have 
revealed that D efb l4  is the mouse orthologue o f  hum an P-de­
fensin 3 (D E F B I0 3 ) (19). The peptide encoded by D efb l4  has 
salt-resistant, wide-range antimicrobial activity very similar to 
tha t o f  the peptide encoded by D EFB103  (hum an p-defensin 
3-hBD3) (6, 16, 20). Like all defensins, hl3D3 has an an tipar­
allel p-sheet scatfold with a short N-terminal a-helix (17), and 
this structure is conserved throughout evolution.
Given the promiscuity o f  the endogenous peptides, u n d e r ­
standing the structure-activity relationships o f  p-defensins is 
essential. W ork in this area aims to find key information for 
designing novel synthetic antibiotics and for clarifying their 
function in immunity. T here  is some controversy as to the 
mode o f  action o f  defensins with m em brane  disruption by 
some mechanism seeming to occur. However, studies with 
hBD3 in Staphylococcus aureus have revealed the occurrence 
of rapid killing and  at the same time blockage o f  all biosyn­
thetic pathways, although significant depolarization o f  the bac­
terial m em branes was not observed and permeabilization was 
incomplete (1).
Wu et al. (23) elegantly used directional disulfide bonding to 
demonstrate  that the disulfide connectivities influenced the 
chemoaltractant potency o f  hBD3 but not the antibacterial 
effect. W e have also shown that hBD3 or D e fb l4  peptides with
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T A B L E  1. S equences o f  D elb l4 -d eriv ed  pep tides 
P e p tide  Sequence"
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D e ib l4   ..........................................................................................................................................f l p k t l r k f f c r i r g g p .c a v l n c l g k e e q ig r c s n s g r k c c r k k k
Dell) 14- IC V..........................................................................................................................................FLPKTLRKFFARIRGGRAAVLNALGKEEQIGRASNSGRKCARKKK
D etb l4- 1CVA( 1 ) ...............................................................................................................................  l p k t l r k f f a r ir g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
D e fb l4 -lC v A ( l-2 ) ............................................................................................................................  p k t l r k f f a r ir g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
Defb 14-1CVA( 1-5)............................................................................................................................  l r k f f a r ir g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
D e fb l4 -lC v A ( l-8 ) ............................................................................................................................  f f a r ir g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
D e fb l4 -lC v A ( l - l l ) .......................................................................................................................... r ir g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
Defb 14- IC VA( 1-14).......................................................................................................................... g g r a a v l n a l g k e e q ig r a s n s g r k c a r k k k
Delb 14- IC VA( 1-17).......................................................................................................................... AAVLNALGKEEQIGRASNSGRKCARKKK
D etb l4 -1C VA( 1-23).......................................................................................................................... LGKEEQIGRASNSGRKCARKKK
Detb 14-1 C v ( 1-23)............................................................................................................................ f l p k t l r k f f a r  ir g g r a a v l n a
Defb 14-1 C v ( 1 -10)............................................................................................................................FLPKTLRKFF
D e lb l4 - lC v (6-17).............................................................................................................................  LRKFFARIRGGR
Defb 14-1 Cv( 18-23)........................................................................................................................... AAVLNA
D e tb l4 - lC v ( 14-23)........................................................................................................................... RGGRAAVLNA
Defb 14-1 C v ( 12-23)........................................................................................................................... RIRGGRAAVLNA
D e fb l4 -lC v ( 13-34)........................................................................................................................... IRGGRAAVLNALGKEEQIGRAS
“ The sequences are g iven using s in g le - le tte r abb rev ia tions  fo r  am ino  acid residues; cysteine residues are in bo ld face . D e le t io n  pep tides are based o n  th e  D e fb l4 - lC v  
active p e p tide  used prev ious ly  (20).
all but one cysteine being replaced by alanine were still active 
as both a chem oattrac tan t and an antimicrobial. The  remaining 
cysteine was at position V o f  the canonical six-cysteine motif 
(-C1-C " -C m -C lv-Cv -Cvl-), where the cysteines are inter­
spersed with a variable num ber of amino acid residues. Hoover 
et al. (8) dem ons tra ted  that peptides from the C-terminal re ­
gion o f  hBD3 had potent activity against Escherichia coli and 
Pseudomonas aeruginosa but not S. aureus. The shortest pep­
tide was a decapeptide based on sequence from the C-terminal 
end of the molecule (R G R K S S R R K K ). The two adjacent cys­
teines in the native peptide were replaced with serines to 
eliminate the potential to form disulfide bonds (8). Further  
work using modifications o f  this decapeptide sequence has 
shown that its antimicrobial activity is more complex than just 
being a function o f  charge (13). In addition, work on an hBD3 
derivative where the cysteines of  the full-length mature peptide 
are changed to alanines has revealed that this peptide is as 
active as the paren t peptide against Gram-positive and -nega­
tive bacteria but is now sensitive to the ionic strength o f  the 
medium (3). As the cysteine content of the peptide does not 
affect the antimicrobial activity of  the peptide, we have focused 
on the D e fb l4 - lC v analogue (20). This peptide has all the 
cysteines replaced with alanines except Cys40, which resides at 
position V o f  the six-cysteine motif. In addition, it can easily be 
controlled to form m onom er or dimer species. We have pre­
viously shown that this peptide analogue has the same salt- 
insensitive bactericidal activity as the parent D efb l4  peptide 
(20). In addition, we divided the active D e fb l4 - lC v peptide 
into an N-terminal and  a C-terminal fragment and found that 
the C-terminal half (residues 24 to 45) was a  very poor anti­
microbial com pared  to the N-terminal fragment (residues 1 to 
23), which was potent. In o rder  to further dissect the residues 
important for the antimicrobial activity o f  D e fb l4 - lC v , we 
created a library of peptide fragments. We show that the a n ­
timicrobial activity o f  the most N-terminal residues is most 
potent, and deletion o f  these residues reveals that the points at 
which the activity is most significantly lost vary for different 
bacterial strains. We conclude that both the sequence and
structure that a given sequence  imposes are im portant for 
antimicrobial activity.
M ATERIALS A ND M ETH ODS
Peptide synthesis and purification. A l l  pep tides w ere  chem ica lly  synthesized 
by standard  so lid -phase m eth odo logy . D e fb  14 and D e fb l4 - lC v  w e re  ob ta ined  
fro m  C hem ica l Synthesis S e rvices-A Ibachem  L td . (G la d sm u ir, U n ite d  K in g ­
dom ). D isu lfid e  conn ec tiv ities  w ere  d e te rm in e d  by pro teo lys is  and p e p tide  mass 
m app ing  by fo llo w in g  the  procedu res o u tlin e d  by C a m po p ian o  et al. (2 ). T he  
sequences are show n in Tab le  1. T h e  defensin  14-insp ired pep tides, in c lu d in g  
a d d itio n a l synthesis o f  D e fb  14-1Cv . w e re  m ade in -house using au tom ate d  pe p ­
tid e  synthesis. T h is  was ca rried  ou t on an A p p lie d  Biosystems m odel 433A  
pep tide  synthesizer using R in k  a m id e -A M  resin fo r  p e p tide  am ides, p re loaded  
NovaSyn T G T  resin fo r  pep tide  acids, and 9 -flu o re n y lm e th o xy  ca rbony l (F m o c) 
am ino acids, a ll f ro m  N o vab io chem . A l l  tru n ca te d  D c f b l4 - lC v  pep tides w ere 
synthesized w ith  an acetyl g ro u p  at the N  te rm in us , ra th e r than  the  free am ino  
g roup , to  best represent the c o n fo rm a tio n  o f  the te rm in a l a m ino  acid. L iq u id  
ch rom a to g ra phy (L C )  mass spectra c o n firm in g  id e n tity  and p u r ity  w e re  ob ta ined  
on a M ic rom ass Q u a ttro  L C  mass spectrom e te r. S em ip re pa ra tive  h ig h -p e rfo r­
m ance liq u id  ch rom a to g ra phy  (IL P L C ) was p e rfo rm e d  using a Phenom enex 
L un a  C ]S co lum n  and a g ra d ien t o f  5 to  95%  a c e to n itr ile  (c o n ta in in g  0.1%  
trif lu o ro a c e tic  ac id ) over 45 m in  ( flo w  ra te  o f  3.0 m l/m in ) . A l l  o th e r chem ica l 
reagents w e re  ob ta ined  fro m  A ld r ic h . A u to m a te d  so lid-phase p ep tide  synthesis 
was ca rried  o u t on  a 0 .05-m m ol scale using 0.5 m m o l o f  each Fm oc am in o  acid 
per coup lin g  reac tion  and 2 - ( l /y -b e n z o tr ia z o l- l-y l) -L l,3 ,3 ,- te tra m e th y lu ro n iu m  
hexa flu o ro p h o sp h a te /l-h yd ro xyb e n zo tria zo le  as co u p lin g  reagents. C o u p lin g  
t im e  was 0.5 h. Pep tide  products  were cleaved fro m  the  resin w ith  95%  t r i f lu ­
o roace tic  acid, 2.5%  e th a n e d ith io l, and 2.5%  w a te r fo r  3 h, the  resin was f ilte re d  
o ff and washed w ith  tr if lu o ro a c e tic  acid, and f ilt ra te  was p ou red  in to  d ie th y l e the r 
(10 vo lum es). F o llo w in g  ce n tr ifu g a tio n  (3.000 rp m  at 15 m in ), the  p re c ip ita te  was 
resuspended in e th e r (5 vo lum es) and re ce n trifu g e d  (3,000 rpm  at 15 m in ). The  
c rude pep tides w ere dissolved in w a te r and loaded  d ire c tly  o n to  a sem ip repa ra ­
tive F IP LC  co lum n. Pep tide  frac tions  w ere id e n tif ie d  by mass sp ectrom e try  (M S ) 
and lyoph ilized .
Bactericidal assays. B a cte ric ida l assays w ere  ca rrie d  o u t as prev ious ly  de ­
scribed (20). B rie fly , test o rganism s w e re  g row n to  m id - lo g a rith m ic  phase in 
Iso-Sensitest b ro th  (O x o id )  g row th  m ed iu m  and then d ilu te d  to  betw een 1 x  106 
C F U /m l and 5 x  10ft C F U /m l in 10 m M  potassium  phosphate co n ta in in g  1% 
(v o l/v o l)  Iso-Sensitest b ro th . p H  7.4. D iffe re n t conce n tra tions  o f  test pep tide  
were incubated in 100 p.1 o f  cells (1 x  10'' to  5 X  105 C F U ) at 37°C fo r  3 h. 
R e duction  o f  the pep tides, w here p e rfo rm ed , was done by a dd ing  10 m M  d i- 
th io th re ito l (D T T )  and in cuba ting  the pep tides at room  tem p e ra tu re  ove rn igh t. 
T h e  ox id a tio n  state o f  each pep tide  was d e te rm in e d  by mass spectrom e try . 
T e n fo ld  seria l d ilu t io n s  o f  the in cuba tion  m ix tu re  w e re  spread on  Iso-Sensitest 
plates and incubated at 37°C\ and the  num bers o f  C F U  w ere de te rm in e d  the
1924 R E Y N O L D S  E T  A L . A n t i m  ic r o b . A g f n t s  C i i f m o t i i f r .
T A B L E  2. M BCs o f  D e fb J4 - lC v derivatives against a range o f  G ram -negative and  G ram -positive bacteria
O rgan ism  and s tra in
M B C  ( p M )  fo r  p ep tide ":
D e tti 14 D e lt i 14-1CV
D e f l i l4 - lC v
(1-23)
D e fb l4 -1 C VA
(1-23)
D e fb l4 - lC v
(1-10)
D e fb l4 - lC v
(6-17)
D e tb l4 - lC v
(14-23)
D e fb l4 - lC v
(13-34)
G ra m  n e g a tiv e
P. aeruginosa P A O l 0.3 0.3 0.6 >20.5 1.2 1 > 4 8 > 2 2
A. baum annii A T C C  19606 0.6 0.6 1.2 >20.5 19 1 > 4 8 > 2 2
Burkholderia cenocepacia  J2315 > 2 0 > 2 0 > 2 0 >20.5 > 4 0 >33 > 4 8 > 2 2
E. coli A T C C  25922 0.6 0.6 1.2 >20.5 9.6 2 > 4 8 > 2 2
G ra n t p o s i t iv e
E. faecalis A T C C  700802 1.2 1.2 2.4 > 20 .5 19 16.5 > 4 8 > 2 2
5. aureus A T C C  25923 0.6 0.6 1.2 >20.5 38.6 9.6 > 4 8 > 2 2
M RSA J2918 1.2 1.2 2.4 > 20 .5 38.6 4.8 > 4 8 > 2 2
"  B a cte ric ida l a c tiv ity  is located in the N -te rm in a l sequence o f  the  fi-de fens in  pep tide . T h e  reg ion  o f  the  m o lecu le  tha t the p e p tide  sequence is de rive d  fro m  is 
indicated beneath  its name by gray shading. B o ld face  ind ica tes M B C  o f  less than 20 [ iM .
fo llow ing  day. T h e  m in im u m  bacte ric ida l conce n tra tion  (M B C )  is the  concen­
tra tion  o f  p e p tide  at w h ich  we observed > 9 9 .99 %  k il l in g  o f  the in it ia l inocu lum . 
A ll assays w ere  p e rfo rm e d  in dup lica te  and repeated on th ree  in dependent 
occasions. T h e  m in im u m  b a c te ric ida l conce n tra tion  was ob ta ined  bv ta k in g  the 
mean o f  a ll o f  the results, and expe rim en ta l e rro rs  were w ith in  one d o u b lin g  
d ilu tion . S ign ifican t d iffe rences between M B C s w ere d e te rm ined  using a M ann - 
W hitney U  test.
M olecular hydrophobicity analysis. T h e  re la tive  m o lecu la r h yd ro p h o b ic ity  o f  
each m onom eric  p e p tide  was eva luated by reverse-phase H P L.C -M S  using an 
U ltim a te  3000 L C  system equ ipped  w ith  a Fam os au tosam pler (D io n e x ) and a 
VG  P la tfo rm  I I  mass spectrom e te r. A  to ta l o f  30 p.! o f  each sam ple, co n ta in in g  
50 p M  pep tide  in 10 n iM  d ith io th re ito l (D T T )  and 50 p M  m e litt in  (S igm a) as an 
in ternal standard , was in jec ted  o n to  a W ate rs Sym m etry C ,s co lum n  (3.9 by 150 
mm). D T I  was used to  prevent d im e riza tio n  o f  any o f  the peptides v ia cysteine 
ox idation; th is was co n firm e d  by mass analysis fo llo w in g  the L C  separation . 
In itia l co n d itio n s  w e re  as fo llow s: 100% e luen t A  (96%  w ater. 3%  a c e to n itr ile , 
1% fo rm ic  ac id ); 0%  e luen t B  (4%  w a te r, 95%  a c e to n itr ile , 1% fo rm ic  ac id ); and 
flow rate, 1 m l m in  '.  Samples w ere  e lu ted  fro m  the co lum n by using a linea r 
gradient o f  0 to  40% e luen t B  over 40 m in. T he  flo w  was sp lit 1/50 p r io r  to  
in troduction  to  the  e lec trospray  io n iza tio n  source o f  the mass spec trom e te r In 
order to  assess the  re la tive  m o lecu la r hydroph ob ic ities . we com pared the re te n ­
tion tim e o f  each p e p tide  to  tha t o f  m e litt in .
AG, the h y d ro p h o b ic ity  score (kca l/m o l) o f  m onom eric  pep tides in w a ter, was 
calculated using the scale o f  W im le y  and W h ite  (22). w here g rea te r hyd ro p h o ­
bicity is in d ica ted  by a less negative value.
Helical wheel projections. H e lic a l wheel p ro je c tions  w ere  constructed w ith  the 
aid o f  the p rogram  at h ttp ://rz lab .ucr.edu /scrip ts /w h ee l/w h ee l.cg i.
RESULTS
Bactericidal activity of peptide fragments. In o rder to nar­
row the antibacterial activity o f  D e fb l4 - lC v to a particular 
region o f  the molecule, we synthesized three overlapping frag- 
ments(l  to 10 [ 1 -10], 6 to 17 [6-17], and 14 to  23 [14-23]) o f  the 
antimicrobially active N-terminal D e fb l4 - lC v . These trag- 
ments (see Table 1 for sequences) were tested against a panel 
of Gram-positive and Gram-negative bacteria. We determined 
the minimum bactericidal concentration (MBC) values tor 
these peptide fragments (Table 2), i.e., the minimum concen­
tration at which less than 99.99% of the initial inoculum is 
viable.
The 23-amino-acid N-terminal fragment D e fb l4 - lC v (l-23) 
has bactericidal activity very similar to that o f  D e fb l4 - lC v (as 
previously repor ted  under the name D14ip 1 [20]) against 
Pseudomonas aeruginosa P A O l and S. aureus A TC C  25923. 
The peptide fragment with the first 10 amino acids ot D efb l4-
1CV [D e fb l4 - lC v (l-10)] shows good activity against P. aerugi­
nosa P A O l (M BC of 1.0 pM ) ,  Acinetobacter baum annii (MBC 
of  0.58 pM ),  and  E. coli (M BC of  2.3 p M ),  and  these are within 
one doubling dilution o f  the D e fb l4 - lC v (l-23) fragment and 
comparable  to the parental peptide activity against these 
strains. The D e fb l4 - lC v peptide fragment with the 12 internal 
amino acids [D e fb l4 - lC v (6-17)[ also has a strong bactericidal 
activity against the three Gram-negative strains tested. The 
peptide fragments containing amino acids 14 to 23 and  13 to 34 
do not achieve an M B C  against the bacteria at the concentra­
tions tested here. Interestingly, only one  o f  the two most N- 
terminal peptides has good activity' against the Gram-positive 
strains tested. Only the fragment with residues 6 to 17 has the 
ability to kill all the Gram-positive strains at a concentration 
less than 19 pM  ( —30 pg/ml). D e f b l4 - lC v (6-17) had good 
activity against methicillin-resistant S. aureus (M R SA ) strain 
J2918 (M BC of 4.8 pM ). comparable  with that o f  the D efb l4-  
l C v (l-23) fragment, and its M B C  against S. aureus was 8.2 
pM . W e previously repor ted  that D e fb l4 - lC v and  the active 
N-terminal fragment D e fb l4 - lC v (l-23) had salt-insensitive 
activity against P. aeruginosa (20). Interestingly, the  bacteri­
cidal activities o f  both D e fb l4 - lC v (l-10) and  D e f b l4 - lC v (6- 
17) against P. aeruginosa are unchanged with increasing salt 
concentrations o f  up to 200 mM NaCI (data  not shown).
Bactericidal activity of N-terminal deletions. In o rder  to 
further dissect the antimicrobial sequence within the N -term i­
nal region o f  D e fb l4 - lC v  and in the context o f  the molecule 
with the C-terminal region included, we made a series o f  N- 
terminal deletions (see Table 1 for sequences). As the de le­
tions are based on D e fb l4 - lC v . they all have a single cysteine 
residue (CysV4(l). This enabled us to examine both monom eric  
and covalent dimeric forms, with the latter occurring via a 
disulfide bridge. Following oxidation, the peptides spon tane­
ously form a hom odim er through the cysteine-cysteine disul­
fide bridge and reduction with D T T  leaves the peptide in the 
reduced  form, as verified by mass spectrometry, and  this slate 
is maintained throughout the assay (data  not shown). We d e ­
termined the MBCs of both the dimeric and  monom eric  mol­
ecules against three Gram-negative and three Gram-positive 
bacterial strains for all the deletion peptides (Table 3).
As the deletions progress, the MBC increases in all cases,
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indicating loss o f  bactericidal activity. The points at which the 
bactericidal activity significantly reduces are not the same for 
all the bacterial strains. Deletion o f  14 amino acids results in 
the monom eric  form o f  the peptide being unable to kill any of 
the six bacterial strains at the concentrations tested. The crit­
ical point for activity against P. aeruginosa and A. baum annii 
ATCC' 19606 is between D e fb l4 - lC v A ( l - l l )  and Defbl4- 
1CVA(1-14). However, against ano ther  Gram-negative strain 
(E. co li), deletion o f  8 amino acids results in the bactericidal 
activity falling 4-fold to 10 p,M (37.3 fxg/ml). Against Gram- 
positive S. aureus A TC C  25923 and M R SA  J2918, the bacte­
ricidal activities d rop significantly after deletion o f  11 amino 
acids. However, deletion o f  only 5 amino acids results in the 
monomeric peptide significantly losing activity against Entero- 
coccus faecalis.
The dimeric peptides are more robust than the m onom ers in 
their ability to kill the bacteria when the N-terminal amino 
acids are progressively deleted. All four strains tested show a 
significant increase in the MBC of the monom eric  species 
before the dimeric species’ M BC is affected. P. aeruginosa is 
killed at only 1.4 p.M with the D efb l4-1C VA(1-14) dimeric 
species, whereas the m onom eric  form is not able to kill the 
bacterium at 16.5 p.M. The same effect was observed with E. 
coli and A. baum annii, where the m onom er species loses bac­
tericidal activity before the dimer forms. The Gram-positive 
strains also display this effect. For  D efb l4 -1C VA( 1-11), there is 
a 6-fold increase in the am ount o f  m onom er required to kill 5'. 
aureus A T C C  25923 com pared to the amount o f  dimer (5.9 
gM versus 0.9 g M ) ,  and  with the same peptide, the m onom er 
MBC against M R S A  is > 1 0  pM , compared to 1.5 p M  for the 
dimer MBC.
The dim er deletion peptide activities against P. aeruginosa in 
increasing sodium chloride concentrations o f  up to 200 mM  
were tested. Like the parent peptide and peptide fragments 1 
to 10 and 6 to 17, the bactericidal activities o f  deletion peptides 
up to and including D efb l4 -1 C VA( 1-5) were not significantly 
affected by addition o f  sodium chloride at concentrations o f  up 
to 200 mM. However, deletion peptide D e fb l4 - lC v A(l-8) had 
a significantly (P  <  0.01) raised MBC of 10 (±0 .0)  p M  in 10 
mM sodium chloride com pared  to 1.7 (±0 .0)  p M  in 0 mM 
NaCl. The subsequent deletions also showed significantly (P <
0.01) increased M B C s o f  > 1 0  mM in 100 mM NaCl, indicating 
that loss of the N-terminal region o f  D e lb l4 - lC v rendered  
these peptides salt sensitive.
In o rder  to check w hether degradation o f  the peptides by 
bacterium-specific proteases could explain the loss of bacteri­
cidal activity, the integrity o f  the inactive peptide D efb l4-  
1CVA( 1-14) was evaluated by LC-MS following incubation 
with .S’, aureus A T C C  25923. After 4 h, the majority o f  the 
peptide rem ained intact (peak area o f  66% relative to that of  
sample prior to incubation; data not shown), indicating that 
proteolysis o f  the peptide by the bacterial strain does not 
explain its inactivity.
Charge versus bactericidal activity. In an effort to determine 
whether charge ra ther  than the primary sequence o f  the pep­
tides had an effect on the ability to kill bacteria, we considered 
the net charge o f  each sequence in the peptide library we had 
synthesized. Figure 1 shows the charge o f  m onom er molecules 
(and dimer molecules where relevant) and is annotated  ac­
cording to which peptides are active against P. aeruginosa
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FIG . 1. C harge  and stru c tu re  are  im portan t fo r an tim icrobia l ac­
tivity o f  ¡3-defensin derivatives. T h e  D e fb l4 - lC v  derivative library was 
plotted according to the  net charge (p ro to n a tio n  sta te ) o f  the synthe­
sized pep tides at a neu tra l pH . T his takes in to  account the  num ber o f 
basic versus acidic am ino  acids and also  the term ini. T he key indicates 
w hether pep tides are  active bactericides and d im ers o r m onom ers.
PAOl with an M B C  of less than 5.0 p.M (shown as filled dots 
or squares in the figure). All the inactive peptides (shown with 
open dots or squares) possess a charge o f  less than +11; how­
ever, six active peptides also have a charge o f  less than +11, 
with D e f b l4 - lC v (l-10) having a charge o f  only + 5  and an 
MBC of 1.2 p.M. The D efb l4 -1 C VA(1-17) dimer has a charge 
of +10 and is a po ten t antimicrobial agent with a low MBC, 
but in contrast,  the D e fb l4 - lC v A(l-23) dimer has an equal 
charge but is an inactive antimicrobial with an M BC in excess 
of 10 p-M.
Hydrophobicity versus bactericidal activity. We also as­
sessed the hydrophobicity of the deletion peptides both ac­
cording to their primary sequences via the Wimley-White scale 
for proteins at a m em brane  interface (Fig. 2a) (22) and exper­
imentally by measuring their retention limes by reverse-phase 
HPLC (Fig. 2b). This second method  is sensitive to the con­
formation o f  the free peptide in solution. Flowever, we observe 
little difference between the hydrophobicities o f  these pep­
tides. as gauged by either method  (Fig. 2). The hydrophobicity 
via H PLC does decrease as the length o f  the peptide decreases, 
with the exception o f  Delb 14-IC VA( 1-17), which shows a slight 
increase relative to that of D efb l4 -1C VA(1-14). The observed 
differences in bactericidal activity with these peptides cannot 
be attributed to any dramatic difference in the hydrophobicity 
of the free peptide.
Structural change as determined by helical wheel projec­
tion. Figure 3 shows a  helical wheel projection of D e fb l4 - lC v 
(residues 1 to 18) which predicts that the N-terminal region of 
the full-length peptide has the potential to form an a-helix with 
charged residues concentra ted  on one face o f  the helix and 
hydrophobic residues on the other. The distinction between 
hydrophilic and hydrophobic faces is less clear in helical wheel 
projections o f  residues 12 to 29 and 15 to 32, which correspond 
to the N-terminal regions o f  the D efb l4-1C VA(1-11) and 
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FIG . 2. A ssessm ent o f  the  relative hydrophobicities o f  the D efb I4 - 
1CV N -term inal de le tion  series, (a) T he re ten tion  tim es o f  each  N- 
term ina l deletion  pep tide , relative to  that o f m elittin , a re  m easu red  for 
bo th  the m onom er and  d im er und er reducing and  nonreducing  con­
ditions. respectively. In creased  relative re ten tio n  tim e is indicative o f 
m ore hydrophobic charac te r, since u n d e r a reversed-phase g rad ien t 
hydrophobic p ep tides will be re ta ined  longer on the  C ,8 colum n. F or 
com parison, panel b show s the theore tica l hydrophobicity  score (in 
kcal m o L 1) o f  each pep tide  in w ater, calcu lated  using th e  scale o f  
W im ley and W hite  (22). G re a te r  hydrophobicity  is ind ica ted  by a less 
negative value.
lesser propensity to form an a-helix, which we have also shown 
by circular dichroism (C D ) (21), and may account, in part, for 
the diminished activity of the truncated peptides. T here  is little 
difference in these projections for residues 12 to 29 and 15
to 32.
DISCUSSION
In order  to fur ther dissect the basis o f  the po ten t bactericidal 
activity o f  the N-terminal region o f  the D e fb l4 - lC v derivative, 
we synthesized several overlapping fragments o f  the 23-amino- 
acid region and a series of D e fb l4 - lC v -derived peptides with 
progressive N-terminal deletions. We determined their MBCs 
against a panel of Gram-positive and -negative bacterial strains. 
Although the D efb l4 - lC v (6-17) fragment is a strong bactericide, 
(he deletion series reveals that there does not appear to be one 
short sequence responsible for activity against all strains.
Primary sequence determines bactericidal activity against 
different bacteria. We show tha t  the m ore C-terminal fragment
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FIG . 3. H elical wheel p ro jec tions o f N -term inal regions o f D e fb l4 - lC v and  inactive/active derivatives. Schem atic  helical w heel p ro jec tions o f 
D e fb l4 -lC v (residues I to  18) (A ), D e lb l4 - lC v A ( l - l l )  (residues 12 to  29) (B). and  D e lb l4 -1 C VA(1-14) (residues 15 to 32) (C ). C harged  residues 
are d eno ted  by white circles. Increasing  hydrophobicity  is d en o ted  by increasing shading. T he positions o f the side chains a re  show n along a 
“regu lar” a-helix . F o r a righ t-handed  helix w ith 3.6 residues p e r  tu rn , ro ta tion  is clockwise as the  polypeptide chain is follow ed from  N to C, and 
the 5th residue ends up in a position  exactly 40° clockwise relative to  th a t o f  residue 1.
D efb l4 - lC v ( 14-23) has very poor activity against both Gram- 
positive and -negative strains, whereas D e fb l4 - lC v (l-10) and 
D e fb l4 - lC v (6-17) retain some aspects o f  the antibacterial 
activity of the parent molecule. Both fragments are potent 
bactericides against the Ihree Gram-negative strains tested; 
however, only D e fb l4 - lC v (6-17) is robust against the Gram- 
positive S. aureus strains. The deletion series allowed us to 
determine w hether  these fragments influence bactericidal ac­
tivity within the context o f  the full-length molecule. W e find 
that as the N-terminal deletions progress, the monomeric pep­
tide M BC increases (indicating loss o f  activity), but the points 
at which significant MBC increase occurs vary between strains. 
The deletion series indicates that the critical amino acid resi­
dues required for bactericidal activity are located between res­
idues 5 and 14 (concordant with the activity of fragments 1 to 
10 and 6 to 17). Gram-positive strains M R SA  J2918 and S. 
aureus A TC C  25923 are effectively killed by D efb l4 -1C VA(6- 
17) but not D efb l4 -1C VA(1-10). In agreem ent with this, the 
ability of the truncated peptides to kill S. aureus ATC C  25923 
and M R SA  J2918 reduces significantly with the deletion of 
residues 9, 10, and 11 (FFA). The charge o f  active Defbl4- 
lCv A(l-8) is the same ( + 8) as that o f  poorly active 
Defbl41Cv A ( l - l l ) ,  with little change in hydrophobicity, sug­
gesting that the difference in activity is indeed primarily se­
quence/structure based. This contrasts with work on hBD3, 
where charge and hydrophobicity have been found to influence 
antimicrobial activity (9).
Although amino acid residues 9 to 11 appear  to be important 
in the killing o f  Gram-positive S. aureus strains, deletion ol 
these residues results in little change to the monomeric MBC 
against Gram-negative P. aeruginosa P A O l and A. baumannii. 
However, the subsequent deletion o f  R IR  in D e tb l4 - lC v ( l -  
14) results in a significant loss o f  activity. This decrease in 
sensitivity is not wholly d ependen t  on the G ram  status of the 
bacteria, since Gram-negative E. coli A TC C  25922 shows sen­
sitivity lo D efb l4 -1 C VA(1-11) in a pattern similar to that of  
Gram-positive S. aureus species.
These data  again suggest that the primary amino acid se­
quence is important for bactericidal activity. This notion is
supported  by a similar study with h B D l  which revealed that 
antimicrobial activity against E. coli was affected mostly by 
amino acid substitutions o f  charged residues in the positively 
charged C-terminal region (15). These substitutions did not 
affect peptide topology, and the study concluded that  it was the 
side chain changes that affected the antibacterial activity. R e­
cently, it was repor ted  that the bactericidal activity o f  a-defen- 
sin cryptdin 4 was a t tenua ted  when all the arginines were 
muta ted  to lysine. L lenado et al. (10) postulate tha t  the  gua­
nidine group in arginine may allow stronger electrostatic 
charges and hydrogen bonding interactions, which may be im­
portant for electronegative bacterial cell m em brane  interac­
tions. However, we have tested whether inclusion o f  the R IR  
sequence results in a peptide with bactericidal activity, but 
p ep tide  D e f b l 4 - l C v (12-23) with seq u en ce  R 1 R G G R A A  
V LN A  is inactive as a  bactericide at 20 p.M against both P. 
aeruginosa and S. aureus (data  not shown).
M ultiple sequences contribute to bactericidal activity. E. 
coli, P. aeruginosa P A O l ,  and A. baum annii are killed effec­
tively by peptide fragments D e fb l4 - lC v (l-10) and D efb l4- 
1CV(6-17). The deletion series m onom er data  support both of 
these fragments containing unique sequence that is important 
in the context o f  the peptide. Sequential deletion o f  amino 
acids 6, 7, and 8 and then 9. 10, and  11 (E . coli) and  amino 
acids 9, 10, and  11 followed by 12, 13, and 14 (P. aeruginosa) 
results in an individual decrease in bactericidal potency. This 
suggests tha t  there  are two regions im portant to bactericidal 
activity, one  in D e fb l4 - lC v l-10 and one  in D e fb l4 - lC v 6-17, 
so that only when both are deleted from the larger molecule is 
the activity very much reduced.
Supporting this is our previous finding that the sequence 
N TL Q K  in hBD3 (corresponding to K T L R K  in Delb 14) has 
been subjected to negalive selection during primate evolution
(19). This sequence is contained fully in D e fb l4 1 C v (l-10) and 
partially in D e fb l4 1 C v (6-17), suggesting that the region is 
important functionally. Interestingly, it is also this region 
(LRK) that appears to be critical in maintaining the salt in­
sensitivity o f  the peptides against P. aeruginosa.
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Dimeric structure retains activity. The bactericidal activity 
of the dimeric deletion peptides is more resistant to the de le­
tion of amino acids than that o f  the monom eric  forms up until 
the D e fb l4 -1C VA(1-14) fragment (against A. aureus) and de­
letion o t  R IR . This indicates that dimer structure, in addition 
to sequence, is im portant for bactericidal activity. The in­
creased charge o f  dimeric molecules may implicate charge as a 
contributor to antibacterial activity; however, the inactivity of 
dimeric D efb l4 -1 C VA(1-14) implies that sequence and struc­
ture are m ore  important than charge for this strain. In o rder  to 
consider this further, we compare the charges and bactericidal 
activities for the various peptides against P. aeruginosa P A O l 
(Fig. 1). Comparison o f  bactericidal activities between D efbl4- 
lC v A(l-23) and D efb l4 -1C VA(1-17) dimers with the same 
charge ( + 5) and similar low hydrophobicities but vastly differ­
ent bactericidal activities supports that sequence and structure 
are more im portant than charge.
The im portance o f  dimeric structure is further supported by 
evidence that covalent dimeric defensins are more active bac­
tericides than monomeric o r  noncovalent dimers (2, 4) and by 
the recent report by Antcheva et al. (1) which demonstrated  
that covalent dimerization of an artificial defensin could im­
prove its antimicrobial activity.
Helical structure may affect function. We performed circu­
lar dichroism (C D ) on an analogue o f  D e lb l4 - lC v A(l-23),  
which has po o r  antimicrobial activity identical to that of 
D e fb l4 - lC v A(l-23) but alanines at all the cysteine positions
(20). W hen com pared  to the potent N-terminal peptide 
D efb l4 - IC v ( 1-23), it is shown to have reduced helical propen­
sity (21; da ta  not shown). W e also show by helical wheel pro­
jection that the helix-forming propensity o f  the N-terminal 
region is likely to be lost as the peptide deletions increase. This 
may be im portant since the formation of helical oligomers is 
implicated in the pore model o f  antimicrobial action. However, 
there is little difference in these projections for residues 12 to 
29 and 15 to 32 to rationalize the lack o f  bactericidal activity 
against P. aeruginosa of the D efb l4 -1C VA(1-14) m onom er rel­
ative to that o f  D e fb l4 - lC v A ( l - l l ) .  In addition, the activities 
found in these deletion peptides and mode o f  action may not 
reflect those present in the full-length disulfide stabilize mol­
ecule.
Of the peptides tested here, D e fb l4 - lC v (6-17) has the most 
potential as a short and effective bactericidal agent in vitro. We 
have, however, found that the bactericidal activities o f  the 
peptide fragments and parental (3-defensin are inhibited by 
serum, although not by trypsin digestion (data not shown), 
which is also observed for hBD3 (12).
In conclusion, our results show that both structure and se­
quence are im portant for the antimicrobial activity o f  these 
P-defensin derivatives. W e find that the activities ot the N- 
terminal peptide fragments are supported  by the N-terminal 
deletions, and we find that the precise sequences that confer 
bactericidal activity vary for different bacteria, showing selec­
tivity at the amino acid level. W e have shown that deletion of 
FFA and R1R is im portant for loss o f  activity against S. aureus, 
deletion of L R K  for E. coli and E. faecalis, and deletion ol R IR  
for P. aeruginosa and A. baum annii. We also show that, in all 
cases, covalent d im er peptides retain activity better  than m o­
nomeric forms. A pproaches aimed at determining the molec­
ular basis o f  structure-activity relationships will greatly assist in
the design o f  novel therapeutic  agents.
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A B S T R A C T
P-D efensins are  bo th  an tim icrob ia l and ab le  to  c h e m o a ttra c t various im m u n e  cells includ ing  im m atu re  
den d ritic  cells and CD4 T cells th rough  CCR6. They are  sho rt, ca tion ic  p ep tid es w ith  a h ighly  conserved  
s ix -cyste ine  m otif. It has been  show n th a t  only  th e  fifth cyste ine  is critical for ch em o attrac tio n  o f cells 
exp ressing  CCR6. In o rd er to identify  o th e r  residues essen tia l for functional in te rac tio n  w ith  CCR6 w e 
used  a library  o f pep tid e  dele tion  derivatives based  on D efbl 4. Loss o f th e  initial tw o  am ino  acids from  
th e  Defbl 4-1 Cv derivative destroys its ab ility  to c h e m o a ttra c t cells exp ress in g  CCR6. As th e  second am ino  
acid is an evo iu tionarily  conserved  leucine, w e m ake fu ll-leng th  D e fb l4 -lC v p ep tid es w ith  su b s titu tio n  
o f th e  leucine2 for glycine (L2G), lysine (L2I<) o r iso leucine (L2I). D efb l4-1  Cv L2G and  L2K and  are  unab le  
to  c h em o a ttrac t CCR6 expressing  cells b u t th e  sem i-co n serv a tiv e  change L2I has activity. By circular 
d ichro ism  spectroscopy  w e can see  no ev idence for a  sign ifican t change in secondary  s tru c tu re  as a 
co n sequence  o f th e se  su b s titu tio n s and  so can n o t a ttr ib u te  loss o f  ch em o tac tic  ac tiv ity  w ith  d isru p tio n  
o f th e  N -term inal helix. W e conclude th a t  iso leuc ine /leucine  in th e  N -term inal a -h e lix  region o f  th is 
3 -d e fe n sin  is essen tial for CCR6-m ediated chem otaxis.
© 2009 Elsevier Ltd. All righ ts reserved.
1. Introduction
P-Defensins are believed to be im portan t com ponents  in innate 
immunity. They are a multigene family which has ~ 4 0  members 
spread over five genomic loci in hum an (Schutte e t  al„ 2002). 
Defensins have a canonical six-cysteine motif but the rem ain­
ing sequence of these short peptides is not highly conserved. In 
vitro they possess a strong, broad spectrum antimicrobial action 
and also have been show n to be chem oattrac tan t for various 
immune cells including CD4 m em ory T helper cells and im mature 
(but not m ature) dendritic cells (iDC) through chemokine recep­
tor 6 (CCR6) (Yang e t  al„ 1999). W e also have show n that the 
murine Defb8 and a five cysteine peptide (encoded by the DefrI 
allele of Defb8) are chem oattrac tan t for CD4+ T cells and iDC but 
not mature DC and not through CCR6 (Taylor et al., 2009). P- 
Defensins are therefore a promiscuous family of ligands. Candille 
tt al. (2007) have show n that hum an p-defensins can interact 
with meianocortin receptors in vitro, and in vivo over-expression
* C orresponding a u th o r  at: MRC H um a n  G enetics U n it, W e s te rn  G eneral H osp ita l, 
M inburglr EH4 2XU, Sco tland , UK. Tel.: +44 131 467  8411; fax: +44 131 4 6 7  8456. 
E -m a i l  a d d re s s : ju lia .d o rin @ h g u .m rc .a c .u k  (J.R. D o rin ).
1 These a u th o rs  c o n tr ib u te d  e q u a lly  to  th is  s tudy
of the  dog CBD103 gene (orthologue to DEFBI03) in transgenic 
mice causes black hair colour through binding to MC1R. Recently, 
increased copy n um ber  of the p-defensins at the chrom osom e 8 
locus has been associated w ith  increase risk of psoriasis (Hollox et 
al., 2008).
Human p-defensin 3 (hBD3, DEFB103) has multiple functions 
(Dhople et al„ 2006) and D efbI4  is the mouse orthologue (Semple 
et al., 2003) and has similar antimicrobial properties (Taylor e t al„ 
2008; Rohrl et al., 2007; Hinrichsen et al„ 2008). Defbl4  m ature  
peptide, with  the full com plem ent of the six-cysteine residues 
characteristic of a p-defensin, can chem oattrac t  cells express­
ing the chemokine receptor CCR6 and monocytes (Taylor et al., 
2008). Wu et al. (2003) elegantly used directional disulfide bond­
ing to dem onstra te  tha t  the disulfide connectivities influenced the 
chem oattrac tant potency of hBD3. W e have show n (Taylor e t  al., 
2008) that hBD3 or D efb l4 peptides w ith  a single cysteine at posi­
tion V of the six-cysteine motif (-C l-C "-C lll-C iv-CvCvl- )  w here  the 
cysteines are in terspersed with a variable n um ber  of amino acid 
residues, are as active as the peptide w ith  the native connectivity 
(Ci-Cv , Qi-Civ, and Cm-Cvi). Peptide with no cysteine (cysteines 
replaced with alanines) or peptide fragments are not active as 
chemoattractants, which implied tha t both s tructure  and residue 
side chains were essential for functional interaction w ith  the CCR6 
receptor.
0161-5890/$ -  see f ro n t  m a tte r  ©  200 9  E lsev ie r Ltd. A ll r ig h ts  reserved. 
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We show  here tha t N-terminal deletions of the peptide -  even 
deletion of only the first two N-terminal residues -  eliminate the 
chemoattractant ability of the  peptide. Further analysis revealed 
that the ability tochem oa tt rac t  CCR6-expressingcells is dependent 
on the residue side chain rather than the helicity of the N-terminal 
region of the peptide.
2. M aterials and m ethods
2. /. Peptide synthesis and purification
All peptides w ere  chemically synthesized by standard  soiid- 
phase methodology. Defb14-lCv and derivatives w ere  m ade "in 
house" using au tom ated  peptide synthesis . This was carried out 
on an Applied Biosystems model 433A peptide synthesizer using 
Rink amide AM resin for peptide amides, preloaded NovaSyn®TGT 
resin for peptide acids, and Fmoc amino acids from Novabiochem. 
All truncated  Defb14-1Cv (Fig. 1) w ere synthesised with an acetyl 
group at the N terminus, ra ther than  the free amino group to 
best represent the conformation of the terminal amino acid. 
LC-mass spectra confirming identity and purity w ere  obtained 
on a Micromass Quattro LC mass spectrometer. Semi-preparative 
FIPLC was performed using a Phenomenex Luna C l8 column 
and a gradient of 5-95% acetonitrile (containing 0.1% trifluo- 
roacetic acid) over 45 m in  (flow rate of 3 .0ml/min). All other 
chemical reagents w ere  obtained from Aldrich. Automated solid- 
phase peptide synthesis was carried out on a 0.05-mmol scale 
using 0.5 mmol of each Fmoc amino acid per coupling reac­
tion and 2-( lH -benzotr iazol-l-y l)-1 ,l ,3 ,3 ,- te tram ethyluronium  
hexafluorophosphate/1-hydroxybenzotriazole as coupling 
reagents. Coupling time was 0.5 h. Peptide products were cleaved 
from the resin w ith  95% trifluoroacetic acid, 2.5% ethanedithiol,  
2.5% w ater  for 3 h; the resin was filtered off and washed with 
trifluoroacetic acid; and filtrate was poured into diethylether (10 
volumes). Following centr ifugation (3000 rpm, 15m in)  the pre­
cipitate was resuspended in e the r  (5 volumes) and recentrifuged 
(3000 rpm, 15min). The crude peptides w ere dissolved in w ater 
and loaded directly onto a semi-preparative HPLC column. Peptide 
fractions were  identified by mass spectrom etry  and lyophilized.
2.2. Cliernotaxis assay
The migration of CCR6-transfected hum an embryonic kidney 
HEK293 cells was assessed with a microchemotaxis cham ber tech­
nique as described (Taylor et al., 2009). Briefly, peptides w ere  
serially diluted in RPMI m edium containing 1% BSA. Dilutions or 
medium alone w ere dispensed into the lower wells of the chamber. 
CCL20 (Peprotech EC, London, UK) w as used as a positive control at 
the same concentrations. A lOpim polycarbonate filter (Receptor 
Technologies, Leamington Spa, UK), coated with 5 p.g/ml human 
type VI collagen (Sigma, Dorset, UK) was placed over the lower 
chamber. 100,000 cells per well w ere then added to the upper 
portion of the chamber. Each dilution was tested in triplicate and 
experiments were carried out a m inim um  of three times. Medium 
alone was used as a control. CCL20 was obtained from Peprotech EC 
(London, UK). Migratory Index was calculated as compared to con­
trol values. Data was analysed by one-way ANOVA with post-test 
when p < 0.01. Chemotactic activity was determined as the concen­
tration of test com pound at which the  highest migratory index was 
achieved.
2.3. Minimum bactericidal concentration (MBC assays)
These assays w ere  carried ou t as previously described (Taylor et 
al., 2008). Briefly, test organisms w ere  grown to mid-logarithmic 
phase in Iso-Sensitest broth (Oxoid) growth medium and then
diluted to 1 -5  x  106 colony-forming units/ml in lO m M  potassium 
phosphate  containing 1% (v/v) Iso-Sensitest broth, pH 7.4. Differ­
en t concentrations of test peptide were  incubated in 100 p.1 of cells 
(1 -5  x 105 colony-fo rm ingun its )a t37  C for 3 h. 10-Fold serial dilu­
tions of the incubation mixture w ere  spread on Iso-Sensitest plates 
and incubated at 37 C, and the colony-forming units w ere de te r­
mined the following day. The m in im um  bactericidal concentration 
is the concentration of peptide w here  w e  observed >99.99% killing 
of the initial inoculum. All assays w ere  performed in duplicate and 
repeated  on four independent occasions. The m in im um  bactericidal 
concentration was obtained by taking the  mean of all of the  results, 
and experimental errors w ere with in  one doubling dilution.
2.4. Circular dichroism spectroscopy
Peptide solutions w ere  prepared at an approximate concentra­
tion of 2 0 0 p-g/rnl in: (i) lO m M  am m onium  acetate (Sigma), pH 
6.8, and (ii) 50% water, 50% 2,2,2-trif luoroethanol (TFE) (Aldrich). 
CD spectra were recorded at 20 C using a Jasco J-810 spectropo- 
larimeter.  Five scans w ere  acquired for each sample at a rate of 
10 nm mi n~1 and averaged to give a final sample spectrum. A ‘blank’ 
buffer CD spectrum, acquired in precisely the same way, w as sub­
tracted from each final sample spectrum. The concentration of each 
peptide solution was determ ined  subsequently  by assaying w ith  
bicinchoninic acid (Smith et al„ 1985) (Pierce) and the mean residue 
ellipticity (#x) was calculated at each wavelength (A). The CDSSTR 
algorithm (Johnson, 1999) on the DICROWEB server (W hitm ore and 
Wallace, 2008) was used to help assign secondary structure.
3. Results and discussion
3.1. Chemoattractant activity is lost follow ing deletion or 
replacement o f Leucine2 o f D efb l4-lC v
Fig. la  shows the ability of N-terminal deletions of Defb14-1Cv 
to chem oattrac t cells expressing hum an CCR6. Supplementary Fig.
1 shows flow cytometry analysis to confirm that these cells strongly 
express CCR6 w ith  an an t ihum an  CCR6 antibody compared to the 
signal obtained w ith  an isotype control. Hek cells no t expressing 
CCR6 do not show  any chemoattraction  to these defensins (data 
not show n and Taylor et al., 2008). Only the paren t peptide Defb 14- 
1CV shows a typical bell-shaped curve and migratory indices are 
significantly different to media alone. Loss of the first two (pheny­
lalanine and leucine) amino acids of Defb14-lCv results in loss of 
chemoattraction (Fig. la). Rohrl e t  al. (2007) describe a recombi­
nant mBD14-lg fusion protein acting as a chem oa ttrac tan t for cells 
expressing murine CCR6, which perhaps implies the C-terminal end 
of the molecule can support som e structural change w ithou t a lter­
ing its ability to interact functionally w ith  CCR6. The results in Fig. 1 
presented here dem onstra te  tha t  losing the first (phenylalanine) 
and second (leucine) amino acids results in the complete  loss of the 
CCR6-mediated chem oattrac tan t activity of the peptide. Thus one 
of these residues appears to be essential for direct interaction with 
the receptor, or alternatively directs the peptide to achieve a con­
formation which presents o ther  residues such that they can bind 
successfully to the receptor.  This postulated conformation may only 
occur in the presence of the receptor.  hBD3, the hum an ortho- 
logue of Defb 14 (which has comparable activity to chem oattrac t 
these CCR6 expressing cells) has glycine (G) and isoleucine (I) as 
the first two amino acids of the  m atu re  peptide w here  Defb14 has 
phenylalanine (F) and leucine (L). Leucine to isoleucine is a highly 
conservative residue change both being hydrophobic residues and 
in o ther m am mals this second residue is also conserved. In Chin­
chilla, Cow, Opossum, Pig and Dog the second residue is either 
isoleucine or leucine. The first residue is how ever less conserved,
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Fig. 1. Leucine a t p o s itio n  2 is essen tia l fo r  th e  ch e m o a ttra c ta n t a c t iv ity  o f  D e fb l4 - lC v aga ins t h u m a n  e m b ry o n ic  k id n e y  cells exp ress ing  CCR6. (A ) The g ra p h  show s  the  
«umber o f  HEK293 ce lls  e xp ress ing  th e  hu m a n  ch e m o k in e  CCR6 ce lls  th a t  m ig ra te  to w a rd  th e  te s t d e le tio n  pe p tid e s  (A ) o r s u b s t itu t io n  pe p tid e s  (B). The m ig ra to ry  in d e x  
(ratio o f th e  n u m b e r o f  ce lls  p e r h igh  p o w e r Held w ith  p e p tid e  to  n u m b e r o f  ce lls m ed ia  a lo n e ) is g ive n . CCL20 (M ip 3 a )  is th e  ch e m o k in e  lig a n d  o f  CCR6 and D e fb1 4-1 C v 
5 the ac tive  p a re n t pe p tid e . Each assay w as repea ted  at least th re e  tim e s , and th re e  fie lds  o f  v ie w  w e re  taken  fo r  each e x p e rim e n t. N u m e rica l data  are  m eans ±S .D . A bove 
graph (A ) is th e  p e p tid e  sequence in  s in g le  le tte r  code o f  D e fb l4 -1 C v w i th  com m as in d ic a t in g  th e  d e le tio n  po in ts . * in d ica te s  d iffe re n ce  fro m  m e d iu m  a lone  c o n tro l p > 0.05, 
"p>0 .01 ,*” p  >0 .001 .
laG in Human, Chinchilla, Cow and Dog but an F in Mouse, R (argi­
nine) in Pig, and W  (tryptophan) in Opossum. This suggests that 
ihe second highly conserved residue might be the essential fac­
tor for this (3-defensin to functionally interact w ith  CCR6 to induce 
jtiiemoattraction. In addition, hBD2, another [3-defensin show n to 
have ability to chem oattrac t  through CCR6 (Yang et al„ 1999), has 
¡isoleucine as its second amino acid.
In order to de term ine  if the loss of chem oattrac tant activity 
ofDefbl4-lCv A ( l - 2 )  was the consequence of the loss of leucine, 
dnd not as result of length reduction, we created three substitu­
tion mutants w here  the second hydrophobic leucine residue was 
jreplaced e ither w ith  the charged residue lysine, the hydro-neutral 
' glycine or the  semi-conservative change to isoleucine. Fig. 1 b shows 
tthat the peptide D efb l4 - lC v w ith  replacement of the leucine to 
lysine (L2I<) was unable to chemoattract the CCR6 expressing cells 
Jnd neither was Defb14-lCv L2G. Defbl4-1Cv L21 had a reduced 
,ability to chem oattrac t  the CCR6 cells with a Migratory Index 
(Ml) of 1.4 at 10 ng/ml. This result indicates that the residue side 
chain at the second position of the N-terminal region is indeed 
important for the pep tide’s ability to interact functionally with 
:CCR6.
The N-terminal region of (3-defensins forms an a -he l ix  and so 
in order to determ ine  w he the r  the above mutations result in a
change in secondary s tructure  of the  molecule we carried ou t cir­
cular dichroism spectroscopy (CD).
3.2. Reduced chemotactic activity is not due to im pairm ent o f the 
N-terminal helix
We investigated the secondary structures of the substitution 
mutan ts  by CD and compared the spectra to those of the active 
full-length paren t peptide Defbl 4-1 Cv .The CD spectrum  of Defbl4- 
1CV in aqueous solution (Fig. 2a) shows an absorption m inim um  
at -2 0 1  nm that is typical of a peptide w hose secondary s truc­
ture is a mixture of (3-sheet or (3-turn and random  coil. This is in 
good qualitative agreem ent with  published CD spectra of o ther  (3- 
defensins, including Defbl4 orthologue hBD3 (Kluver et al., 2005; 
Liu et al., 2008). In buffer, D efb l4 - lC v exhibits a slightly more 
intense absorption m inim um  than that of the o ther peptides but 
was found to contain the sam e proportions of secondary s tructure  
as all of the o ther peptides according to analysis by the CDSSTR 
algorithm (Johnson, 1999).
HBD1 and 2 interact with  CCR6 to induce cell migration but with 
less affinity than hBD3. A comparison of the crystal s tructures of 
CCL20/MlP-3a (the chemokine ligand of CCR6) and (3-defensins 
has revealed some structural similarities despite a lack of linear
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Table 1
MBC va lues fo r  D e fb l4 -1 C v Leucine 2 s u b s titu tio n s  are n o t d iffe re n t to  th e  p a re n ta l pep tide .-1
B acte rium Peptide
D e fb l4 - lC v D e fb l 4-1 Cv L2I D e fb l4 - lC v L2G D e fb l4 - lC v L2I<
P. a e r u g in o s a  PA O l 0.2 (± 0 .0 ) 0.5 (± 0 .1 ) 0.3 (± 0 .0 ) 0.3 (± 0 .0 )
S. a u r e u s  ATCC 25923 0.5 (± 0 .0 ) 1.1 (± 0 .2 ) 0.9 (± 0 .2 ) 0.8 (± 0 .2 )
The c o n c e n tra tio n  o f  p e p tid e  re q u ire d  to  k il l 99.99% o f  th e  in it ia l in o c u lu m  o f  e ith e r  P. a e r u g in o s a  o r  S. a u r e u s  w as d e te rm in e d  (±S E M ).
sequence similarity (Hoover et al., 2002). The Asp4-Leu9 motif in 
HBD2 and Asp1 -Val6 motif in HBD1 resemble the Asp5-Leu8 motif 
of CCL20, which has been suggested to be responsible for specific 
interaction with CCR6, providing a structural basis for the capacity 
of (3-defensins and CCL20 to interact with  the same receptor. These 
regions include the N-terminal ct-helix of the defensin structure.
The addition of 2,2,2-trif luoroethanol (TFE) to an aqueous pep­
tide solution can induce helix formation and it is commonly used to 
evaluate the propensity of a given peptide to form a helix (Kelly et 
al., 2005). The minima observed in all spectra of the deletion pep­
tides at 208 and 222 nm are characteristic of a-helical structure, 
which strongly suggests tha t  all of these peptides can readily form 
a-helices under  increased hydrophobic conditions, as would exist 
at or in a bacterial m em brane. The CD spectrum of Defb14-lCv in 
50% water, 50% TFE is indistinguishable from those of the substi tu ­
tion m utan ts  (Fig. 2b). This dem onstrates  that substitution of the 
leucine at position 2 has not diminished the helix-forming po ten­
tial of the peptide and so the reduced chemotactic activity of the 
mutants is no t due to im pairm ent of the N-terminal helix.
Inspection of the nuclear magnetic resonance s tructures of 
hBD3 reveals a long, disordered amino terminal region im m edi­
ately before the a-helix, composed of residues 1 0-14  (Schibli et 
al„ 2002). The predom inantly  hydrophobic na ture  of the  first 9 
amino acids of both hBD3 and Defbl4 suggests that a longer helix 
(involving residues 1 -9 )  may be formed at the N term inus in more 
hydrophobic condit ions such as those found in a m em b rane  or 
at a p ro te in -p ro te in  interface. W e also analysed the secondary 
s tructure  of the deletion peptides by CD (supplem entary  data Fig. 
2). W e observed tha t  D efb l4- lC v A ( l - 2 )  has similar spectra to 
D efb l4 - lC v again indicating tha t  the loss of chemotactic abil­
ity is not easily explained by a loss of helicity. Loss of the first 
amino acid (phenylalanine) from the peptide does not alter its 
ability to chem oattrac t  CCR6 expressing cells w h en  synthesised 
with a free amine at the N-terminal (data not show n) and its 
CD is indistinguishable from the paren t peptide (supplem entary  
Fig. 2). Beyond D efb l4- lC v A( 1 —2), deletion of fur ther amino acids 
from the N-terminus results in a decrease in helix-forming po ten ­
tial.
x l  nm
\ l  nm
Fig. 2. S u b s titu t io n  o f  le u c in e  a t p o s itio n  2 does n o t s ig n if ic a n tly  change th e  sec­
ondary s tru c tu re  o f  D efb 14-1 Cv . (a ) Spectra o f  Deflo 14-1 Cv and s u b s t itu t io n  pep tides  
recorded in  10 m M  a m m o n iu m  acetate, (b )  Spectra o f  th e  sam e p ep tides  recorded  in 
50% w a te r  and 50% 2 ,2 ,2 -tr if lu o ro e th a n o l (TFE). Each spec trum  has been n o rm a lised  
for co n ce n tra tio n  as described  in  th e  te x t.
3.3. Leucine2 substitution peptides retain bactericidal activity
In order to ensure tha t the substitu tion  peptides w ere  active 
as antimicrobials despite being less active as chem oattrac tan ts  we 
tested their ability to kill e ither Gram-negative bacterial strain 
Pseudomonas aeruginosa PAOl or the Gram-positive strain Staphy­
lococcus aureus ATCC 25923. Table 1 shows tha t  the substitution 
peptides w ere still potent bactericidals and not significantly dif­
ferent from the parental peptide in their ability to kill the bacteria 
tested.
4. Conclusion
We show  here tha t  deletion or substitution of the second amino 
acid of the D efb l4 - lC v peptide results in a loss of chem oattrac tan t 
activity. This loss of function is not the result of any observable 
change in the secondary structure  of the free peptide. It is more 
likely a consequence of the  conserved leucine at position 2 of the 
m atu re  peptide being part of the ligand m otif  required for in te r­
action with CCR6. Isoleucine can partially substitu te  for leucine to 
allow chemoattraction of CCR6-expressing cells. Thus residues at 
both the N-terminal (L/I at residue 2) and C-terminal regions (C at 
residue 40) of Defbl 4 are essential for a chemotactically com peten t 
peptide. (3-Defensins are known to be im portan t in host defence 
and as a link be tw een  innate and adaptive immunity, thus iden­
tification of residues essential for chemoattraction  of CD4 T cells 
and im m ature DC is im portan t for unders tanding the functional 
consequence of mutation and designing therapeutics w ith  defined 
action.
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“So long and thanks fo r  all the fish  ” 
Douglas Adams
